PROTOCOL AMENDMENT APPROVA L
CONFIDENTIA L
This clinical study is being sponsored globally by F. Hoffmann -La [COMPANY_002] Ltd of Basel, 
Switzerland. However, it may be implemented in individual countries by [CONTACT_26702]'s local affiliates, 
including Genentech, Inc. in the [LOCATION_002].  The information contain ed in this document, especially 
any unpublished data, is the property of F.Hoffmann -La [COMPANY_002] Ltd (or u nder its control) and therefore 
is provided to you in confidence as an investigator, potential investigator, or consultant, for review by 
[CONTACT_10825], your staff , and an applicable Ethics Committee or Institutional Review Board.  It is understood that 
this information will not be disclosed to others without written authorization from [COMPANY_002] except to the 
extent necessary to obtain informed consent from persons to w hom the drug may  be administered.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
Protocol BN40955, Version 7PROTOCOL
TITLE: AN OPEN -LABEL EXTENSION STUDY TO 
EVALUATE THE LONG- TERM SA FETY AND 
TOLERA BILITY OF INTRA THECA LLY 
ADMINISTERED RO7234292 (RG6042) IN 
PATIENTS WITH HUNTINGTON’S DISEA SE
PROTOCOL NUMBER: BN40955
VERSION NUMBER: [ADDRESS_835389] NUMBER: [ADDRESS_835390] NUMBER [STUDY_ID_REMOVED]
IND NUMBER: [ADDRESS_835391]: Tominersen ( RO7234292 )
MEDICA L MONITOR: , M.D., Ph.D.
SPONSOR: F. Hoffmann -La [COMPANY_002] Ltd
APPROV AL DATE: See electronic date stamp below
 
02-Apr-2021 18:15:14
Title
Approver's Name
[CONTACT_26862] (UTC)

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
2/Protocol BN40955, Version 7PROTOCOL HISTORY
Protocol Associated Country -Specific Protocol
Version Date Final Country Version Date Final
7See electronic date 
stamp on title page
  6a16 March 2021   
5 3 September 2020   
4 13 February 2020   
3 16 April 2019   
1 20 November 2018 [LOCATION_013] 2 14 February 2019
aVersion 6 was finalized but not distributed to sites or Health Authorities and is superseded by 
[CONTACT_15261] 7.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
3/Protocol BN40955, Version 7PROTOCOL A MENDMENT, VERSION 7:
RATIONA LE
Protocol BN40955 has been amended to pause study treatments based on sponsor 
decision.  The GENERATION HD1 phase III study, BN40423, has been amended in 
accordance with the Urgent S afety Measure Dear Investigator Letter issued on 22 March 
2021. A pre- planned review of safety and efficacy data from Study BN40423, as well as 
available open -label data , was conducted by [CONTACT_626886]40423 independent Data Monitoring 
Committee (iDMC). Followin g review of the data, the iDMC has recommended that all 
dosing (120 mg Q8 W and Q16 W and placebo) in Study BN40423 be permanently 
stopped. This iDMC recommendation was not based on any new emergent safety 
concerns, but on a totality of evidence indicating that the treatment arms demonstrated 
unfavorable safety and efficacy trends compared to the placebo arm over time. The 
iDMC has also made a recommendation for the ongoing patients in the Study BN40423 
to be followed for safety and efficacy outcomes until study completion as per protocol, 
without study drug administration. Study BN40955 (open -label extension [OLE]) is 
exploring the same dosing regimens ( i.e., tominersen [RO7234292] 120 mg Q8 W and 
Q16W); therefore, the Sponsor has made a decision to pause dosing in the OLE until 
further data assessments can be conducted.
Changes to the protocol, along with a rationale for each change, are summarized below:
Language has been added to indicate effective 22 March 2021 study treatment will 
be paused. Patients already on the study will continue to be followed for safety and 
efficacy outcomes until study completion   (Section s1.3, 3.1.1, 3.3.1, and 4.5,and 
Appendices 1a, 1b, and 2a ).
It has been clarified that neurologic examinations should continue to be perfor med 
at each clinic visit and before the lumbar puncture, if there is no study treatment 
administration (Section 4.5.3 and Appendi ces1a, 1b, and 12) .
It has been clarified that patients should not perform any activity that is associated 
with a change in the ambient air pressure for at least [ADDRESS_835392] lumbar 
procedure, irrespective if study treatment is administered or not (Section 4.5.5,  
Appendix 1a and 1b) .
Wording in Section 5.1.[ADDRESS_835393] available risk data as per the RO7234292 Investigator’s Brochure 
Version 7.
Plasma and cerebral spi[INVESTIGATOR_872] (CSF) sample collection for pharmacokinetics (PK) 
analysis has been stopped (Appendi ces1a and 1b) .
Plasma samples for immunogenicity analysis willcontinue to be collected while 
study treatment is paused (Appendix 1a ).
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
4/Protocol BN40955, Version 7The schedules of activities have been modified to indicate the pause in study 
treatment administration and to clarify the frequency of safety and biomarker 
assessments (Appendices 1a,  1b , 2b, 3, 4, and 7 )
–Neurological examinations, C -SSRS, EQ -5D-5L will continue to be perform ed 
as per the original schedule
–In order to reduce patient burden and continue to monitor safety , the LP will be 
performed every 16 weeks for both treatment arms . CSF (for safety and 
biomarkers ),and local PT and/or INR, aPTT and platelet count will continue to 
becollected at every LP visit
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
5/Protocol BN40955, Version 7TABLE OF CONTENTS
1. BACKGROUND .......................................................................................... 24
1.1 Background on Huntington's Disease .................................... 24
1.2 Background on RO7234292 .................................................. 25
1.3 Study Rationale and Benefit -Risk Assessment ...................... 26
2. OBJECTIVES AND ENDPO INTS ............................................................... 28
2.1 Safety Objective .................................................................... 28
2.2 Exploratory Efficacy Objectives ............................................. 28
2.3 Exploratory Pharmacokinetic/Pharmacodynamic 
Objectives .............................................................................. 29
2.4 Exploratory Immunogenicity Objectives ................................ .29
2.5 Exploratory Biomarker Objective ........................................... 29
2.6 Health Status Utility Objective ............................................... 30
3. STUDY DESIGN ......................................................................................... 30
3.1 Description of the Study ......................................................... 30
3.1.1 Overview of Study Design ..................................................... 30
3.2 End of Study and Length of Study ......................................... 35
3.3 Rationale for Study Design .................................................... 35
3.3.1 Rationale for RO7234292 Dose and Schedule ...................... 35
3.3.2 Rationale for Biomarker Assessments ................................... 38
[IP_ADDRESS] Cerebrospi[INVESTIGATOR_116252] ............................................ 38
[IP_ADDRESS] Blood Biomarkers .................................................................. 38
[IP_ADDRESS] Magnetic Resonance Imaging ............................................... 38
[IP_ADDRESS] Safety Biomarkers ................................................................ .39
4. MATERIALS AND METHOD S.................................................................... 39
4.1 Patients.................................................................................. 39
4.1.1 Inclusion Criteria .................................................................... 39
4.1.2 Exclusion Criteria ................................................................... 41
4.2 Method of Treatment Assignment and Blinding ..................... 43
4.3 Study Treatment and Other Treatments Relevant 
to the Study Design ............................................................... 44

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
6/Protocol BN40955, Version 74.3.1 Study Treatment Formulation, Packaging, and 
Handling ................................................................................ 44
[IP_ADDRESS] RO7234292 ........................................................................... 44
4.3.2 Study Treatment Dosage, Administration, and 
Compliance ............................................................................ 44
[IP_ADDRESS] RO7234292 ........................................................................... [ADDRESS_835394] Accountability ................... 44
4.3.4 Continued Access to RO7234292 ......................................... 45
4.4 Concomitant Therapy ............................................................ 45
4.4.1 Permitted Therapy ................................................................ .46
4.4.2 Proh ibited Therapy ................................................................ 46
4.5 Study Assessments ............................................................... 46
4.5.1 Informed Consent Forms and Screening Log ........................ 47
4.5.2 Medical History, Concomitant Medication, and 
Demographic Data ................................................................ .47
4.5.3 Physical and Neurologic Examinations .................................. 48
4.5.4 Vital Signs .............................................................................. 48
4.5.5 Collection of Cerebrospi[INVESTIGATOR_17106] (Lumbar 
Puncture Procedure) ............................................................. [ADDRESS_835395] in Patients from 
Study BN40697 ..................................................................... 52
4.5.9 Electrocardiograms ................................................................ 52
4.5.10 Patient -Reported, Clinician -Reported, and 
Performance Outcomes ......................................................... 53
[IP_ADDRESS] Composite Unified Huntington's Disease Rating 
Scale ...................................................................................... 54
[IP_ADDRESS] Total Functional Capacity Scale ............................................ 54
[IP_ADDRESS] Total Motor Score .................................................................. 54
[IP_ADDRESS] Symbol Digit Modalities Test ................................................. 54
[IP_ADDRESS] Stroop W o rd Reading Test .................................................... 55
[IP_ADDRESS] Independence Scale .............................................................. 55
[IP_ADDRESS] Huntington's Disease Daily Activities Scale ........................... 55

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
7/Protocol BN40955, Version [IP_ADDRESS] Clinical Global Impression Severity and Change 
Scales .................................................................................... 55
[IP_ADDRESS] Montreal Cognitive Assessment ............................................ 56
[IP_ADDRESS] Columbia -Suicide Severity Rating Scale ............................... 56
[IP_ADDRESS] EuroQol 5 -Dimension, 5-Level Questionnaire ....................... 56
[IP_ADDRESS] [COMPANY_002] HD Mobile Application:  Remote Testing 
(Smartphone and Wrist-Worn Wearable) ............................... 56
4.6 Treatment, Pat ient, Study, and Site 
Discontinuation ................................
...................................... 58
4.6.1 Study Treatment Discontinuation ........................................... 58
4.6.2 Patient Discontinuation from Study ........................................ 58
4.6.3 Study Discontinuation ............................................................ 59
4.6.4 Site Discontinuation ............................................................... 59
5. ASSESSMENT OF SAFETY ....................................................................... 59
5.1 Safety Plan ............................................................................ 59
5.1.1 Known Risks Associated with Lumbar Puncture .................... 60
[IP_ADDRESS] Post Lumbar Puncture Syndrome ......................................... 61
[IP_ADDRESS] Spi[INVESTIGATOR_626839] .................................................................. 62
[IP_ADDRESS] Meningitis .............................................................................. 62
5.1.2 Potential Risks Associated with RO7234292 ......................... 62
[IP_ADDRESS] Neurologic Changes .............................................................. 62
[IP_ADDRESS] Elevations in CSF WBCs and Protein ................................ ....63
[IP_ADDRESS] Thrombocytopenia ................................................................ .64
[IP_ADDRESS] Kidney Effects ........................................................................ 64
[IP_ADDRESS] Liver Effects ........................................................................... 64
[IP_ADDRESS] Hydrocephalus ....................................................................... 65
[IP_ADDRESS] Neur opsychiatric Changes ..................................................... 65
[IP_ADDRESS] Potential Risk due to Reduction of Target Protein 
HTT........................................................................................ 65
5.1.3 Management of Patients who Experience 
Adverse Events ..................................................................... 66
[IP_ADDRESS] Dose Modifications ................................................................ 66
5.1.3. 2 Treatment Interruption ........................................................... 66
[IP_ADDRESS] Management Guidelines ........................................................ 67

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
8/Protocol BN40955, Version 75.2 Safety Parameters and Definitions ........................................ 70
5.2.1 Adverse Events ..................................................................... 71
5.2.2 Serious Adverse Events (Immediately Reportable 
to the Sponsor) ...................................................................... [ADDRESS_835396] (Immediately 
Reportable to the Sponsor) .................................................... 72
5.3 Methods and Timing for Capturing and 
Assessing Safety Parameters ................................................ 72
5.3.1 Adverse Event Reporting Period ........................................... 72
5.3.2 Eliciting Adverse Event Information ....................................... 73
5.3.3 Assessment of Severity of Adverse Events ........................... 73
5.3.4 Assessment of Causality of Adverse Eve nts......................... 73
5.3.5 Procedures for Recording Adverse Events ............................ 74
[IP_ADDRESS] Injection Reactions ................................................................ 74
5.3.5. 2 Diagnosis versus Signs and Symptoms ................................ .74
[IP_ADDRESS] Adverse Events That Are Secondary to Other 
Events.................................................................................... 75
[IP_ADDRESS] Persistent or Recurrent Adverse Events ................................ 75
[IP_ADDRESS] Abnormal Laboratory Values ................................................. 75
[IP_ADDRESS] Abnormal Vital Sign Values ................................................... 76
[IP_ADDRESS] Abnormal Liver Function Tests .............................................. 77
[IP_ADDRESS] Deaths ................................................................................... 77
[IP_ADDRESS] Preexisting Medical Conditions .............................................. 77
[IP_ADDRESS] Lack of Efficacy or W orsening of Huntington's 
Disease .................................................................................. 78
[IP_ADDRESS] Hospi[INVESTIGATOR_26589] .......................... 78
[IP_ADDRESS] Reporting Requirements for Cases of Accidental 
Overdose or Medication Error ................................................ 78
[IP_ADDRESS] Patient -Reported Outcome Data ........................................... 79
[IP_ADDRESS] Safety Biomarker Data ........................................................... [ADDRESS_835397] ..................... 81

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
9/Protocol BN40955, Version [IP_ADDRESS] Events That Occur prior to Study Drug Initiation .................... 81
[IP_ADDRESS] Events That Occur after Study Drug Initiation ........................ 81
5.4.3 Reporting Requirements for Pregnancies .............................. 81
[IP_ADDRESS] Pregnancies in Female Patients ............................................ 81
[IP_ADDRESS] Pregnancies in Female Partners of Male Patients ................. 82
[IP_ADDRESS] Abortions ............................................................................... 82
[IP_ADDRESS] Congenital Anomalies/Birth Defects ...................................... [ADDRESS_835398] of Study ............................................ 84
6.4 Summaries of Treatment Group Comparability ..................... 84
6.5 Safety Analyses ..................................................................... 84
6.6 Exploratory Efficacy Analyses ............................................... 85
6.7 Exploratory Pharmacokinetic Analyses .................................. 85
6.8 Exploratory Immunogenicity Analyses ................................... 85
6.9 Exploratory Biomarker Analyses ............................................ 86
6.10 Health Status Utility Analysis ................................................. 86
6.11 Optional Interim Analyses ...................................................... 86
7. DATA COLLECTION AND MANAGEMENT ............................................... 86
7.1 Data Quality Assurance ......................................................... 86
7.2 Electronic Case Report Forms ............................................... 87
7.3 Electronic Patient -Reported, Clinician -Reported, 
and Performance Outcome Data ........................................... 87
7.4 Electronic Data Obtained by [CONTACT_626887] ....................................................... 87

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
10/Protocol BN40955, Version 77.[ADDRESS_835399] OF TA BLES
Table 1 Treatment Regimen in Study BN40955 Based on Previous 
Study Treatment ................................ ......................................... 33
Table 2 Guidelines for Manage ment of Patients Who Experience 
Adverse Events ................................ ........................................... 68
Table 3 A dverse Eve nt Severity Grading Scale ................................ ....... 73
Table 4 Causal Attribution Guidance ................................ ....................... 74

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
11/Protocol BN40955, Version 7LIST OF A PPENDICES
Appendix [ADDRESS_835400] 2 Years of Study Participation 
While on Treatment Pause ................................ ........................ 115
Appendix 3 Clinician-Reported Outcomes ................................ ................... 116
Appendix 4 Patient- Reported Outcomes, Performance Outco mes, and 
[COMPANY_002] HD Mobile Application ................................ ................... 117
Appendix 5 Clinical Assessments Order 
and Duration for Patients 
Required to Undergo Screening Only ................................ ....... 119
Appendix 6 Diagnostic Confidence Level for Patients Required to 
Underg o Screening  Only........................................................... 120
Appendix 7 Clinical Assessments Order and Duration ................................ 121
Appendix 8 Remote Clinical Assessments Order and Duration 
(COVID -19 Impacted Sites where a Patient Cann ot Attend 
the Clinic or the Investigator Site Has Closed due to 
Restrictions Imposed as a Result of COVID- 19)....................... 122
Appendix 9 [COMPANY_002] HD Mobile Application:  Active Test ............................... [ADDRESS_835401] of Preceding  Clinical Trials ................................ ................. 131
Appendix 12Guid ance for Neurological Examination ................................ ....132

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
12/Protocol BN40955, Version 7PROTOCOL AMENDMENT ACCEPTA NCE FORM
TITLE: AN OPEN -LABEL EXTENSION STUDY TO 
EVALUATETHE LONG- TERM SA FETY AND 
TOLERA BILITY OF INTRA THECA LLY 
ADMINISTERED RO7234292 (RG6042) IN 
PATIENTS WITH HUNTINGTON’S DISEA SE
PROTOCOL NUMBER: BN40955
VERSION NUMBER: [ADDRESS_835402] NUMBER: [ADDRESS_835403] NUMBER [STUDY_ID_REMOVED]
IND NUMBER: [ADDRESS_835404]: Tominersen ( RO7234292 )
MEDICA L MONITOR: , M.D., Ph.D.
SPONSOR: F. Hoffmann -La [COMPANY_002] Ltd
I agree to conduct the study  in accordance with the current protocol.
Principal Investigator's Name  (print)
Principal Investigator's Signature [CONTACT_33505].  Please return a copy of 
the signed form as instructed by [CONTACT_27860].

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
13/Protocol BN40955, Version 7PROTOCOL SYNOPSIS
TITLE: AN OPEN -LABEL EXTENSION STUDY TO EVA LUATE THE 
LONG -TERM SA FETY A ND TOLERA BILITY OF INTRA THECA LLY 
ADM INISTERED RO7234292 (RG6042) IN PA TIENTS WITH 
HUNTINGTON’S DISEA SE
PROTOCOL NUMBER: BN40955
VERSION NUMBER: [ADDRESS_835405] NUMBER: 2018- [ADDRESS_835406] NUMBER [STUDY_ID_REMOVED]
IND NUMBER: [ADDRESS_835407]: Tominersen (RO7234292)
PHASE: Phase III
INDIC ATION: Huntington's disease
SPONSOR: F. Hoffmann -La [COMPANY_002] Ltd
Objectives and Endpoints
This study will evaluate the long -term safety and tolerability of RO7234292 in patients with 
Huntington's disease (HD).  In addition, the study will obtain long -term data on the efficacy , 
immunogenicity, exposure, and biomarkers of RO7234292.  Specific objectiv es and 
corresponding endpoints for the study are outlined below.
Objectives will be achieved primarily by [CONTACT_626888] -label extension (OLE) 
study, but may  also be informed by  [CONTACT_626889].  Data may be linked and, if appropriate, may be analyzed by [CONTACT_626890].
Safety Objective
The safety  objective for this study is to evaluate the safety and tolerability of RO7234292 on the 
basis of the following endpoints:
Incidence and severity of adverse events (AEs) , with severity determined according to the 
Adverse Event Severity Grading Scale
Change from baseline in targeted vital signs
Change from baseline in physical findings
Change from baseline in neurological findings
Change from baseline in behavioral findings, as assessed by [CONTACT_48649] -Suicide Severity 
Rating Scale (C-SSRS)
Change from baseline in cognition
Change from baseline in targeted ECG results
Change from baseline in targeted clinical laboratory test results
Relationship between lab oratory parameter change and safety -targeted endpoints
Relationship between MRI parameter change and safety -targeted endpoints
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
14/Protocol BN40955, Version 7Exploratory Efficacy Objective
The exploratory efficacy  objective for this study is to evaluate the efficacy of RO7234292 on the 
basis of the following endpoints:
Change from baseline in the composite Unified Huntington's Disease Rating Scale score as
assessed every 16 weeks (Q16 W)
Change from baseline in scores for the following individual scales as assessed Q16W:
– Total Functional Capacity Scale .
– Total Motor Score .
– Symbol Digit Modalities Test.
– Stroop Word Reading Test .
Change from baseline in the Clinical Global Impression, Severity Scale score as assessed 
Q16W
Proportion of patients with an unchanged or improved score on the Clinical Global 
Impression, Change Scale score from baseline as assessed Q16W
Change from baseline in the Huntington's Disease Daily Activities Scale score as assessed 
Q16W
Change from basel ine in the sensor -based measures collected by [CONTACT_626891] (smartphone and wrist- worn wearable) as assessed Q16W
Exploratory Pharmacokinetic /Pharmacodynamic Objectives
The exploratory pharmacokinetic (PK) objective for this study is to characterize the RO7234292 
PK trough plasma and trough cerebrospi[INVESTIGATOR_872] ( CSF)samples on the basis of the following 
endpoints:
Trough concentration of RO7234292 in plasma at specified timepoints
Trough concentration of RO7234292 in CSF at specified time points
The exploratory PK/pharmacodynamic (PK/PD) objective for this study is to evaluate potential 
relationships between drug exposure and the efficacy  and safety of RO7234292 on the basis of 
the following endpoints:
Relationship between trough plasma and/or trough CSF concentrations of PK parameters 
for RO7234292 and efficacy endpoints
Relationship between trough plasma and/or trough CSF concentrations of PK parameters 
for RO7234292 and safety endpoints
Exploratory Immunogenicity Objective
The exploratory immunogenicity objectives for this study are as follows:
To evaluate the immune response to RO7234292 on the basis of the following endpoints:
– Incidence of anti -drug antibodies (ADAs) at specified timepoints relative to the 
prevalence of ADAs a t baseline .
– Determination of the ADA specificity followed by [CONTACT_626892] (titer) 
of the ADA response .
To evaluate potential effects of ADAs on the basis of the following endpoint:
– Relationship between ADA status and efficacy , safety, or PK endpoints .
Exploratory Biomarkers Objective
The exploratory biomarker objective for this study is to identify biomarkers that are early 
surrogates of efficacy , are associated with progression to a more severe disease state 
(i.e., prognostic biomarkers), are associated with acquired resistance to RO7234292, are 
associated with susceptibility to developi[INVESTIGATOR_626840] (i.e., safety biomarkers), can provide evidence of RO7234292 activity (i.e., PD 
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
15/Protocol BN40955, Version 7biom arkers), o r can increase the knowledge and understanding of disease biology and drug 
safety, on the basis of the following endpoints:
Relationship between biomarkers (e.g., tau and neurofilament light chain protein [NfL] ) in 
plasma and CSF efficacy, safety, PK, immu nogenicity, or other biomarker endpoints
Relationship between imaging biomarkers and efficacy , safety, PK, immunogenicity, or 
other biomarker endpoints
Health Status Utility Objective
The exploratory health status utility objective for this study is to ev aluate health status utility 
scores of patients treated with RO7234292 on the basis of the following endpoint:
Change from baseline in patient -reported EuroQol 5 -Dimension, 5 -Level Questionnaire 
(EQ-5D-5L)Index and Visual Analog Scale ( VAS)scores at spec ified timepoints
Study Design
Description of Study
This OLE study will evaluate the long -term safety  and tolerability of RO7234292 administered 
intrathecally (IT) to patients with HD.  In addition, the study will obtain long -term data on the 
efficacy , immunogenicity, exposure, and biomarkers of RO7234292.
Effective [ADDRESS_835408]/ Ethics Committee in a country in order for a patient from that country 
to be included in the OLE.
For patients who have participated in previous R oche studies, entr y into this long -term, 
open- label extension study will occur at an inclusion visit. This inclusion visit is a combined visit 
with the preceding study's last applicable visit where patients are due for their end of treatment 
visit, last CSF collection ,or safety follow -up unless otherwise specified, and serves as the 
baseline visit for the long -term,open -label extension study. For participants who have not 
participated in a previous [COMPANY_002] study, a separate screening visit will occur to determine 
eligibility into the long -term,open -label extension study. Patients who successfully meet 
eligibility criteria will then enter the study and attend the baseline study visit .  Patients who were 
enrolled in Study BN40423 before implementation of V ersion 4 of that protocol will be 
prematurely discontinued by [CONTACT_626893]40423 and offered treatment in this 
study ( Study BN40955) when it is available at sites.
If dosing at the inclusion visit is not possible, the Medical Monitor should be consulted and a 
short treatment interruption may  be permitted.  For patients entering from Study BN40423 prior 
to im plem entation of p rotocol Version 4, the inclusion visit should occur at the end -of-treatm ent 
visit for Study BN40423.
Patients Impacted by [CONTACT_205888]- 19 during Study BN40423 Screening
Patients who were screened and eligible for the placebo -controlled Phase III Study BN40423 
(Generation -HD1) but were not randomized prior to the close of Study BN40423 enrollment due 
to logistical challenges resulting from the COVID- 19 pandemic, will be offered open- label 
RO7234292 as part of this study, Study BN40955.  Participation can occur once approved and 
available at sites and so long as the patient meets Study BN40955 eligibility.  These patients 
will undergo screening assessments during a 4 -week screening period.  A maximum of 1 re-
screening will be allowed within 8 weeks of an initial screening failure in Study BN40955.
The CAG repeat length testing from Q2 Solutions will be accepted for this study.  If re-screening 
is required, the CAG repeat length testing from Q2 Solutions does not need to be repeated.  
The screening MRI and viral serology from the initial screening, including from other [COMPANY_002] 
RO7234292 studies, may be acceptable as part of the screening as sessments if performed 
within 12 weeks of the inclusion visit.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
16/Protocol BN40955, Version 7For patients entering from Study BN40697, in the event of any delay in start -up activities where 
it is not possible to conduct the inclusion visit at the time of the last applicable visit in 
StudyBN40697, a separate inclusion visit should be scheduled.   For patients entering from 
StudyML41885, the inclusion visit will take place at the safety follow -up visit of Study ML41885 
(i.e., SFU1).
Upon completion of the inclusion visit, eligible patien ts will receive either 120 mg RO7234292 
Q8W (RO7234292 Q8 W arm) or 120 mg RO7234292 Q16 W (RO7234292 Q16W  arm) by [CONTACT_626894]. Patients will be assigned to treatment groups as described below:
Preceding Study Treatment Treatment Regimen
Open -label 120 mg RO7234292 Q4 W Randomized 1:1 to 120 mg RO7234292 Q8W  
or 120 mg RO7234292 Q16 W
Open -label 120 mg RO7234292 Q8 W 120 mg RO7234292 Q8W
No treatment or 4 doses of 120 mg or 
lessRO7234292 with a treatment -free 
follow -up periodRandomized 1:1 to 120 mg RO7234292 Q8W  
or 120 mg RO7234292 Q16 W 
Blinded placebo Q8W Randomized 1:1 to 120 mg RO7234292 Q8W  
or 120 mg RO7234292 Q16 W 
Blinded 120 mg RO7234292 Q8 W 120 mg RO7234292 Q8W
Blinded 120 mg RO7234292 Q16W 120 mg RO7234292 Q16W
For Patients enrolled into Study BN40423 prior to implementation of Study BN40423 
Protocol Version 4:
Blinded 120 mg RO7234292 Q4 W Randomized 1:1 to 120 mg RO7234292 Q8W  
or 120 mg RO7234292 Q16 W
Blinded 120 mg RO7234292 Q8 W 120 mg RO7234292 Q8W
Blinded Placebo Q4 W Randomized 1:1 to 120 mg RO7234292 Q8W  
or 120 mg RO7234292 Q16 W 
Open -label 120 mg RO7234292 Q16W 120 mg RO7234292 Q16W
Q4Wevery 4 weeks; Q8 Wevery 8 weeks; Q16 Wevery 16 weeks.
For patients who did not previously receive treatment withRO7234292 (e.g., from a natural 
history study) or received short- term treatment ( 4 doses), the end of study visit for the 
preceding study will serve as the inclusion visit for Study BN40955.  For patients who completed 
the full treatment course in the preceding study, the inclusion visit for Study BN40955 will take 
place at the visit at which the last dose was administered.  For patients enrolled in 
StudyBN40423 prior to implementation of Protocol Version [ADDRESS_835409] applicable visit in Study BN40697, a separate inclusion visit should be scheduled. 
Atthe inclusion visit for Study BN40955, clinical ratings and assessments that are common 
betwe en the preceding study and Study BN40955 will be completed once and will serve both 
studies.  Clinical ratings and assessments required in Study BN40955 that were not completed 
as part of the preceding study will also need to be completed at the inclusion visit. Patients who 
were eligible for Study BN40423 (GENERATION- HD1) but were not randomized due to 
logistical challenges resulting from the COVID -19 pandemic will undergo screening and 
inclusion visits.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
17/Protocol BN40955, Version 7Patients will undergo safety and tolerability evalu ations that include neurologic examinations, 
vital signs, ECGs, clinical laborator y tests, Montreal Cognitive Assessment (MoCA) , C-SSRS, 
neuroimaging assessments and reporting of AEs and concomitant medications. Patients 
enrolling from Study BN40697 will have an optional MRI of brain and spi[INVESTIGATOR_402356] h contrast media, 
in addition to the other brain neuroimaging assessments.
In case of a failed IT bolus dosing procedure (e.g., due to an inadequate establishment of 
access to the IT space), a second dosing attempt may occur up to 7 days after the originally 
scheduled dosing attempt. For this additional visit, safety and tolerability evaluations on the day 
of lumbar puncture ( LP)administration will be performed as detailed in Appendix 1a and
Appendix 1b , including neurological examination (predose and postdose), vital signs, and a 
review of AEs and concomitant medication. If the second dosing attempt occurs more than 
72hours after the last coagulation panel and platelet stest, local laborator y analysis of 
coagulation factors ( INRand/or PT, aPTT) and platelets need to be conducted again and results 
reviewed prior to the LP attempt .
Telephone safety follow -up calls will be conducted between dosing visits to check for any 
change in patient status (i.e., AEs , concomitant medications) since last visit. Depending on the 
patient’s health status, an unscheduled clinic visit may  be arranged. If a patient is due for a 
telephone safety call and they are in- clinic then this telephone safety follow -upcallcan be 
completed in-clinic at the site’s discretion. As a result of theCOVID -[ADDRESS_835410] meet the following criteria for study entry:
Signed Informed Consent Form (ICF)
If capacity to consent is in question, formal capacity assessment by [CONTACT_626895].  In cases where capacity to consent is not 
fully present, but the participant is known previously to have favored participation in an 
open- label study and is able to assent, consent may be obtained by a legally
authorized representative.  (Note:  Patients in [LOCATION_013] who are not fully capable of 
providing informed consent are not eligible for inclusion) .
Prior enrollment in a [COMPANY_002] sponsored or Genentech -sponsored study in HD for the 
RO7234292 development program that made provision for entry into an OLE study
Ability and willingness to comply  with the study protocol including the visit schedule and all 
assessments, in the investigator's judgment
For women of childbearing potential:  A greement to remain abstinent (refrain from 
heterosexual intercourse) or use contraceptive measures, as defined below:
Women must remain abstinent or use [ADDRESS_835411] 
one method with a failure rate of  1% per year, during the treatment period and for 
5months a fter the final dose of study drug.
A woman is considered to be of childbearing potential if she is postmenarcheal, has 
not reached a postmenopausal state ( 12continuous months of amenorrhea with no 
identified cause other than menopause), and has not under gone surgical sterilization 
(removal of ovaries and/or uterus).  The definition of childbearing potential may be 
adapted for alignment with local guidelines or requirements.
Examples of contraceptive methods with a failure rate of 1%per year include 
bilateral tubal ligation, male sterilization, established proper use of hormonal 
contraceptives that inhibit ovulation, hormone -releasing intrauterine devices, and 
copper intrauterine devices.   A vasectomized man must undergo a medical 
assessment that confirm s the success of the surger y before he can be considered 
surgically sterile.
Hormonal contraceptive methods must be supplemented by a barrier method.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
18/Protocol BN40955, Version 7The reliability of sexual abstinence should be evaluated in relation to the duration of 
the clinical trial and the preferred and usual lifestyle of the patient.  Periodic 
abstinence (e.g., calendar, ovulation, sy mptothermal, or postovulation methods) and 
withdrawal are not acceptable methods of contraception.
For men:  Agreement to remain abstinent (refrain f rom heterosexual intercourse) or use a 
condom, and agreement to refrain from donating sperm, as defined below:
With a female partner of childbearing potential or pregnant female partner, men must 
remain abstinent or use a condom during the treatment period and for [ADDRESS_835412] refrain from 
donating sperm during this same period.
The reliability of sexual abstinence should be evaluated in relation to the duration of 
the clinical trial and the preferred and usual lifestyle of the patient.  Periodic 
abstinence (e.g., calendar, ovulation, sy mptothermal, or postovulation methods) and 
withdrawal are not acceptable methods of preventing drug exposure.
The following eligibility criteria only app ly to patients who were eligible for Study BN40423 
(GENERATION -HD1) but were not randomized due to logistical challenges resulting from the 
COVID -[ADDRESS_835413] meet the following criteria for study entry during screening (some will be 
reassess ed at the inclusion visit prior to randomization and study drug dosing):
Signed ICF
Age 25 65years, inclusive, at the time of signing the ICF and at the time of first dose 
administration.
Manifest HD diagnosis, defined as a diagnostic confidence level (DCL) score of 4
Independence Scale (IS) score 70
Genetically confirmed disease by [CONTACT_626896] a CAG -Age product (CAP) score 
400 (Zhang et al. 2011), calculated as follows:
CAPAge(CAG repeat length 33.66)
Ability to read the words  red, blue, and green in native language
Ability to walk unassisted without a cane or walker and move about without a wheelchair on 
a daily basis as determined at screening and baseline visit
Long- distance (e.g., 50meters) use of wheelchairs for convenie nce or transfer is 
permitted.
Body mass index 16 32kg/m2; total body weight 40kg
Ability to undergo and tolerate MRI scans (e.g., no claustrophobia, no severe chorea or 
other condition that precludes MRI scans or renders scanning intolerable for the pat ient, no 
MRI- incompatible intrauterine devices, metallic dental braces, or other metal implants)
Ability to tolerate blood draws and LPs
Creatinine clearance (CrCl) 60mL/min (Cockcroft -Gault formula)
Ability and willingness, in the investigator's judgmen t, to comply with all aspects of the 
protocol including completion of interviews and questionnaires for the duration of the study
Stable medical, ps ychiatric, and neurological status for at least 12 weeks prior to screening 
and at the time of enrollment
Exclusion Criteria
Patients who meet any of the following criteria will be excluded from study entry:
Withdrawal of consent from the preceding study
Permanent discontinuation of RO7234292 for any drug -related safety concern during the 
preceding study or me eting of any study treatment discontinuation criteria specified in the 
preceding study at the time of enrollment into this study
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
19/Protocol BN40955, Version 7An ongoing, unresolved, clinically significant medical problem that in the judgment of the 
investigator would make it unsafe fo r the patient to participate in this study
Antiplatelet or anticoagulant therapy within 14 days prior to inclusion or anticipated use 
during the study, including, but not limited to, aspi[INVESTIGATOR_248] (unless 81mg/day), clopi[INVESTIGATOR_7745], 
dipyridam ole, warfarin, dabigat ran, rivaroxaban, and api[INVESTIGATOR_3822]
History of bleeding diathesis or coagulopathy
Platelet count less than the lower limit of normal
Platelet counts between 125,000 and 150,000 mm3are permissible as long as the 
investigator confirms there is no evidence of cur rent bleeding diathesis or 
coagulopathy.
Concurrent participation in any therapeutic clinical trial (other than the preceding study )
Study treatment (RO7234292) is commercially marketed in the patient’s countr y for the 
patient -specific disease and is acces sible to the patient
Pregnant or breastfeeding, or intending to become pregnant during the study or within 
5months after the final dose of study drug
Women of childbearing potential must have a negative urine pregnanc y test at the 
inclusion visit (obtained as part of the preceding study assessments).
The following exclusion criteria only apply to patients who were eligible for Study BN40423 
(GENERATION -HD1) but were not randomized due to logistical challenges resulting from the 
COVID -19 pandemic.
Patients who meet any of the following criteria will be excluded from study entry:
History of attempted suicide or suicidal ideation with plan (i.e., active suicidal ideation) that 
required hospi[INVESTIGATOR_601316]/or change in level of care within 12 months pri or to screening
Current suicidal ideation is demonstrated by [CONTACT_941] C -SSRS per judgment of the 
investigator.  If suicidal ideation is present, a risk assessment should be completed by 
[CONTACT_626897].  Mild passive suicidal ideation (i.e., occasional 
thoughts that life is not worth living or is hard) without history of attempts or 
hospi[INVESTIGATOR_601317] 12 months is generally acceptable for stu dy participation, 
but final decision on participation should be made carefully and in consultation with an 
appropriately qualified mental health professional.
Current active ps ychosis, confusional state, or violent behavior
Any serious medical condition or clinically significant laborator y, or vital sign abnormality or 
claustrophobia at screening that, in the investigator's judgment, precludes the patient's safe 
participation in and completion of the study
History known to the investigator or presence of an abnormal ECG that is clinically 
significant in the investigator's opi[INVESTIGATOR_1649], including complete left bundle branch block, 
second -or third -degree atrioventricular heart block, or evidence of prior m yocardial 
infarction
Lifetime clinical diagnosis of chronic migraines
Presence of an implanted shunt for the drainage of CSF or an implanted central nervous 
system ( CNS )catheter
Positive for hepatitis C virus (HCV) or hepatitis B surface antigen (HBsAg) at screening
Known HIV infection
Current or previous use of an antisense oligonucleotide ( ASO; including small interfering 
RNA)
Current or previous use of anti -psychotics prescribed for a primary independent psychotic 
disorder (i.e., schizophrenia, schizoaffective disorder, bipolar disorder type I, severe with 
psychotic features), cholinesterase inhibitors, memantine, amantadine, or riluzole within 
12weeks from initiation of study treatment
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
20/Protocol BN40955, Version 7Treatment with investigational therapy within 4 weeks or 5 drug-elimination half -lives prior to 
screening, whichever is longer
History of gene therapy, cell transplantation, or any experimental brain surger y
Drug (i.e., cannabis, opi[INVESTIGATOR_2480], stimulant, hallucinogen, designer) and/or alcohol abuse or 
psychological or physiological dependenc y within 12 months prior to screening, as per the 
investigator's judgment
Abuse is defined as a maladaptive pattern of use that leads to failure to fulfill major 
work or social obligations or use in situations where it leads to physical danger or legal 
problems, and may  be the focus of clinical atten tion.
Poor peripheral venous access
Scoliosis or spi[INVESTIGATOR_626841]7234292 up the neuraxis
An infection requiring oral or intravenous ( IV)antibiotics within 14 days prior to and during 
screening and prior to randomization
Antiretroviral medications, including antiretroviral medication taken as prophylaxis within 
12months of study enrollment
Malignanc y within 5 years prior to screening, ex cept basal or squamous cell carcinoma of 
the skin or carcinoma in situ of the cervix that has been successfully treated
Preexisting intra -axial or extra -axial lesions (e.g., tumor, arterio -venous malformation, 
meningiom as, hydrocephalus, subdural haematoma ) as assessed by a centrally read MRI 
scan during the screening period
End of Study
The end of this study is defined as the date when the last patient, last visit occurs.  The end of 
the study is expected to occur a minimum of [ADDRESS_835414] (Investigational Drug)
The investigational medicinal product (IMP) for this study is RO7234292.
Statistical Methods
Primary A nalysis
The safety  analysis population will consist of all randomized patients who received at least one 
dose of study drug, with patients grouped according to treatment received.
All verbatim AEterms will be mapped to Medical Dictionary of Regulatory Activities ( MedDRA )
thesaurus terms.  The Adverse Event Severity Grading Scale will be used for assessing 
AEseverity.  Laboratory values determined as an AEshould be graded as detailed in the 
protocol and based on the National Cancer Institute Common Terminology Criteria f or Adverse 
Events ( NCI CTCAE )v5.0.
All safety data, including AEs , laboratory tests, neurologic examination, C -SSRS, MoCA ,ECG, 
and vital signs, will be reported in individual listings and summarized by [CONTACT_626898].  For continuous variables, both the original value 
as well as the change from baseline will be reported.
The incidence of AEs will be summarized on the basis of body s ystem s and dictionary preferred 
terms.  The incidence of AEs by [CONTACT_626899].
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
21/Protocol BN40955, Version 7Determination of Sample Size
The sample size for this study is determined by [CONTACT_626900] 
1100patients.
Optional Interim A nalyses
The Sponsor may choose to conduct one or more interim analyses including safety, PK, PD 
biom arkers and clinical endpoints as relevant.   Details of each interim analysis will be described 
in a dedicated S tatistical Analysis Plan (SAP) , which will be finalized before the conduct of the 
interim analysis.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
22/Protocol BN40955, Version 7LIST OF A BBREVIA TIONS A ND DEFINITION S OF TERMS
Abbreviation Definition
ADA anti-drug antibody
AE adverse event
AESI adverse event of special interest
app application
ASO antisense oligonucleotide
CAG cytosine, adenine, guanine
CAP CAG -Age Product
CGI-C Clinical Global Impression Change
CGI-S Clinical Global Impression Severity
ClinRO clinician -reported outcome
CSF cerebrospi[INVESTIGATOR_872] 
C-SSRS Colum bia-Suicide Severity Rating Scale
cUHDRS composite Unified Huntington's Disease Rating Scale
DCL diagnostic confidence level
DIL Dear Investigator Letter
EC Ethics Committee
Ecrf electronic Case Report Form
EDC electronic data capture
EQ-5D-5L EuroQol 5 -Dimension, 5 -Level Questionnaire
FDA Food and Drug Administration
HA health authority
HBsAg hepatitis B surface antigen
HCV hepatitis C virus
HD Huntington's disease
HD-DAS Huntington's Disease Daily Activities Scale
HDID Huntington's Disease Identification Number
HIPAA Health Insurance Portability and Accountability Act
HRQoL health- related quality of life
HTT huntingtin (gene)
HTT huntingtin (protein)
ICF Informed Consent Form
ICH International Council for Harmonisation
iDMC independent Data Monitoring Committee
IMP investigational medicinal product
IND Investigational New Drug (Application)
IRB Institutional Review Board
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
23/Protocol BN40955, Version 7Abbreviation Definition
IS Independence Scale
IT intrathecal
ITT intent- to-treat (population)
IxRS interactive voice or web -based response system
LP lumbar puncture
MAD multiple ascending dose
mHTT mutant huntingtin (protein)
MoCA Montreal Cognitive Assessment
MRI magnetic resonance imaging
NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse 
Events
NfL neurofilament light chain (protein)
OLE open- label extension
PD pharmacodynamic
PerfO performance outcome
PK pharmacokinetic
PRO patient -reported outcome
Q4W every [ADDRESS_835415] Reading
TFC Total Functional Capacity Scale
TMS Total Motor Score
UHDRS Unified Huntington's Disease Rating Scale
USM Urgent Safety Measure
VAS Visual Analog Scale
WPAI Work Productivity and Activity impairment
wtHTT wild-type huntingtin (protein)
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
24/Protocol BN40955, Version 71. BACKGROUND
1.1 BACKGROUND ON HUNTINGTON'S DISEA SE
Huntington's disease (HD) is an autosomal dominant neurodegenerative disease caused 
by [CONTACT_626901], adenine, and guanine ( CAG )repeats inexon 1 of the 
Huntingtin gene (HTT) onchromosome 4, which encodes for a mutant huntingtin (mHTT)
protein .  Based upon non clinical and clinical evidence, mHTT is considered the primary 
driver of HD pathophysiology (WildandTabrizi 2017).  Individuals who carry at least 
40CAG repeats inevitably experience progres sive motor, cognitive, and functional 
decline usually in adult life, with a mean age of motor onset of 45years .  The average 
illness course post motor onset is approximately 10 20 years, with pneumonia, heart 
failure, or other complications frequently cit ed as the cause of death 
(Sorensen andFenger 1992 ).  Individuals with end- stage disease have complete 
physical disability and profound body wasting.
The estimated prevalence of HD in North America, northwestern Europe, and Australia 
ranges from 5.96 13.17 cases per 100,000 ( Baig et al. 2016).   Although genetic testing 
can be used to identify individuals who will develop the disease, the diagnosis of HD is 
clinical through neurologic examination of the motor system.  The clinical diagnosis of 
HD is made whe n the patient exhibits unequivocal presence of an otherwise 
unexplained extrapyramidal movement disorder (e.g.,chorea, dystonia, bradykinesia, 
rigidity )or motor onset (Huntington Study Group 1996 ; Hogarth etal.2005 ).
Themanifest disease period can be subdivided into 5stages based on functional 
capacity ( Ross et al. 2014) .  Stage [ADDRESS_835416] level of capacity and is 
characterized by [CONTACT_626902].  
Stage 5 represents severe disabilit y and dependence on full -time care 
(Shoulson andFahn 1979).  The 5clinical stages are defined by [CONTACT_626903]'s Disease Rating Scale ( UHDRS) Total Functional Capacity ( TFC)
Scale , with Stage 1 corresponding to TFC scores of 1113, Stage 2 to scores of 710, 
Stage 3 to scores of 36, Stage 4 to scores of 12, and Stage 5 to a score of 0 
(Shoulson and Fahn 1979).
To date, there are no approved treatments able to slow or stop the clinical progression 
ofHD.  Currently approved treatments aim to reduce the burden of symptoms, maximize 
function ,and improve the patient 's quality of life (Nance et al. 2011).  Tetrabenazine and 
deutetrabenazine target abnormal involuntary movements (i.e., chorea) associated with 
HD, and these symptomatic therapi[INVESTIGATOR_159358] a challenging benefit risk profile.  These 
drugs have been linked to many significant adverse events (AEs) , including 
parkinsonism, akathisia, sedation, and depression and suicidal thoughts.  T heyare 
contraindicated in patients who are active ly suicidal and in patients with untreated or 
inadequately treated depression.  Additionally, they may prolong the corrected 
QTinterval (QTc) , and caution is advised when used in combination with other drugs or 
medical conditions that potentially prolong the QTc.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
25/Protocol BN40955, Version 7Other medications are utilized in HD to address particular symptoms, such as 
antidepressants (for depression, agitation, irritability), anticonvulsants (for irritability, 
impulsive behavior), anxiolytics (for anxiety), cognitive -enhancing agents (for cognitive 
disturbances) ,and neuroleptics (for chorea ; Paulson and Albin 2011).
1.2 BACKGROUND ON RO7234292
Neuropathological abnormalities in HD appear to be the consequence of a toxic 
gain-of-function of the mHTT protein ( Wexleretal.1987; W alker2007 ; 
Moumné etal.2013).  Therefore, a therapy that reduces synthesis of the toxic mHTT
protein should directly target the primary disease mechanism.  As the genetic origin of 
HD is localized to just one gene, inhibiting the expression of this HTT gene is a 
promising therapeutic option (Stanek et al. 2013) .
RO7234292 ( RG6042 ) was originally developed by [CONTACT_81801], Inc. and was 
formerlyknown as ISIS 443139 and IONIS -HTT Rx.  This antisense oligonucleotide (ASO)
is being developed to reduce the synt hesis of all forms of the HTT protein by [CONTACT_626904] -type and the mutant alleles and directing its catalytic 
degradation through the action of ribonuclease H1, an endogenous enzyme present in 
most mammalian cells ( Cerritelli and Crouch 2009 ; Crooke and Bennett 1996), including 
cells of interest in the CNS (e.g., neurons and neuroglia).  Reduction of the HTT gene 
mRNA could potentially inhibit downstream toxic effects of mHTT and lead to a
sustained reversal in HD symptoms.
Pharmacology data support selective targeting of HTT mRNA transcripts from both 
alleles as a potentially safe and effective mechanism for the treatment of HD .  Using 
ASOs targeting human HTT mRNA in rodents, s ignificant reduction of mutant HTT
mRNA transcript s, wild -type HTT mRNA transcripts ,and mH TTprotein has been 
achieved throughout most brain regions (Kordasiewicz et al. 2012).  Furthermore , 
transient delivery of these ASOs in transgenic mouse models of HD delayed disease 
progression andmediated a sustained reversal of disease phenotype that persisted 
longer than HTT mRNA knockdown ( Kordasiewiecz et al. 2012 ;Stanek etal.2013 ).
Nonclinical proof -of-concept studies with ASOs targeting HTT have been conducted in 
three models of HD, including YAC128 mice expressing the full -length mutant human 
HTT transgene with a 128 CAG repeat expansion, BACHD mice expressing the 
full-length mutant human HTT genomic sequence with 97 CAG/CAA repeats, and 
R6/2 mice expressing e xon 1 of the mutant human HTT gene with 110135CAG 
repeats.  These studies demonstrate that ASOs targeting human HTT mRNA improve 
motor function and protect against human HTT transgene expression in YAC128 mice; 
improve motor function, hypoactivity ,and stress response in BACHD mice ; and p reserve 
striatal volume and increase survival in R6/2 mice.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
26/Protocol BN40955, Version 7The pharmacokinetics (PK) and toxicity of intrathecal (IT) administration of RO7234292 , 
an ASO that targets human HTT mRNA, were assessed in cynomolgus monkeys for 
13weeks (biweekly for the first month, t hen monthly ther eafter) at dose levels up to 
50mg/dose (5 bolus administrations, for a total dose o f 250 mg) and chronically for 
9months, up to 35 mg/dose ([ADDRESS_835417] rations for a total dose of 
350mg).  The drug was safe and well -tolerate d in these studies.
In a first -in-human, Phase I/IIa double -blind, placebo -controlled, dose -escalation study 
(Clinicaltrials.gov Identifier [STUDY_ID_REMOVED]) (ISIS 443139 -CS1) 4doses of RO7234292 
(ranging from 10 mg to 120 mg) were well-tolerated and achieved significant 
dose- dependent lowering of cerebrospi[INVESTIGATOR_872] ( CSF) mHTT protein when administered 
IT every 4 weeks (Q4W; monthly) to [ADDRESS_835418] HD.   Exploratory 
analyses identified a relationship between lowering of mHTT pr otein and improvement in 
some clinical measures.  Taken together, these data supported further clinical testing to 
demonstrate definitive clinical benefit of mHTT protein reduction in the CNS. The data 
from this study also supported the initiation of Study ISIS 443139 -CS2 (Study BN40697; 
Clinicaltrials.gov Identifier [STUDY_ID_REMOVED]) , a15-month, Phase II open- label extension 
(OLE) study for patients who participated in Study ISIS 443139 -CS1.
Preliminary data from analysis conducted when all individuals in Study BN40967 had 
reached 9 months of treatment showed that a 120 mg every -8-week (Q8 W; every 
2months) dosing regimen of RO7234292 achieve d a47% median CSF mHTT lowering 
at trough (i.e., sample taken immediately before the next dose) and the 120 mg Q4 W 
dosing regimen achieve d a66% median lowering at trough.  Both results exceed the 
20%40% target for CSF mHTT lowering at trough and steady state based upon efficacy 
data from nonclinical models, and exceed t he result of approximately 40% median 
lowering observed in the completed Phase I/IIa study. Details on the most recent 
information from nonclinical and clinical studies can be found in the 
RO7234292 Investigator’s Brochure.
1.[ADDRESS_835419] participated in other
F.Hoffmann -La[COMPANY_002], Ltd.sponsored (hereafter referred to as [COMPANY_002]) and/or 
Genentech- sponsored studies in HD in the development program for RO7234292 .  
Presently, there are no therapi[INVESTIGATOR_626842], 
which is relentless until patients ex perience premature death.  The ASO RO7234292 is 
designed to target the cause of HD and offers the potential to meet this unmet medical 
need.
To date, nonclinical and clinical data support further investigation of RO7234292 in 
patients with HD.  Current planned or ongoing studies in the RO7234292 clinical 
development plan are designed for durations of up to approximately [ADDRESS_835420] safety data in a larger number of patients and will also study the 
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
27/Protocol BN40955, Version 7benefit and potential risks of RO7234292 when administered by [CONTACT_626905] Q8 W 
or every 16 weeks (Q16W ) over a longer period.
Review of preliminary 9 -month safety and tolerability data for RO7234292 from the 
Phase II OLE (Study BN40697) suggest edthat, relative to the Q4 W treatment regimen, 
the Q8 W treatment regimen may be more suitable for chronic IT dosing, as evidenced 
by [CONTACT_626906].  This issupported by [CONTACT_626907], decreased proportion of patients with moderate AEs, and fewer 
AEs considered possibly related to study drug in the Q8 W regimen compared to the 
Q4W regimen (for details see the RO7234292 Investigator’s Brochure).
There were no acute safety concerns meriting a change to the ongoing Phase II OLE 
study protocol (Study BN40697) .  However, given the [ADDRESS_835421] the dose rationale.   As a 
result, the results from OLE Study BN40697 justif ieda change in Study BN40955 to 
explore less frequent dosing regimens by [CONTACT_626908] Q8 W RO7234292 arm and 
replacing the Q4 W arm with a Q16W  arm.
The existing dose rationale tests a mo re frequent dosing regimen (i. e., 120 mg Q8 W), 
whichfrom present d atais anticipated to maintain trough CSF mHTT reduction of 
atleast approximately 40%, and a less frequent regimen (i.e., 120mg Q16W ), which is 
still anticipated to lower mHTT acutely, but will allow greater recovery of HTT levels 
between doses.  From present data, trough CSF mHTT reduction of approximately 25% 
is predicted to be maintained in a 120 mg Q16 W paradigm.
A pre -planned review of safety and efficacy data from the GENERATION HD1 phase 
III Study BN40423, as well as available open -label data , was conducted by [CONTACT_626909]40423 independent Data Monitoring Committee (iDMC). Following review of the 
data, the iDMC recommended that all dosing (120 mg Q8W and Q16W and placebo) in 
Study BN40423 be permanently stopped. This iDMC recommendation was not based 
on any new emergent safety concerns, but on a totality of evidence indicating that the 
treatment arms demonstrated unfavorable safety and efficacy trends compared to the 
placebo arm over time. The iDMC also made a recommendation for the ongoing 
patients in the Study BN40423 to be followed for safety and efficacy outcomes until 
study completion as per protocol, without study drug administration. Study BN40955 
(open -label extension [OLE]) is exploring the same dosing reg imens ( i.e., tominersen 
[RO7234292] 120 mg Q8W and Q16W); therefore, the Sponsor made a decision to 
pause dosing in the OLE until further data assessments can be conducted.
The known potential risks associated with RO7234292 and additional risks related t o 
lumbar punctures (LPs), along with mitigation measures, a re elaborated in Section 5.1.

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
28/Protocol BN40955, Version 72. OBJECTIVES A ND ENDPO INTS
This study will evaluate the long-term safety andtolerability of RO7234292 in patients
with HD.  In addition, the study will obtain long -term data on the efficacy, immunogenicity, 
exposure, and biomarkers of RO7234292 .  Specific objectives and corresponding 
endpoints for the study ar e outlined below.
Objectives will be achieved primarily by [CONTACT_626910], but may 
also be informed by [CONTACT_626911].  Data may be linked and, if appropriate, may be analyzed by [CONTACT_626912].
2.1 SAFETY OBJECTIVE
The safety objective for this study is to evaluate the safety and tolerability of RO7234292
on the basis of the following endpoints:
Incidence and severity of AEs, with severity determined according to the Adverse 
Event Severity Grading Scale (see Table 3 )
Change from baseline in targeted vital signs
Change from baseline in physical findings
Change from baseline in neurological findings
Change from baseline in behavioral findings, as assessed by [CONTACT_65921] -Suicide Severity Rating Scale (C-SSRS)
Change from baseline in cognition
Change from baseline in targeted ECG results
Change from baselin e in targeted clinical laboratory test results
Relationship between lab oratory parameter change and safety -targeted endpoints
Relationship between magnetic resonance imaging ( MRI)parameter change and 
safety-targeted endpoints
2.2 EXPLORA TORY EFFICA CY OBJECTI VES
The exploratory efficacy objective for this study is to evaluate the efficacy of RO7234292
on the basis of the following endpoint s:
Change from baseline in the composite Unified Huntington's Disease Rating Scale 
(cUHDRS) score as assessed Q16W
Change from baseline in scores for the following individual scales as assessed 
Q16W:
–Total Functional Capacity Scale.
–Total Motor Score (TMS) .
–Symbol Digit Modalities Test (SDMT) .
–Stroop Word Reading (SW R) test.

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
29/Protocol BN40955, Version 7Change from baseline in the Clinical Global Impression, Severity Scale (CGI -S) 
score as assessed Q16W
Proportion of patients with an unchanged or improved score on the Clinical Global 
Impression, Change Scale (CGI -C) score from baseline as assessed Q16W
Change from baseline in the Huntington's Dise ase Daily Activities Scale (HD -DAS) 
score as assessed Q16W
Change from baseline in the sensor -based measures collected by [CONTACT_626913] (app; smartphone and wrist -worn wearable) as assessed Q16W
2.3 EXPLORA TORY PHA RMA COKINETIC /PHA RMA CODYNA MIC
OBJECTIVE S
The exploratory PK objective for this study is to characterize the RO7234292 PK trough 
plasma and trough CSF samples on the basis of the following endpoints:
Trough concentration of RO7234292 in plasma at specified timepoints
Trough concentration of RO7234292 in CSF at specified timepoints
The exploratory PK/pharmacodynamic (PK/PD) objective for this study is to evaluate 
potential relationships between drug exposure and the efficacy and safety of 
RO7234292 on the basis of the fol lowing endpoints:
Relationship between trough plasma and/or trough CSF concentrations of 
PKparameters for RO7234292 and efficacy endpoints
Relationship between trough plasma and/or trough CSF concentrations of PK 
parameters for RO7234292 and safety endpoints
2.4 EXPLORA TORY IMMUNOGENICITY OBJEC TIVE S
The exploratory immunogenicity objectives for this study are as follows:
To evaluate the immune response to RO7234292 on the basis of the following 
endpoints:
–Incidence of anti -drug antibodies (ADAs) at specified timepoints relative to 
the prevalence of ADAs at baseline.
–Determination of the ADA specificity followed by [CONTACT_626914] (titer) of the ADA response .
To evaluate potential effects of ADAs on the basis of the following endpoint:
–Relationship between ADA status and efficacy, safety, or PK endpoints .
2.5 EXPLORA TORY BIOMA RKER OBJECTIVE
The exploratory biomarker objective for this study is to identify biomarkers that are early 
surrogates of efficacy, are associated with progression to a more severe disease state 
(i.e., prognostic biomarkers), are associated with acquired resistance to RO7234292, are 
associated with susceptibility to developi[INVESTIGATOR_626843] (i.e., safety biomarkers), can provide evidence of RO7234292 activity 
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
30/Protocol BN40955, Version 7(i.e., PDbiomarkers), or can increase the knowledge and understanding of disease 
biology and drug safety, on the basis of the following endpoint s:
Relationship between biomarkers (e.g., tau and 
neurofilament light chain protein 
[NfL] ) in plasma and CSF (listed in Section 4.5.6 ) and efficacy, safety, PK, 
immunogenicity, or other biomarker endpoints
Relationship between imaging biomarkers and efficacy, safety, PK, immunogenicity, 
or other biomarker endpoints
2.6 HEA LTH STA TUS UTILIT Y OBJECTIVE
The exploratory health status utility objective for this study is to evaluate health status 
utility scores of patients treated with RO7234292 on the basis of the following endpoint:
Change from baseline in patient -reported EuroQol 5 -Dimension, 5 -Level 
Questionnaire ( EQ-5D-5L)Index and Visual Analog Scale ( VAS) scores at specified 
timepoints
3. STUDY DESIGN
3.[ADDRESS_835422] udy Design
This OLE study will evaluate the long -term safety and tolerability of RO7234292
administered ITto patients with HD.  In addition, the study will obtain long -term data on 
the efficacy, immunogenicity, exposure, and biomarkers of RO7234292 .
Effec tive 22 March 2021, dosing is paused, including enrollment. Patients already on 
the study will continue to be followed for safety and efficacy outcomes until study 
completion (see Appendix 1a, Appendix 1b, and Appendix 2b).
Only patients with prior enrollment in a [COMPANY_002] -sponsored or Genentech -sponsored study 
in HD for the RO7234292 development program that made provision for entry into an 
OLE study will be eligible for this OLE study.  The preceding [COMPANY_002] -sponsored or 
Genente ch-sponsored study must have been approved by [CONTACT_626915] ( IRB)/ Ethics Committee 
(EC) in a country in order for a patient from that country to be included in the OLE.
For patients who have participated in previous [COMPANY_002] studies, entry into this long -term, 
open -label extension study will occur at an inclusion visit. This inclusion visit is a 
combined visit with the preceding study's last applicable visit where patients are due for 
their end of treatment visit, last CSF collection, or safety follow -up unless otherwise 
specified, and serves as the baseline visit for the long -term, open -label extension study.  
For participants who have not participated in a previous [COMPANY_002] study, a separate 
screening visit will occur to determine eligibility into the long -term, open- label extension 
study. Patients who successfully meet eligibility criteria will then enter the study and 
attend the baseline study visit.   Patients who were enrolled in Study BN4 0423 before 
implementation of Version 4of that prot ocolwill be prematurely discontinued by [CONTACT_626916]7234292 F. Hoffmann -La [COMPANY_002] Ltd
31/Protocol BN40955, Version 7Sponsor from Study BN40423 and offered treatment in this study (Study BN40955) 
when it is available at sites.
If dosing at the inclusion visit is not possible, the Medical Monitor should be consulted 
and a short treatment interruption may be permitted.  For patients entering from 
Study BN40423 prior to implementation of Protocol Version 4, the inclusion visit should 
occur at the end- of-treatment visit for Study BN40423.
Patients who were screened and eligible for the placebo -controlled Phase III 
Study BN40423 (Generation -HD1) but were not randomized prior to the close of 
Study BN40423 enrollment due to logistical challenges resulting from the COVID -[ADDRESS_835423] applicable visit 
in Study BN40697, a separate inclusion visit should be scheduled (see Appendix 1a).
Upon completion of the inclusion visit, eligible patients will receive either 120 mg 
RO7234292 Q8 W (RO7234292 Q8 W arm) or 120 mg RO7234292 Q16W 
(RO7234292 Q16W arm) by [CONTACT_626917]. Patients will be assigned to treatment 
groups as described below and in Table 1 :
Patients who previously received open -label [ADDRESS_835424] 
CSF collection of the preceding study (if the inclusion visit is at the last visit in 

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
32/Protocol BN40955, Version 7the preceding study) or will be the first dose in Study BN40955 if a separate 
inclusion visit is required (see Appendix 1a).
After implementation of Study BN40955 Protocol Version 3, patients who are 
already enrolled in Study BN40955 will sign the amended Informed Consent Form 
(ICF) ator before their next clinic visit ,and will beassigned to either the 120mg 
RO7234292 Q8Wor 120mgRO7234292 Q16Warm, and then follow the schedule
of activities for Protocol Version 3 ( see Appendix 1a)matching treatment week 
according to Appendix 2at the clinic visit and going forward.
Patients who did not previously receive treatment with RO7234292 (e.g., from a 
natural history study ,eligible patients from Study BN40423 study who were not 
randomized due to logistical challenges resulting from theCOVID -19 pandemic ) or 
received short -term treatment ( 4 doses) with a treatment -free follow -up period will 
be randomly allocated to receive [ADDRESS_835425] at the inclusion 
visit.
Patients who previously received blinded placebo Q8W will be randomly allocated to 
receive [ADDRESS_835426] at the inclusion visit .
Patients who previously received blinded 120 mg of RO7234292 Q8W  will receive 
open -label 120 mg of RO7234292 Q8 W.
Patients who previously received blinded [ADDRESS_835427] safety follow -up visit of Study ML41885 (i.e .,safety follow -up [SFU1 ]).  The drug 
administered at the inclusion visit will be the firstdose in Study BN40955.  Patients who 
consent to be enrolled into this study (Study BN40955) will be assigned to a treatment 
group as shown below:
Patients who received open- label 120 mg of RO7234292 Q16 W will receive 
open -label 120 mg of RO7234292 Q16 W.
Patients enrolled in Study BN40423 prior to implementation of Protocol Version 4 will be 
prematurely discontinued from that study .  Patients who consent to be enrolled into this 
study (Study BN40955) will be assigned to treatment groups as shown below:
Patients who received blinded 120 mg of RO7234292 Q4W will be randomly 
allocated to receive open -label 120 mg of RO7234292 Q8 W or 120 mg of 
RO7234292 Q16 W.
Patients who received blinded 120 mg of RO7234292 Q8W will receive open -label 
120 mg of RO7234292 Q8 W.
Patients who received blinded placebo Q4 W will be randomly allocated to receive 
open -label 120 mg of RO7234292 Q8 W or 120 mg of RO7234292 Q16W .

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
33/Protocol BN40955, Version 7Table 1Treatment Regimen in Study  BN40955 Based on Previous 
Study Treatment
Preced ing Study Treatment Treatment Regimen
Open -label 120 mg RO7234292 Q4 W Randomized 1:1 to 120 mg RO7234292 Q8W  or 
120 mg RO7234292 Q16W
Open -label 120 mg RO7234292 Q8 W 120 mg RO7234292 Q8W
No treatment or 4 doses of 120 mg or less
RO7234292 with a treatment -free follow -up 
periodRandomized 1:1 to 120 mg RO7234292 Q8W  or 
120 mg RO7234292 Q16W  
Blinded placebo Q8W Randomized 1:1 to 120 mg RO7234292 Q8W  or 
120 mg RO7234292 Q16W  
Blinded 120 mg RO7234292 Q8 W 120 mg RO7234292 Q8W  
Blinded 120 mg RO7234292 Q16W 120 mg RO7234292 Q16W  
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
34/Protocol BN40955, Version 7Table 1Treatment Regimen in Study  BN40955 Based on Previous 
Study Treatment (cont.)
Preceding Study Treatment Treatment Regimen
For Patients enrolled into Study BN40423 prior to implementation of Study BN40423 Protocol 
Version 4:
Blinded 120 mg RO7234292 Q4 W Randomized 1:1 to 120 mg RO7234292 Q8W  or 
120 mg RO7234292 Q16W
Blinded 120 mg RO7234292 Q8 W 120 mg RO7234292 Q8W
Blinded Placebo Q4 W Randomized 1:1 to 120 mg RO7234292 Q8W  or 
120 mg RO7234292 Q16W
Open -label 120 mg RO7234292 Q16W 120 mg RO7234292 Q16W
Q4Wevery 4 weeks; Q8 Wevery 8 weeks; Q16Wevery 16 weeks.
For patients who did not previously receive treatment withRO7234292 (e.g. , from a 
natural history study ) or received short -term treatment (4 doses) , the end of study visit 
for the preceding study will serve as the inclusion visit for Study BN40955.   Forpatients 
who completed the full treatment course in the preceding study, the inclusion visit for 
Study BN40955 will take place at the visit at which the last dose was administered . 
Forpatients enrolled in Study BN40423 prior to implementation of Protocol Version [ADDRESS_835428] applicable visit in 
Study BN40697, a separate inclusion visit should be scheduled (see Appendix 1a). 
Atthe inclusion visit for Study BN40955, clinical ratings an d assessments that are 
common between the preceding study and Study BN40955 will be completed once and 
will serve both studies. Clinical ratings and assessments required in Study BN40955 
that were not completed as part of the preceding study will also nee d to be completed at 
the inclusion visit.Patients who were eligible for Study BN40423 (GENERATION -HD1) 
but were not randomized due to logistical challenges resulting from theCOVID -19 
pandemic will undergo screening and inclusion visit s, see details of assessments in 
Appendix 1band Appendix 5.
Patients will undergo safety and tolerability evaluations that include neurologic 
examinations, vital signs, ECGs, clinical laboratory tests, Montreal Cognitive 
Assessment (MoCA), C -SSRS, neuroimaging assessments and reporting of AEs and 
concomitant medications, as detailed in Appendix 1aandAppendix 1b. Patients 
enrolling from Study BN40697 will have an optional MRI of brain and spi[INVESTIGATOR_626844], in addition tothe other brain neuroimaging assessments.

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
35/Protocol BN40955, Version 7In case of a failed IT bolus dosing procedure (e.g., due to an inadequate establishment 
of access to the IT space), a second dosing attempt may occur up to 7 days after the 
originally scheduled dosing attempt . Forthis additional visit, safe ty and tole rability 
evaluations on the da y of LP a dministration  will be performed as detailed inAppendix 1a
and Appendix 1b, including neurological examination (predose and postdose), vital signs, 
and a review of AEs and concomitant medication .If the second dosing attempt occurs 
more than [ADDRESS_835429], local laboratory 
analysis of coagulation factors (INR and/or PT, aPTT) and platelets need to be 
conducted again  and results revi ewed prior to the LP attempt (see Appendix 1aand 
Appendix 1b).
Telephone safety follow -up call swill be conducted between dosing visits to check for 
any change in patient status (i.e.,AEs, concomitant medications) since last visit
(see Appendix 2).Depending on the patient’s health status, an unscheduled clinic visit 
may be arranged.  If a patient is due for a telephone s afety call and they are in -clinic 
then this telephone safety follow -up call can be completed in-clinic at the site’s discretion. 
As a result of the COVID -[ADDRESS_835430] patient to the end of the study, is 
expected to be approximately 6years. It is expected that patients may participate for a 
minimum of 6 months and a maximum of approximately 6years in Study BN40955.
3.3 RATIONA LE FOR STUDY DESIGN
3.3.1 Rationale for RO7234292 Dose and Schedule
Effective 22 March 2021 dosing in this study (BN40955) is paused. On 18 Mar 2021, 
the BN40423 iDMC recommended that dosing be stopped in the Phase III randomized 
controlled trial .  Because the OLE is exploring the same dosing regimens (i.e., 
RO7234292 120 mg Q8W and Q16W )the Sponsor made a decision to pause dosing in 
the OLE until further data assessments can be conducted.
In this study, RO7234292 will be administered either Q8W(RO7234292 Q8W  arm) or 
Q16W(RO7234292 Q16W  arm) by [CONTACT_626918].   The dose and dosing regimen 
administered in this study was initially the same as the dose and dosing regimen 
selected for the Phase III Study BN40423, a double -blind, placebo -controlled study of 
RO7234292 administered Q4 W and Q8W  by [CONTACT_626919] [ADDRESS_835431] the 

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
36/Protocol BN40955, Version 7120mgQ4W regimen with a [ADDRESS_835432] that brain tissue lowering of mHTT protein in the range of 
30%60% is associated with beneficial effects on the disease phenotype , which 
corresponds to a trough CSF lowering range of 2 0%40%based on a non -human 
primate PK/PD model.
Because of this uncertainty, 2active dosing regimens will be used in this study:  
RO7234292 Q8 W (RO7234292 Q8 W arm) and RO7234292 Q16W  (RO7234292 Q16 W 
arm), by [CONTACT_626918].
The 120 -mg dose has been chosen for the Q8Wdosing group based on the following:
In the chronic toxicology study in cynomolgus monkeys, the 
no-observed -adverse- effect level was determined to be at least 35 mg/dose 
(thehighest dose tested) .  Conservatively correcting for differences in CSF volume 
between cynomolgus monkeys ( 15 mL) and humans ( 150 mL) with a scaling 
factor of 10, the human equivalent dose corresponds to 350 mg, representing a 
3-fold safety margin to the proposed 120 -mg clinical dose.
Both the 90 -mg and 120 -mg RO7234292 Q4 W groups in the Phase I/IIa study 
(ISIS 443139 -CS1) resulted in a median CSF mHTT protein reduction of 
approximately 40%, with individual cases reaching approximately 60% reduction at 
trough, well above the described nonclinical threshold for efficacy.  The 120- mg
dose group exhibited a more consistent decline compared with the 90 -mg dose 
group .
In the same Phase I/IIa study, 120 mg of RO7234292 administered ITQ4W  for 
4doses was safe and well -tolerated compared with placebo.  See additional details 
in the RO7234292 Investigator's Brochure.
In approximately 70% of patients (23 of 34 patients) assigned to receive 
RO7234292 in the Phase I /IIastudy, CSF mHTT protein was declining at the last 
trough measurement (either Day 113 or 141), suggesting sustained reduction of 
CSF mHTT protein up to 2 months postdose (last timepoint assessed) .
In the 120 -mg RO7234292 group in the Phase I/IIa study, CSF mHTT protein levels 
were reduced by [CONTACT_2669] 35% in all 5 cases for which a Day 141 sample was 
collected (i.e., [ADDRESS_835433] dose), in line with the observe d Q8 W OLE 
data).
Data from the ongoing Phase II OLE Study BN40697 (ISIS 443139 -CS2) showed 
that 120-mg doses administered in Q4W and Q8W  regimens achieved 66% and 47% 
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
37/Protocol BN40955, Version 7median reductions of CSF mHTT from baseline at trough, respectively, after 
9months.  Bot h results exceed the 20% 40% target for CSF mHTT lowering at 
trough and steady state based upon efficacy data from nonclinical models, and 
exceed the result of approximately 40% median lowering observed in the completed 
Phase I/IIa study.  The observed eff ects on CSF mHTT lowering in the OLE after 
administration of 3or 4doses of 120 mg were also approximately 40%, consistent 
with results from the Phase I/IIa study (ISIS 443139 -CS1) .
Review of safety and tolerability data for RO7234292 from the ongoing Phase II 
OLE suggest sthat relative to the Q4 W treatment regimen, the Q8 W treatment 
regimen may be more suitable for chronic IT dosing.  This is supported by 
[CONTACT_626920], decreased proportion of patients with moderate 
AEs, and fewer AEsconsidered possibly related to study drug in the Q8 W regimen 
compared to the Q4 W regimen (for details see the RO7234292 Investigator’s 
Brochure).
The 120 -mg dose has been chosen for the Q16W  dosing group based on the following:
The nonclinical PK/PD model and updated clinical PK/PD model predicted the 
observed Q8 W 9-month reductions (for details see the 
RO7234292 Investigator’s Brochure).  From th esemodel s, a Q16 W regimen is 
predicted to result in median CSF HTT trough lowering of 20% -25%, within the 
range of the 20% 40% target for CSF mHTT lowering at trough and steady state .
Model predicted a cute lowering for the 120 mg Q16W  regimen is around 
35%40% CSF mHTT reduction, above observed threshold for efficacy based upon 
nonclinical models .
Maintenance of trough lowering is not a necessary feature of this less frequent arm 
to test the primary hypothesi s.  The hypothesis of this 120 mg Q16 W arm (acute 
lowering, followed by [CONTACT_626921]) is supported by [CONTACT_626922] -mediated lowering of HTT protein is associated with 
sustained phenotypic benefit in the BACHD model (Kordas iewicz et al. 2012).  
Efficacy in this model is sustained for 6months even after a complete recovery of 
target mRNA and protein .
Testing the less frequent regimen is of high interest to mitigate potential unknown 
long-term complications associated with a more frequent IT dosing of [ADDRESS_835434] 
concentrations when administered systemically (Schoch andMiller 2017).  Therefore , 
the IT drug delivery method will be used in this trial, as presently no alternatives exist.
In summary, a 120mg Q8W  dosing regimen and the less frequent dosing regimen of 
120mg Q16 W have been selected for this OLE extension study to be consistent with 
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
38/Protocol BN40955, Version 7changes to the Phase III Study BN40423 in order to evaluate the long -term safety and 
tolerability of RO7234292 in patients with HD.
3.3.2 Rationale for Biomarker A ssessments
[IP_ADDRESS] Cerebrospi[INVESTIGATOR_626845].  A toxic gain -of-function mechanism of mHTT
protein is widely considered to be the primary driver of disease pathophysiology in HD 
(WildandTabrizi 2017 ).  Mutant HTT protein in human CSF is as sociated with disease 
stage and severity and with biomarkers of neuronal damage, including CSF (NfL) and
CSF tau levels ( Wildet al. 2015 ).  Neurofilament light chain protein levels in CSF predict 
progressive MRI measures of brain atrophy, as well as progressive clinical decline in 
patients (W ild and Tabrizi 2017). Longitudinal analysis of mHTT, NfL, tauandother 
biomarkers related to HD ,neurodegeneration, and inflammation in CSF may extend the 
current understanding of HD pathophysiology and progression and provide further data 
on how these putatively prognostic and potentially predictive biomarkers will respond to 
disease- modifying treatment.
[IP_ADDRESS] Blood Biomarkers
Neurofilament light chain protein levels in blood correlate with NfL levels in CSF and 
could serve as prognostic blood biomarkers of disease onset and progression in HD 
(By[CONTACT_129120].2017; Johnson etal.2018 ).  Longitudinal analysis of NfL and other 
biomarkers related to HD, neurodegeneration, and inflammation in blood may facilitate 
understanding of HD pathophysiology and progression.
[IP_ADDRESS] Magnetic Resonance Imaging
Magnetic resonance imaging is a non -invasive method to assess structure and function 
of the human brain and can provide insights into pathophysiological mechanisms of 
neurologic and neuropsychiatric disease. Several MRI techniques have shown 
sensitivity to detect abnormal structure and function within brains of individuals suffering 
from HD.
All patients will u ndergo MRIs every [ADDRESS_835435] of long -term 
treatment and LP on brain structure and function. All of the measures will be assessed 
in a consistent manner with the preceding study, including those designated to be 
optional .The acquisition parameters of each sequence, structure, and length of each 
MRI session and image processing algorithms will be outlined in a separate MRI 
manual.
Unscheduled MRIs in 3 patients who received monthly IT procedures in Study BN40697 
reported enhanc ement in the cauda equina region; MRIs will be explored in this 
extension study to further assess the impact of frequent IT procedures.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
39/Protocol BN40955, Version 7For this purpose, in consenting patients from Study BN40697, optional MRI scans of 
brain and spi[INVESTIGATOR_626846] w ill be collected upon study entry and every 
32weeks thereafter (for additional details refer to 
Study BN40955 IxicoSafety Read Manual ). The contrast brain and spi[INVESTIGATOR_626847] -house or by [CONTACT_298756]- hoc independen t external neuroimaging expert sto look for 
the occurrence of abnormal MRI findings .
[IP_ADDRESS] Safety  Biomarkers
Exploratory research on safety biomarkers may be conducted to support future drug 
development.  Research may include further characterization of a safety biomarker or 
identification of safety biomarkers that are associated with susceptibility to developi[INVESTIGATOR_626848].  Adverse event reports will 
not be derived from safety biomarker data by [CONTACT_1034], and safety biomarker data 
will not be included in the formal safety analyses for this study.  In addition, safety 
biomarker data will not inform decisions on patient management.
4. MATERI ALS AND METHOD S
4.[ADDRESS_835436] meet the following criteria for study entry:
Signed ICF
If capacity to consent is in question, formal capacity assessment by [CONTACT_626923].  In cases where 
capacity to consent is not fully present, but the participant is known previously 
to have favored participation in an open -label study and is able to assent, 
consent may be obtained by a legally authorized representative.  
(Note: Patients in [LOCATION_013] who are not fully capable of providin g informed 
consent are not eligible for inclusion).
Prior enrollment in a [COMPANY_002] sponsored or Genentech -sponsored study in HD for the 
RO7234292 development program that made provision for entry into an OLE study
(refer to Appendix 11)
Ability and willingness to comply with the study protocol including the visit schedule and 
all assessments, in the investigator's judgment
For women of childbearing potential:  Agreement to r emain abstinent (refrain from 
heterosexual intercourse) or use contraceptive measures, as defined below:

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
40/Protocol BN40955, Version 7Women must remain abstinent or use 2methods of contraception, including at 
least 1method with a failure rate of 1% per year, during the treatment period 
and for [ADDRESS_835437] -menarchal, 
has not reached a postmenopausal state ( 12continuous months of 
amenorrhea with no identified cause other than menopa use), and has not 
undergone surgical sterilization (removal of ovaries and/or uterus).  
Thedefinition of childbearing potential may be adapted for alignment with local 
guidelines or requirements.
Examples of contraceptive methods with a failure rate of 1% per year include 
bilateral tubal ligation, male sterilization, established proper use of hormonal 
contraceptives that inhibit ovulation, hormone -releasing intrauterine devices, 
and copper intrauterine devices.  A vasectomized man must undergo a medical 
assessment that confirms the success of the surgery before he can be 
considered surgically sterile.
Hormonal contraceptive methods must be supplemented by a barrier method.
The reliability of sexual abstinence should be evaluated in relation to the 
duration of the clinical trial and the preferred and usual lifestyle of the patient.  
Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation 
methods) and withdrawal are not acceptable methods of contraception.
For men:  Agreement t o remain abstinent (refrain from heterosexual intercourse) or 
use a condom, and agreement to refrain from donating sperm, as defined below:
With a female partner of childbearing potential or pregnant female partner, men 
must remain abstinent or use a condo m during the treatment period and for 
5months after the final dose of study drug to avoid exposing the embryo.  
Men must refrain from donating sperm during this same period.
The reliability of sexual abstinence should be evaluated in relation to the 
durat ion of the clinical trial and the preferred and usual lifestyle of the patient.  
Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation 
methods) and withdrawal are not acceptable methods of preventing drug 
exposure .
The following eligibility criteria only apply to patients who were eligible for 
Study BN40423 (GENERATION -HD1) but were not randomized due to logistical 
challenges resulting from the COVID -[ADDRESS_835438] meet the following criteria for study entry during scr eening (some will be 
reassessed at the inclusion visit prior to randomization and study drug dosing):
Signed ICF
Age 25 65years, inclusive, at the time of signing of ICFand at the time of first dose 
administration
Manifest HD diagnosis, defined as a diagnostic confidence level (DCL) score of 4 
(refer to Appendix 6)

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
41/Protocol BN40955, Version 7Independence Scale (IS) score 70
Genetically confirmed disease by [CONTACT_626896] a CAG -Age product (CAP) 
score 400 (Zhang et al. 2011), calculated as follows:
CAPAge(CAG repeat length 33.66)
Ability to read the words red, blue,and green in native language
Ability to walk unassisted without a cane or walker and move about without a 
wheelchair on a daily basis as determined at screening and baseline visit
–Long -distance (e.g., 50meters) use of wheelchairs for convenience or transfer 
is permitted.
Body mass index 16 32kg/m2; total body weight 40kg
Ability to undergo and tolerate MRI scans (e.g., no claustrophobia, no severe chorea 
or other condition that precludes MRI scans or renders scanning intolerable for the 
patient, no MRI -incompatible intrauterine devices, m etallic dental braces, or other 
metal implants)
Ability to tolerate blood draws and LPs
Creatinine clearance (CrCl) 60 mL/min (Cockcroft -Gault formula)
Ability and willingness, in the investigator's judgment, to comply with all aspects of 
the protocol including completion of interviews and questionnaires for the duration of 
the study
Stable medical, psychiatric, and neurological status for at least 12 weeks prior to 
screening and at the time of enrollment
4.1.2 Exclusion Criteria
Patients who meet any of the following criteria will be excluded from study entry:
Withdrawal of consent from the preceding study
Permanent discontinuation of RO7234292 for any drug-related safety concern
during the preceding study or meeting of any study treatment discontinuation cr iteria 
specified in the preceding study at the time of enrollment into this study
An ongoing, unresolved, clinica lly significant medical problem that in the judgment of 
the investigator would make it unsafe for the patient to participate in this study
Antiplatelet or anticoagulant therapy within 14 days prior to inclusion or anticipated 
use during the study, including, but not limited to, aspi[INVESTIGATOR_248] (unless 81 mg/day), 
clopi[INVESTIGATOR_7745], dipyridamole, warfarin, dabigatran, rivaroxaban, and api[INVESTIGATOR_3822]
History of bleeding diathesis or coagulopathy
Platelet count less than the lower limit of normal
Platelet counts between 125,000 and 150,000 mm3are permissible as long as 
the investigator confirms there is no evidence of current bleeding diathesis or 
coagulopathy.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
42/Protocol BN40955, Version 7Concurrent participation in any therapeutic clinical trial (other than the preceding 
study)
Study treatment ( RO7234292 ) is commercially marketed in the patient’s country for 
the patient -specific disease and is accessible to the patient
Pregnant or breastfee ding, or intending to become pregnant during the study or 
within 5months after the final dose of study drug
Women of childbearing potential must have a negative urine pregnancy test at 
the inclusion visit (obtained as part of the preceding study assessmen ts).
The following exclusion criteria only apply to patients who were eligible for 
Study BN40423 (GENERATION -HD1) but were not randomized due to logistical 
challenges resulting from the COVID -19 pandemic.
Patients who meet any of the following criteria wi ll be excluded from study entry:
History of attempted suicide or suicidal ideation with plan (i.e., active suicidal 
ideation) that required hospi[INVESTIGATOR_601316]/or change in level of care within 12 months 
prior to screening
Current suicidal ideation is demonstrated by [CONTACT_941] C -SSRS per judgment of the 
investigator.  If suicidal ideation is present, a risk assessment should be 
completed by [CONTACT_626924].  Mild passive 
suicidal ideation (i.e., occasional thoughts that life is not worth living or is hard) 
without history of attempts or hospi[INVESTIGATOR_601317] 12 months is 
generally acceptable for study participation , but final decision on participation 
should be made carefully and in consultation with an appropriately qualified 
mental health professional.
Current active psychosis, confusional state, or violent behavior
Any serious medical condition or clinically sign ificant laboratory, or vital sign 
abnormality or claustrophobia at screening that, in the investigator's judgment, 
precludes the patient's safe participation in and completion of the study
History known to the investigator or presence of an abnormal ECG th at is clinically 
significant in the investigator's opi[INVESTIGATOR_1649], including complete left bundle branch block, 
second- or third -degree atrioventricular heart block, or evidence of prior myocardial 
infarction
Lifetime clinical diagnosis of chronic migraines
Presence of an implanted shunt for the drainage of CSF or an implanted CNS 
catheter
Positive for hepatitis C virus (HCV) or hepatitis B surface antigen (HBsAg) at 
screening
Known HIV infection
Current or previous use of an ASO (including small interfering RNA)
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
43/Protocol BN40955, Version 7Current or previous use of anti -psychotics prescribed for a primary independent 
psychotic disorder (i.e., schizophrenia, schizoaffective disorder, bipolar disorder 
type I, severe with psychotic features), cholinesterase inhibitors, memantine, 
amantadi ne, or riluzole within 12 weeks from initiation of study treatment
Treatment with investigational therapy within 4 weeks or 5 drug-elimination half -lives 
prior to screening, whichever is longer
History of gene therapy, cell transplantation, or any experime ntal brain surgery
Drug (i.e., cannabis, opi[INVESTIGATOR_2480], stimulant, hallucinogen, designer) and/or alcohol abuse 
or psychological or physiological dependency within 12 months prior to screening, 
as per the investigator's judgment
Abuse is defined as a maladaptive pattern of use that leads to failure to fulfill 
major work or social obligations or use in situations where it leads to physical 
danger or legal problems, and may be the focus of clinical attention.
Poor peripheral venous access
Scoliosis or spi[INVESTIGATOR_626849]7234292 up the 
neuraxis
An infection requiring oral or IV antibiotics within 14 days prior to screening and prior 
to randomization
Antiretroviral medications, including antiretroviral medication taken as prophylaxis 
within 12 months of study enrollment
Malignancy within 5 years prior to screening, except basal or squamous cell 
carcinoma of the skin or carcinoma in situ of the cervix tha t has been successfully 
treated
Preexisting intra- axial or extra -axial lesions (e.g., tumor, arterio -venous 
malformation, meningiomas, hydrocephalus, subdural haematoma) as assessed by 
a centrally read MRI scan during the screening period
4.[ADDRESS_835439] the opportunity to receive treatment with either 
120mgRO7234292 Q8W  or 120 mg RO7234292 Q16 Wand will be assigned to 
treatment as described in Table 1 . An independent interactive voice or web -based 
response system (IxRS) provider will assign patients to treatment and conduct 
randomization where required. If, during the course of the study , a single regimen is 
selected for the development program, all patients will then be assigned to the selected 
regimen .
All patients, study site personnel, Sponsor agents, and Sponsor personnel will be 
unblinded to the treatment assignment of this study; h owever, the treatment assignment 
from a blinded preceding study will remain blinded until the preceding study is unblinded.

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
44/Protocol BN40955, Version 7An IxRS provider will hold the treatment assignment code to maintain the integrity of the 
blinding (active versus placebo) in the preceding study.
4.[ADDRESS_835440] (IMP) for this study is RO7234292.
4.3.1 Study Treatment Formulatio n, Packaging, and Handling
[IP_ADDRESS] RO7234292
RO7234292 will be supplied by [CONTACT_319071], preservative -free liquid in a 
20-mL single -use vial containing 10 mL of 6.0 mg/mL RO7234292 drug product for 
ITinjection. For a 120- mg dose (20 -mL dosing volume), 2vials containing 10 mL of 
6.0mg/mL RO7234292 will be pooled by [CONTACT_626925] 20 mL of study drug.
For information on the formulation, study drug preparation, storage, and handling of 
RO7234292, refer to the p harmacy manual.
4.3.2 Study Treatment Dosage, A dministration, and Compliance
The treatment regimens are summarized in Section 3.1.
Any dose modification sh ould be noted on the Study Drug Administration electronic 
Case Report Form (eCRF) .  Cases of accidental overdose or medication error, along 
with any associated AEs, should be reported as described in Section [IP_ADDRESS].
Guidelines for treatment interruption or discontinuation for patients who experience AEs
are provided in Section 5.1.3 .
[IP_ADDRESS] RO7234292
Each dose of RO7234292 (120 mg) will be administered as a single IT bolus injection of 
20mLby a qualified physician experienced in performing LPs.  Inexceptional 
circumstances, study staff who are licensed physician assistants or nurse practitioners 
with extensive experience of performing LPsand administrating IMP for ASOs ITmay be 
acceptable with Sponsor approval.
Guidelines for treatment interruptio n or discontinuation for patients who experience AEs
are provided in Section 5.1.[ADDRESS_835441] A ccountability
All IMPs required for completion of this study ( RO7234292 ) will be provided by [CONTACT_626926] (HA) regulations.  The study site will 
acknowledge receipt of IMPs supplied by [CONTACT_1034], using the IxRS to confirm the 
shipment condition and content.  Any damaged shipments will be replaced.

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
45/Protocol BN40955, Version 7IMPs will either be disposed of at the study site according to the study site's institutional 
standard operating procedure or be returned to the Sponsor (if supplied by [CONTACT_1034]) 
with the appropriate doc umentation.  The site's method of destroying Sponsor -supplied 
IMPs must be agreed to by [CONTACT_1034].  The site must obtain written authorization from 
the Sponsor before any Sponsor -supplied IMP is destroyed, and IMP destruction must 
be documented on the ap propriate form.
Accurate records of all IMPs received at, dispensed from, returned to, and disposed of by 
[CONTACT_25729].
4.3.4 Continued A ccess to RO7234292
The Sponsor will offer continued access to [COMPANY_002] IMP (RO7234292 ) free of charge to 
eligible patients in accordance with the [COMPANY_002] Global Policy on Continued Access to 
Investigational Medicinal Product , as outlined below.
A patient will be eligible to receive [COMPANY_002] IMP (RO7234292) after completing the study i f 
allof the following conditions are met:
The patient has a life- threatening or severe medical condition and requires 
continued [COMPANY_002] IMP treatment for his or her well -being
There are no appropriate alternative treatments available to the patient
The patient and his or her doctor comply with and satisfy any legal or regulatory 
requirements that apply to them
A patient will not be eligible to receive [COMPANY_002] IMP (RO7234292) after completing the 
study if anyof the following conditions are met:
The [COMPANY_002] IMP is commercially marketed in the patient's country and is reasonably 
accessible to the patient (e.g., is covered by [CONTACT_102]'s insurance or wouldn't 
otherwise create a financial hardship for the patient)
The Sponsor has discontinued development of th e IMP or data suggest that the IMP 
is not effective for HD
The Sponsor has reasonable safety concerns regarding the IMP as treatment for 
HD
Provision of the [COMPANY_002] IMP is not permitted under the laws and regulations of the 
patient's country
The [COMPANY_002] Global Policy on Continued Access to Investigational Medicinal Product is 
available at the following website:
http://www.roche.com/policy_continued_access_to_investigational_medicines.pdf
4.4 CONCOMITA NT THERA PY
Concomitant HD therapy should constitute the optimal supportive care for the individual 
according to the investigator's own best clinical judgment.   Concomitant therapy consists 
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
46/Protocol BN40955, Version 7of any medication (e.g., prescription drugs, over -the-counter drugs, vaccines, herbal or 
homeopathic remedies, nutritional supplem ents) used by a patient in addition to 
protocol -mandated treatment from the time of entry into Study BN40955 to the study 
completion/discontinuation visit.  All such medications should be reported to the 
investigator and recorded on the Concomitant Medicat ions eCRF.
4.4.1 Permitted Therapy
Throughout the study, investigators or treating physicians may prescribe concomitant 
medications or treatment deemed necessary to provide adequate supportive care or for 
treatment of AEs.
In general, investigators should manage a patient's care with supportive therapi[INVESTIGATOR_40801], per local standard practice.
4.4.2 Prohibited Therapy
Use of the following concomitant therapi[INVESTIGATOR_204721]:
Experimental agents or marketed HD agents at experimental doses that are being 
tested for the treatment of HD, including, but not limited to, cholinesterase inhibitors, 
memantine, amantadine, and riluzole
Antiplatelet or anticoagulant therapy, including, but not limited to, aspi[INVESTIGATOR_248] 
(unless 81mg/day), clopi[INVESTIGATOR_7745], dipyridamole, warfar in, dabigatran, rivaroxaban, 
and api[INVESTIGATOR_3822]
Sedation for LPor IT bolus procedures in the study
Depending on institutional guidelines , local anesthesia is permissible for the LP
procedure .
Anti-anxiety medication is strongly discouraged during scheduled MRI scans .
Ifanti-anxiety medication is used, the scan must be performed at the end of the 
assessment day (before the LP )or preferably on a different day, to avoid impacting 
other assessments.
4.5 STUDY ASSESSMENTS
The schedule of activities to be performed during the study is provided in Appendix 1a
and Appendix 1b.  All activities should be performed and documented for each patient.
Patients will be closely monitored for safety and tolerability throughout the study.  
Patients should be assessed for toxicity prior to each dose; dosing will occur only if the 
clinical assessment and local laboratory test values are acceptable.   Effective 22 March 
2021, dosing is paused, including enrollment.  Patients already on the study will 
continue to be followed for safety and efficacy o utcomes until study completion (see
Appendix 1a, Appendix 1b, and Appendix 2b).

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
47/Protocol BN40955, Version 74.5.[ADDRESS_835442] be obtained before 
performing any study -related procedures (including any screening evaluations , 
ifapplicable ).  Informed Consent Forms for patients will be maintained at the study site, 
regardless of whether the patient is subsequently enrolled .  If a patient's capacity to 
consent is in question, the investigator should consult an appropriately qualified 
colleague who will independently assess capacity.  This additional assessment should 
also be documented.  If the patient is judged to have questionable capacity, then assent 
of the patient in addition to signed consent by a legally authorized representative is 
required for study participation.  (Note: Patients in [LOCATION_013] who are not fully capable of 
providing informed conse nt are not eligible for inclusion) .  If the patient’s capacity is 
confirmed, the investigator may proceed with the patient's signing of the ICF.
All screening (if required) and inclusion visit evaluations must be completed and
reviewed to confirm that patients meet eligibility criteria before enrollment.  
Theinvestigator will maintain a screening log to record details of all patients evaluated
and to confirm eligibility or record reasons for inclusion failure, as applicable.
Patients who are required to undergo screening will be allowed a maximum of 
1re-screening within 8 weeks of the initial screening failure for patients who fail the initial 
screening (e.g., as a consequence of abnormal laboratory values or general medical 
status not meeting inclusion or exclusion criteria). The CAG repeat length testing from 
Q2 Solutions will be accepted for this study. If re-screening is required, the CAG repeat 
length testing from Q2 Solutions does not need to be repeated.
4.5.2 Medical Histor y, Concomitant Medication, and Demographic 
Data
Medical history, including clinically significant diseases, surgeries, and reproductive 
status will be recorded atscreening (patients required to undergo screening only) and
baseline (inclusion visit) .  In addition, all medications (e.g .,prescription drugs, 
over-the-counter drugs, vaccines, herbal or homeopathic remedies, nutritional 
supplements) used by [CONTACT_626927]40955 to the study 
completion/discontinuation visit .  At the time of each study drug administration, a n 
interval medical history should be obtained and any changes in medications should be 
recorded.
Demographic data will include age, sex, self -reported race/ethnicity , and education level 
based on the International Standard Classification of Education scale will be recorded at 
screening (patients required to undergo screening only) and baseline (inclusion visit) for 
all patients except those undergoing screening .  Race/ethnicity is recorded because of 
the poten tial contribution of this variable to differences in observed PK, PD , toxicity, 
and/or response to treatment.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
48/Protocol BN40955, Version 7The protocol number and patient number of the preceding study will be collected, as well 
as the patient’s H untington’s disease identification number (HDID ).  For patients without 
an HDID, the number will be created via a web portal (see Section 8.4).
4.5.3 Physical and Neurologic Examinations
A complete physical examination, performed at specified visits (see Appendix 1aand 
Appendix 1b), should include an evaluation of the head, eyes, ears, nose, and throat, 
and the cardiovascular, dermatologic, musculoskeletal, respi[INVESTIGATOR_696], gastrointestinal, and 
neurologic systems; genitourinary examinations may be performed if clinically indicated.  
The physical examinati ons should be conducted in the same manner on each occasion 
to ensure comparability to previous examinations , including weight at each visit . 
Height will be obtained from thepreceding study. For patients required to undergo 
screening, height will be col lected at screening only.
A neurologic examination , including fundoscopy , performed at screening (patients 
required to undergo screening only), inclusion and at every clinical visit, should include
assessment of mental status, level of consciousness, crani al nerve function, motor 
function, sensory function, reflexes, gait, and coordination (see Appendix 12).  
Theneurologic examinations should be conducted in the same manner on each 
occasion to ensure comparability to previous examinations.  Neurologic examinations 
should be performed before and after treatment on each dosing day , or before the 
lumbar puncture, if there is no study treatment administration .
Any abnormality identified at screening (patients required to undergo screening only) 
and baseline (inclusion visit) should be recorded on the General Medical History and
Baseline Conditions eCRF.  Changes from baseline abnormalities should be recorded in 
patient notes.  New or worsened clinically significant abnormalities (i.e., beyond 
expected variation ;normal age -related change ; or HD -relate d clinical progression )
should be recorded as AEs on the Adverse Event eCRF.
4.5.[ADDRESS_835443] 5 minutes.  All data should be recorded on the appropriate eCRF.
4.5.5 Collection of Cerebrospi[INVESTIGATOR_17106] (Lumbar Puncture Procedure)
Within 72 hours prior to performing each scheduled LP , local laboratory analysis of 
coagulation factors (INR and/or PT, aPTT) and platelets must be conducted and the 
results reviewed.  The LPshould be performed at approximately the same time at each 
visit (ideally in the morning between 8:00 a.m. and 12:00 p.m.or in the early afternoon 
between 12:00 p.m.and 3:00 p.m.) to minimize potential diurnal variation of CSF 
parameters.  Cerebrospi[INVESTIGATOR_75528](20 mL) is to be collected for analyses using a 
LPcollection kit.  If there are difficulties in collecting 20 mL of CSF, a minimum of 5 mL 

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
49/Protocol BN40955, Version 7should be collected over a maximum of [ADDRESS_835444] LPsyndrome.
Depending on institutional guidelines, local anesthesia should be used for the procedure.  
Sedation may not be used.  Spi[INVESTIGATOR_626850], but ultrasound is not required.  Ultrasound guidance may be used i f 
attempts at LPwithout imaging are unsuccessful , if it is local practice to use ultrasound, 
or if institutional guidelines dictate use of ultrasound with each LP.Fluoroscopy 
guidance can also be used, if local institutional guidelines dictate and local ECs /IRBs
and HAs have approved the use of the technique, but it is not required. Where 
fluoroscopy is used, patients should also be informed and consent obtained .
For details on the LPand IT bolus dosing procedure, refer to the LP procedure and CSF 
collection guidelines and instructional video.
When applicable, study treatment administration will occur via a LPusing a needle 
inserted into the L3/L4 space, although placement at a different level (either in the space 
above or the space below) is allowed if patient anatomy or clinical judgment dictates.  
The left lateral position is mandatory in the first instance for the procedure for 
consistency of procedure practic e across sites and within patients, unless patient -
specific factors require use of the upright, sitting position or the physician/operator has 
preexisting experience using LP/ITbolus dosing in the sitting position and prefers the 
use of the upright sittin g position.  W hichever position is used, once access is 
established to the IT space, the entire IT bolus procedure should be completed in the 
same position, to limit the risk of the needle losing position while the spi[INVESTIGATOR_626851]. Subsequent LP administrations should preferably occur using the same 
position.
Patients will be discouraged from resting supi[INVESTIGATOR_626852] a minimum and, if feasible, 
walking briskly for approximately [ADDRESS_835445] LP 
procedure (e.g., air travel, scuba diving, or hot air balloons).
In case of a failed IT bolus dosing procedure (e.g., due to an inadequate establis hment 
of access to the IT space), a second dosing attempt may occur up to 7 days after the 
originally scheduled dosing attempt. For this additional visit, safet y and tolerability 
evaluations on the day o f LP adminis tration will  be performed  as det ailed in Appendix 1a
and Appendix 1b, including n eurological examination (predose and postdose), vital signs, 
and a review of AEs and concomitant medication. If the second dosing attempt occurs 
more than [ADDRESS_835446] , local laboratory 

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
50/Protocol BN40955, Version 7analysis of coagulation factors (INR and/or PT, aPTT) and platelets need to be 
conducted again and results reviewed prior to the LP attempt (see Appendix 1aand 
Appendix 1b).
Lumbar punctures will be performed as specified in the schedule of activities 
(s
eeAppendix 1a,Appendix 1b,and Appendix 2b), with the last CSF sample obtained at 
the end -of-treatment visit for this study.  No study drug will be administered at that visit.
4.5.6 Laboratory , Biomarker, and Other Biological Samples
Samples for the following laboratory tests will be sent to the study site's local laboratory 
for analysis:
Coagulation:  INR and/or PT, aPTT, and platelet count
Urine pregnancy test
Urine pregnancy tests will be performed for women of childbearing potential at 
specified visits.  If aurine pregnancy test is positive, it must be confirmed by a 
serum pregnancy test (analyzed at a central laboratory) .
Cerebrospi[INVESTIGATOR_626853]:  cel l count (including RBCs and WBCs), glucose , and 
protein
Samples for the following laboratory tests will be sent to acentral laboratory:
Hematology:  WBC count, RBC count, platelet count, hemoglobin, hematocrit, and 
differential count (neutrophils, eosino phils, basophils, monocytes, lymphocytes)
Serum chemistry panel:  bicarbonate or total carbon dioxide (if considered standard 
of care for the region), sodium, potassium, chloride, glucose, BUN or urea, 
creatinine, total protein, albumin, phosphorus, calciu m, total and direct bilirubin, ALP, 
ALT, AST, uric acid, gamma- glutamyl transferase, and CPK
Serum pregnancy test
Serum pregnancy tests will be performed for women of childbearing potential to 
confirm a positive urine pregnancy test (if applicable) .
Serum pregnancy test will be performed for women of childbearing potential at 
screening (patients undergoing screening only ).At subsequent visits it will be 
performed to confirm a positive urine pregnancy test (if applicable).
Urinalysis, including dipstick (pH, specific gravity, glucose, protein, ketones, blood) 
and microscopic examination for all abnormal dipstick results (sediment , RBCs,
WBCs, casts, crystals, epi[INVESTIGATOR_1663], bacteria)
Cerebrospi[INVESTIGATOR_535965] (plasma) samples for PK analyses
Blood (plasma) samples for immunogenicity analyses
Cerebrospi[INVESTIGATOR_626854]
Plasma and CSF samples for exploratory research on biomarkers and biomarker 
assay development

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
51/Protocol BN40955, Version 7Patients who are required to undergo screening will have the following additional 
laboratory tests sent to central laboratory:
Thyroid panel: thyroid- stimulating hormone and free thyroxine (also known as T4)
levels
Viral serology: HBsAg and HCV antibody (or viral RNA if HCV antibody assay is
positive)
Blood sample for determination of CAG repeat length in HTT for patient eligibility . 
The CAG repeat length testing from Q2 Solutions will be accepted for this study.
Exploratory biomarker sresearch may include, but will not be limited to, total HTT or 
isoforms of HTT,NfL, tau ,and other proteins related to HD, neuro degeneration, and 
inflammation.
For sampling procedures, storage conditions, and shipment instructions, see the 
laboratory manual.
Biological samples will be destroyed when the final Clinical Study Report has been 
completed, with the following exceptions:
Plasma and CSF samples collected for biomarker research and biomarker assay 
development will be destroyed no later than 10years after the final 
Clinical Study Report has been completed
Plasma and CSF samples collected for PK or immunogenicity analysis may be 
needed for additional immunogenicity characterization and for PK or immunogenicity 
assay development and validation; these samples will nevertheless be destroyed no 
later t han 5years after the final Clinical Study Report has been completed
When a patient withdraws from the study, samples collected prior to the date of 
withdrawal may still be analyzed, unless the patient specifically requests that the 
samples be destroyed o r local laws require destruction of the samples.  However, if 
samples have been tested prior to withdrawal, results from those tests will remain as 
part of the overall research data.
Data arising from sample analysis will be subject to the confidentiality standards 
described in Section 8.4.
Given the complexity and exploratory nature of exploratory biomarker analyses, data 
derived from these analyses wi ll generally not be provided to study investigators or 
patients unless required by [CONTACT_2371].  The aggregate results of any conducted research will 
be available in accordance with the effective Sponsor policy in the study data publication.
4.5.7 Magnetic Resonance Ima ging
Mandatory s tructural MRI will be used to assess brain volume , optional 
diffusion -weighted MRI /Neurite Orientation Dispersion and Density Imaging will be used 

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
52/Protocol BN40955, Version 7to examine structural brain connectivity, and optional resting- state functional MRI will be 
employed to identify functional connectivity. All of the measures will be assessed at the 
whole -brain and regional levels and will continue as in the preceding study . Patients will 
be required to undergo and tolerate the mandatory structural MRI .Patients who are 
required to under goscreening will undergo structural MRI at screening toconfirm 
eligibility for the study. Patients will be encouraged to receive the diffusion- weighted 
MRI/Neurite Orientation Dispersion and Density Imaging and Resting -State functional 
MRI scans, but they will not be required.
The MRI should be performed using a 3- Tesla (3T) magnet.  The acquisition parameters 
of each sequence, structure, and length of each MRI session, as well as image 
processing algorithms, will be outlined in a separate MRI manual.   Magnetic resonance 
imaging scans will be managed by a central laboratory to monitor and ensure the 
integrity and quality of the acquired data.  During central review, the Sponsor and/or site 
staff will be notified of any unexpected findings requir ingclinical follow -up.
At specified timepoints, the MRI should be scheduled to occur before the LP
(see Appendix 1aand Appendix 1b). The MRI scan should be performed 7 14days 
prior to the LPto allow time for re -scanning if the quality of the initial MRI is inadequate.
If the re -scan cannot be performed prior to the LP, then it can be conducted the day after 
the LP, as long as there are no post -LPcontraindications and it occurs within [ADDRESS_835447] 
brain and spi[INVESTIGATOR_626855] -house or by [CONTACT_298756]-hoc i ndependent external 
neuroimaging expert sto look for the occu rrence of abnormal MRI findings.
4.5.9 Electrocardiograms
Single ECG recording w ill be obtained  at specif ied timepoint s, as outlin ed in the 
schedule of activities (see Appendix 1aand Appendix 1b), and may be obtained at 
unscheduled timepoints as clinically indicated.
The ECG recordings must be performed using a standard high -quality, high -fidelity 
digital electrocardiograph machine equipped with computer -based interval 
measurements.  Lead placement should be as consistent as possible.  
Electrocardiogram recording must be performed after the patient has been resting in a 
supi[INVESTIGATOR_21683] 10 minutes.  Electrocardiograms for each patient should be 

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
53/Protocol BN40955, Version 7obtained from the same machine whenever possible.   All ECGs are to be obtained prior 
to other invasive procedures s cheduled at that same time (e.g., blood draws) and should 
not be obtained within 30minutes after any meal .  Circumstances that may induce 
changes in heart rate, including environmental distractions (e.g., television, radio, 
conversation) should be avoided during the pre -ECG resting period and during ECG 
recording. All data should be recorded on the appropriate eCRF.
The ECG recordings may be electronically transferred to a central vendor.  The
investigator must review, sign, and date all ECG tracings.  Paper copi[INVESTIGATOR_626856]'s permanent study file at the site.
4.5.10 Patient -Reported, Clinician -Reported, and Performance
Outcomes
Patient -reported outcome (PRO), clinician- reported outcome (ClinRO), and performance 
outcome ( PerfO) data will be collected in the clinic to document the change from 
baseline over time.   Additionally, PRO and PerfO data will be collected remotely in 
patients issued with devices.   The instruments , translated into the local language as 
appropriate, w ill be completed in their entirety at specified timepoints during the study.  
To ensure instrument validity and that data standards meet HArequirements, 
instruments will be self -administered or administered by a trained rater (as appropriate) .  
In-clinic data should be collected prior to the performance of the LPprocedure .
Patients and clinicians will use an electronic device to capture ClinRO, PRO ,and PerfO 
data during clinic visits, and scoring of ClinRO and PerfO measures will be supervised 
during acquisition and entry into a tablet to ensure instructions are given and 
appropriately followed.  Patients who were issued with a smartphone and wrist -worn 
wearable in their preceding study will continue to use the smartphone andwrist-worn 
wearable to captur e outcome data remotely and at specified visits 
(see Section [IP_ADDRESS]).
In exceptional circumstances where a patient cannot attend clinic or investiga tor site has 
closed due to restrictions imposed as a result of theCOVID -19 pandemic, ClinRO (refer 
to Appendix 8) can be collected remotely via telephone. For all other situations these all 
need to be completed in the clinic ,otherwise it is a protocol deviation.
SeeAppendix 1aandAppendix 1b for the schedule of activities and Appendix 3and 
Appendix 4for a summary of timing and duration of each PRO, ClinRO, and PerfO 
assessment.  Appendix 7shows the o rder and  approximate timing of  assessmen ts at 
each clinic visit.  Appendix 5show s the clinical assessments order and  duration  for 
patients required to undergo screening only.   Appendix 8shows the remote clinical 
assessments order and duration for patients who could not attend an in -clinic visit due to 
COVID -19 pandemic.

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
54/Protocol BN40955, Version [IP_ADDRESS] Composite Unified Huntington's Disease Rating Scale
The cUHDRS is a composite motor, cognitive, and global functional clinical outcome 
measure in patients with HD comprised of an equally weighted sum of Z scores of the 
TFC, the TMS, the SDMT, and the S WR scores from the UHDRS 
(Huntington Study Group 1996). It is a multidomain measure of clinical decline that 
tracks underlying progressive brain changes and is related to changes in daily functional 
ability (Schobel et al. 2017).
The formula for cUHDRS scoring was originally developed for use in HD Stages 1 and 2 
(TFC 713) but has since been updated to encompass early HD Stage 3. This led to an 
update to the reference population (using ENROLL -HD data) from TFC 713 to 
TFC513 (in both cases, a lower age cutoff of 20 years was used to limit the number of 
individuals included with juvenile -onset HD). The cUHDRS is scored using the following 
formula:
cUHDRS =  TFC− 8.8
2.8  −  TMS−34.4
17.4  +  SDMT −25.2
12.4  +  SWRT −58
21.2  [PHONE_13048].10.2 Total Functio nal Capacity  Scale
The TFC is a validated measure of global patient function in HD.  The TFC represents 
the investigator's assessment of the patient's capacity to perform a range of activities of 
basic daily living, including working, chores, managing finances, eating, dressing, and 
bathing.  The 5 -item assessment is based on a brief interview with the patient.  The 
TFC score ranges from 0 13, with a higher score representing better functioning.  
A 1-point change in TFC score is a clinically meaningful change in patient function 
(e.g., a 1-point decline may indicate the loss of ability to work in a normal capacity) 
(Huntington Study Group 1996).  The TFC takes approximately 10 minutes to administer 
and will be completed at specified clinic visits .
[IP_ADDRESS] Total Motor Score
The TMS is a holistic measure of motor function in HD that is linked to both functional 
capacity based on the TFC score, independence, and driving status 
(Beglinger etal.2012; Schobel et al. 2017).
The TMS score is the sum of the individual m otor ratings obtained from administration of 
the 31 -item motor assessment portion of the UHDRS by [CONTACT_093].  The score 
ranges from 0124, with a higher score representing more severe impairment.  The TMS 
takes approximately 15 minutes to administer and will be completed at clinic specified 
visits.
[IP_ADDRESS] Symbol Digit Modalities Test
The SDMT is used to assess attention, visuoperceptual processing, working memory, 
and psychomotor speed.  It has been shown to have strong reliability and validity 
(Smith 1982 ).  The patient pairs abstract symbols with specific numbers according to a 
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
55/Protocol BN40955, Version 7translation key.  The test measures the number of items correctly paired (maximum 
of110 correct pairs) in 90 seconds.  The SDMT will be administered at specified clinic 
visits and can be completed in less than 5 minutes.  It will also be administered at 
specified timepoints on the [COMPANY_002] HD mobile app (via electronic SDMT) in patients 
issued with devices.
[IP_ADDRESS] Stroop Word Reading Test
The S WR Test is a measure of attention, processing, and psychomotor speed and 
depends upon quick verbal motor output.  Patients are presented with a page of color 
names (i.e., BLUE,  RED, or GREEN ) printed in black ink and are asked to read 
aloud as m any words as possible within a given amount of time (in 45 seconds).  
Thenumber of words read correctly is counted, with a higher score indicating better 
cognitive performance.  It will also be administered at specified timepoints on the [COMPANY_002] 
HD mobile app (via electronic S WR) in patients issued with devices.
[IP_ADDRESS] Independence Scale
A patient's IS score is a measure of disease progression in functional disability and will
be completed to evaluate a patient's degree of independence at screening. It is a 
subscale of the UHDRS. The scale consists of 19 discrete levels ranging from 10 100 
(by 5), in which a score of 100 indicates no special care is needed and a score of 10 
indicates the patients is fed by [CONTACT_626928].   This scale will only be 
performed for patients who were screened and eligible for Study BN40423 but could not 
be randomi zed due to challenges relating to the COVID -19 pandemic.
[IP_ADDRESS] Huntington's Disease Daily  Activities Scale
The HD -DAS assesses patients' daily function.   Following a semi -structured interview 
with the patient, the patient's ability level to perform daily tasks such as eating or using a 
telephone will be recorded.  Each item is scored on a [ADDRESS_835448]. The HD -DAS can be completed in 
approximately 25 minutes.
[IP_ADDRESS] Clinical Global Impression Severity  and Change Scales
The CGI -S is a single- item measure of current global severity and is completed by [CONTACT_626929]. The CGI -S is assessed using an 11 -point numeric 
rating scale, where higher scores indicate greater severity.  The CGI -S can be 
completed in approximately 2 minutes.
The CGI -C is a single- item measure of change in global status (since starting the study) 
and is completed by [CONTACT_626930] -baseline visits.  The CGI -C has 
seven response options:  very much worse,  much worse,  minimally worse, 
nochange,  minimally improved,  much improved, and very much improved.   
TheCGI-C can be completed in approximately 2 minutes.  To assess the relevance of 
this change, a follow -up question with dichotomous response options ( yesor no) 
asks if the change has had a meaningful impact on the patient’s well- being.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
56/Protocol BN40955, Version [IP_ADDRESS] Montreal Cognitive Assessment
The MoCA is a patient -completed assessment used to detect cognitive impairment.  
Itcontains a series of basic assessments, including attention and visuospatial tasks.  
The total score ranges from 0 30, where lower scores indicate greater impairment.  
TheMoCA will be used in this study to assess cognitive status at regular intervals 
throughout the study and takes approximately 10 minutes to administer.
[IP_ADDRESS] Columbia- Suicide Severity Rating Scale
The C -SSRS is a structured tool to assess suicidal ideation and b ehavior.  
Four constructs are measured:  severity of ideation, intensity of ideation, behavior, and 
lethality of actual suicide attempts.  Binary (yes/no) data are collected for 10 categories, 
and composite endpoints based on the categories are followed ov er time to monitor 
patient safety ( Posner et al. 2011).  It maps to the Columbia -Classification Algorithm for 
Suicide Assessment and meets the criteria listed in the U.S. Food and Drug 
Administration (FDA) draft guidance for assessment of suicidality in cl inical trials 
(FDA 2012).  The C -SSRS will be used to assess eligibility forthe study for patients 
required to undergo screening (full version at screening , requiring approximately 
20minutes to administer) andto monitor patients throughout the study at clinic visits 
(follow -up version, requiring approximately 5 minutes to administer, assuming absence 
of suicidal ideation and no change in clinical status from previous administration).
The patient should be referred for im mediate psychiatric evaluation in any event of 
suspected active suicidal intent, significant suicidal behavior, or clinical finding 
suggesting that the patient is dangerous to himself or herself.
[IP_ADDRESS] EuroQol 5 -Dimension, 5 -Level Questionnaire
The EQ -5D-5L is a validated self -report health status questionnaire used to calculate a 
health status utility score for use in health economic analyses (EuroQol Group 1990; 
Brooks 1996 ; Herdman et al. 2011; Janssen et al. 2013).  There are two components to 
the EQ -5D-5L:  a 5 -item health state profile that assesses mobility, self -care, usual 
activities, pain/discomfort, and anxiety/depression, as well as a VAS that measures 
health state.  Published weighting systems allow for creation of a single composite score 
of the pati ent's health status (Index score) from the 5 -item scores (i.e., does not include 
the VAS).  The EQ -5D-5L takes approximately 5 minutes to complete.  The Index score 
will be used in this study for informing pharmacoeconomic evaluations.  The VAS score 
will be used to assess health -related quality of life (HRQoL).  The EQ -5D-5L will be 
completed by [CONTACT_626931].  In 
addition, it will be completed remotely by [CONTACT_626932].
[IP_ADDRESS] [COMPANY_002] HD Mobile A pplication:  Remote Testing (Smartphone 
and Wrist -Worn Wearable)
Smartphones and wrist -worn wearables have high -quality sensors that enable the 
remote, non -invasive, frequent ,and preci se measurement of motor and non -motor 
symptoms (Maetzler etal.2013 ; Andrzejewski et al. 2016 ; Adams et al. 2017; 
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
57/Protocol BN40955, Version 7Lipsmeier et al. 2018).  If a patient already has a preconfigured smartphone and 
wrist-worn wearable with installed software for the [COMPANY_002] HD mobile app assessments 
from the preceding study, they wi ll continue to use those devices in this study.  Although 
the majority of assessments on the [COMPANY_002] HD mobile app are consistent across the 
preceding studies, some of the PROs will differ. Patients will continue to complete the 
PROs from the preceding stud y, thus not all patients will complete all PROs (e.g., the 
WHODAS 2.0 will not be complet ed by [CONTACT_328856] p reviously in Study BN40423). Details 
of remote assessments are contained in Appendix 7.If patients did not have a 
preconfigured smartphone and wrist -worn wearable in the preceding study, they will not 
be provided devices in this study. Patients screened in Study BN40423 but not 
randomi zed due to logistical challenges resulting from COVID -[ADDRESS_835449] -worn wearable. The devices and software will monitor motor 
symptoms, non -motor symptoms, and activities associated with routine daily living 
throughout t he course of the study.  Additional details are available in the [COMPANY_002] HD 
mobile app (smartphone) manual.
Patients will be asked to complete an active test every day at approximately the same 
time (ideally in the morning, after breakfast).  The active test consists of a short, 
preconfigured schedule of tasks that assess motor symptoms (upper and lower body 
movements, upper limb dexterity, and voice) and non- motor symptoms (processi ng 
speed, voice).  These tasks are described in Appendix 9.  Testing  will last  approximately  
510minutes in tot al on a typi[INVESTIGATOR_626857].  Not all tests are daily.  Additional 
information on the approach, tasks, and schedule are available in the [COMPANY_002] HD mobile 
app manual.
For passive monitoring, patients will be instructed to carry the smartphone in a manne r 
convenient to them (e.g., in a pocket or in a Sponsor -provided pouch) and wear the 
wrist-worn wearable throughout the day as they go about their daily routines.
Patients will be encouraged to adhere to the daily schedule of tasks as much as possible; 
however, patients will not be excluded from the study for poor adherence nor will missing 
a daily test be considered a protocol deviation.  Device sensor data will be recorded 
continuously, throughout the active tests and passive monitoring.  Sound will only be 
recorded during selected active test tasks.  Data will be encrypted and uploaded to 
secure servers when the smartphone is connected to Wifi.  Patients will be asked to 
charge the devices overnight.  If patients have a W ifi network at home, they will be 
encouraged to connect their smartphone to enable data transfer.  If no W ifi network is 
available, the sensor data will be transferred during clinic visits or after the devices have 
been returned.
Devices may reach the end of their lifespan or be broken during this study .  In those
cases, they may be replaced upon discussion on a case- by-case basis .

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
58/Protocol BN40955, Version 7During the course of this study (ca. 2022 ), the [COMPANY_002] HD mobile app may be available 
for download by [CONTACT_626933].  All patients, will have 
the option to download the app on their personal smartphones and continue (or restart) 
with the [COMPANY_002] HD mobile app assessments and passive monitoring.  If p atients 
download the app on their personal smartphone, they should return the provisioned 
devices.
[IP_ADDRESS].1 [COMPANY_002] HD Mobile A pplication:  In -Clinic Assessments
Patients will be instructed to bring the smartphone and wearable to every clinic visit to 
check adherence and technical status of the devices.  Every 16week s, when clinical 
ratings will occur, patients will be asked to conduct the In-Clinic Assessments 
(Fullactive test )under the supervision of trained site staff, with the exception of the 
EQ-5D-5L, which will be completed on the electronic device at the site . Patients should 
be instructed to not complete the [COMPANY_002] HD mobile app EQ -5D-5L on days that coincide 
with the study drug administration visit.
The smartphone and wearable must be returned to the clinic in cases where the patient 
does not meet eligibility criteria, at the end of the study, or upon early termination from 
the study.
4.[ADDRESS_835450] permanently discontinue study treatment if they experience any of the 
following:
Any medical condition that the investigator or Sponsor determines may jeopardize 
the patient's safety if he or she continues to receive study treatment
Investigator or Spo nsor determination that treatment discontinuation is in the best 
interest of the patient
Pregnancy
The primary reason for study treatment discontinuation should be documented on the 
appropriate eCRF.  Patients who discontinue study treatment prematurely w ill not be 
replaced.
Patients will return to the clinic for an end -of-treatment visit and safety follow -up visit 
(ifapplicable) after the final dose of study drug ( see Appendix 1aand Appendix 1bfor 
additional details).
4.6.[ADDRESS_835451] the right to voluntarily withdraw from the study at any time for any reason.  
In addition, the investigator has the right to withdraw a patient from the study at any time.  
Reasons for withdrawal from the study may include, but are not limited to, the fol lowing:
Patient withdrawal of consent

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
59/Protocol BN40955, Version 7Study termination or site closure
Loss of capacity to consent , if legal guardian consent is not possible
Note:  W ithdrawal of patients who lose capacity to consent is a requirement in 
[LOCATION_013].
Every effort should be made to obtain information on patients who withdraw from the 
study but have not withdrawn consent.  The primary reason for withdrawal from the 
study should be documented on the appropriate eCRF.  If a patient requests to be 
withdrawn from the study, this request must be documented in the source documents 
and signed by [CONTACT_093].  Patients who withdraw from the study will not be 
replaced.
4.6.3 Study Discontinuation
The Sponsor has the right to terminate this study at any time.  Reasons for terminating 
the study may include, but are not limited to, the following:
The incidence or severity of AEs in this or other studies indicates a potential health 
hazard to patients
Patient enrollment is unsatisfactory
The Sponsor will notify the investigator if the Sponsor decides to discontinue the study.
4.6.4 Site Discontinuation
The Sponsor has the right to close a site at any time.  Reasons for closing a site may 
include, but are not limited to, the following:
Excessively slow recruitment
Poor prot ocol adherence
Inaccurate or incomplete data recording
Non-compliance with the International Council for Harmonisation (ICH) guideline for 
Good Clinical Practice
No study activity (i.e., all patients have completed the study and all obligations have 
been f ulfilled)
5. ASSESSMENT OF SA FETY
5.1 SAFETY PLA N
RO7234292 is not approved and clinical development is ongoing.  The safety plan for 
patients in this study is based on clinical experience with RO7234292 in completed and 
ongoing studies.  Safety risks for the LPprocedure and RO7234292 are outlined below
in Sections 5.1.1 and 5.1.2 , respectively.  Please refer to the 
RO7234292 Investigator's Brochure for a compl ete summary of safety information.

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
60/Protocol BN40955, Version 7Several measures will be taken to ensure the safety of patients participating in this study , 
including the eligibility criteria .  Patients will undergo safety monitoring during the study, 
including assessment of the incidence and severity of AEs.  Guidelines for managing
AEs, including criteria for treatment interruption or discontinuation, are provided below .
5.1.[ADDRESS_835452]lumbar puncture syndrome, spi[INVESTIGATOR_626858] ,and meningitis 
(see Sections [IP_ADDRESS] [IP_ADDRESS] ) are potential risks associ ated with LP.
In the completed Phase I/IIa study, the most commonly reported AEs across all 
treatment groups (RO7234292, N34; placebo, N12) were procedural pain 
(54% ofpatients) and post LPsyndrome (37% of patients).
In the recently completed Phase II OLE Study BN40697, potential LP procedure -
associated selected AEs were reported with similar incidence across the cohorts despi[INVESTIGATOR_626859] (16 patients [69.6%] in the Q4W cohort and 
17patients [73.9%] in the Q8W cohort).  Overall , the most frequently reported event 
was procedural pain (41.3%).  In the ongoing Phase III Study BN40423, patients 
enrolled under Protocol Versions 1 3 (receiving Q4W blinded treatment) were 
discontinued following discontinuation of the Q4W dosing.  These patients ’ treatment 
assignments are now unblinded and hereby [CONTACT_626934] (ODC).  
In the ODC, potential LP procedure associated selected AEs were reported with similar 
incidence across the three cohorts (17 patients [47.2%] in the placebo cohort, 14 
patients [40%] in the Q4W cohorts, and 17 patients [47.2%] in the Q8W cohort).  
Overall, the events reported with highest incidence were procedural pain and post -
lumbar puncture syndrome (14% each).
As of [ADDRESS_835453] 2020, in the ongoing Study BN40955, potential LP procedure 
associated selected AEs were reported in 30 patients [22.9%] in the Q8W cohort and 
11patients [15.1%] in the Q16W cohort.  Overall the most frequently reported event 
was procedural pain (9.2% in the Q8W cohort and 4.1 % in the Q16W cohort).  Many of 
the complications associated with LPcan be avoided by [CONTACT_626935] a 24G 
atraumatic needle with a stylet, adherence to procedural guidelines (see LPmanual and 
instructional video), and careful assessment of the patient, including neurologic 
examination with fundoscopy both prior to and post LPprocedure.  Lumbar puncture
should be avoided when a contraindication is present.
Cerebrospi[INVESTIGATOR_626860] e is more likely with larger bore needles.  To minimize this risk, 
a 24G atraumatic needle will be used.  Training for use of the 24G atraumatic needle in 
this study will be provided prior to initiation of LP, as will a review of extension tubing use 
and t he need to gently aspi[INVESTIGATOR_626861].  If headache with 
characteristics of low -pressure syndrome is present after the procedure and persists 
despi[INVESTIGATOR_626862], a blood patch should be considered.  Formation of a 
subarachnoi d epi[INVESTIGATOR_626863] (i.e., when a skin plug is introduced into the arachnoid 

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
61/Protocol BN40955, Version 7space) can be avoided by [CONTACT_2363] a needle with stylet, which is mandatory.  Rarely, brain 
herniation can occur in the setting of LP and increased intracranial pressure.
There are spec ific contraindications to performing LP.  These include unstable 
cardiorespi[INVESTIGATOR_82219], where positioning patient for LPmay not be tolerated, signs of 
cerebral herniation or incipi[INVESTIGATOR_626864], signs of increased intracranial 
pressure, or fo cal neurological findings on examination.  In those patients, LP(and IT 
treatment administration) should not be performed and appropriate diagnostic work -up 
should be initiated.  On a case -by-case basis and following discussion with the 
Medical Monitor, such pa tients may be able to resume treatment.
In the setting of H D, for the purposes of LPand IT bolus injection of RO7234292 , 
moderate to severe truncal chorea may also be prohibitive.
[IP_ADDRESS] PostLumbar Puncture Sy ndrome
RO7234292 is delivered directly to the CNS by [CONTACT_626936][INVESTIGATOR_92630].  Post LPsyndrome 
(e.g., headaches, nausea, vomiting, infection, hemorrhage, nerve irritation pain) can 
occur with IT administration.  Experience to date with post LPsyndrome, as reported in 
the completed Phase I/IIa study, includes headache, which occurred after 10% of 
procedures and was transient and mild in the vast majority of patients.  
In the recently completed Phase II OLE Study BN40697, post -LP syndrome events 
(such as post -LP syndrom e, headache, migraine, nausea, vomiting or procedural 
headache) occurring within 5 days of LP were reported in 9 patients (39.1%) in the 
Q4W cohort and 13 patients (56.5%) in the Q8W cohort.
In the Study BN40423 ODC, post -LP syndrome events (post -LP syndro me, headache, 
migraine, nausea, vomiting or procedural headache) occurring within 5 days of LP were 
reported in 14 patients (38.9%) in the placebo cohort, 8 patients (22.9%) in the Q4W 
cohort and 14 patients (38.9%) in the Q8W cohort.
As [ADDRESS_835454] -LP syndrome events (such as 
post-LP syndrome, headache, migraine, nausea, vomiting or procedural headache) 
occurring within 5 days of LP were reported in 7 patients (5.3%) in the Q8W cohort 
and 2 patients (2.7%) in the Q16W cohort.  
The majority of these events were mild or moderate and non -serious.  No events led to 
treatment interruption or discontinuation.
Patients should walk post LP, (see Section [IP_ADDRESS] ).However , if a patient develops a 
headache after the LPwith characteristic features, which makes walking intolerable, the 
patient should be encouraged to first sit down and if the headache persists then the 
patient should lie in a comfortable position, which is most likely in the supi[INVESTIGATOR_626865].  Supportive treatment may include 

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
62/Protocol BN40955, Version 7rehydration, consumption of caffeinated drinks, simple analgesics, o pi[INVESTIGATOR_2438], and 
antiemetics.  If these conservative measures fail, more specific measures may be 
indicated.
[IP_ADDRESS] Spi[INVESTIGATOR_626866]lumbar puncture spi[INVESTIGATOR_626867] a very rare but important potential risk that 
can present as persistent back pain, radicular pain, new sensory or motor symptoms, 
sphincter disturbance, or meningism.  Prompt MRI scanning should be performed if 
suspi[INVESTIGATOR_626868].  Patients with susceptibility to bleeding, patients 
with coagulopathy, and patient sreceiving anticoagul ant therapy are at an increased risk 
of spi[INVESTIGATOR_626869] (see Section 4.1.2 ).
Management of spi[INVESTIGATOR_626870].
[IP_ADDRESS] Meningitis
Meningitis is a rare potential risk of LP.  Patients may present with headache, meningi sm, 
photophobia, neck stiffness, and pyrexia.  Guidelines for management of patients with 
suspected meningitis are provided in Table [ADDRESS_835455] 2020 , including the completed Phase I/IIa study and its
Phase II OLE Study (BN40697 ),Study BN40423 (ODC), and the ongoing Study 
BN40955.
[IP_ADDRESS] Neurologic Changes
In cynomolgus monkeys, acute, transient deficits in lower spi[INVESTIGATOR_154531] (patellar reflex 
in particular) were typi[INVESTIGATOR_218206] 2 8 hours following dosing, in the 13 -week and the 
chronic toxicity s tudies.  The transient changes in patellar reflex were observed in all 
treatment groups, including controls, with a slightly higher incidence in the high -dose 
groups.  These findings were fully reversible within 24 hours following dosing.  No other 
treatme nt-related changes in general sensory and motor function parameters nor 
changes in the cerebral reflexes were observed.
In the Phase I/IIa multiple ascending dose (MAD) study (ISIS 443139 -CS1), no adverse 
trends in neurological examinations were detected a nd only a few drug- related 
neurological AEs were observed in ≥2 patients.  See the RO7234292 Investigator’s 
Brochure for more information.
In the other completed and ongoing studies, among events associated with peripheral 
nervous system, 2 cases of asymptomatic lumbar radiculopathy that were characterized 
by [CONTACT_626937] (SAE) of radiculopathy and hyporeflexia (Suspected Unexpected Serious 
Adverse Reaction [S[LOCATION_003]R] case) have been observed in the Phase II OLE Study 

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
63/Protocol BN40955, Version 7BN40697 at the Q4W 120 mg cohort.  In Study BN40423 ODC, one case of lumbar 
radiculopathy (post traumatic, considered not related to study drug by [CONTACT_093]) 
was reported in the Q8W cohort.   In Study BN40955, no treatment -emergent 
radiculopathy cases have been reported .
Among reflex change events in Study BN40697, areflexia and reflexes abnormal were 
reported in [ADDRESS_835456] been reported in Study 
BN40423 ODC.  For details, see the RO7234292 Investigator’s Brochure.
Among events associated with the central nervous system in Study BN40697, 
dysarthria was reported in 2 patients in the Q4W cohort; coordination abnormal was 
reported in 1 patient in the Q4W cohort; pleocytosis was reported in 1 patient in the 
Q4W arm; and ataxia was reported in 1 patient each in the Q4W and Q8W cohorts, 
respectively.  An SAE of cerebrovascular accident was reported in 1 patient in the Q4W 
cohort, which was considered not related to study drug by [CONTACT_3433] e investigator.  SAEs of 
hemiparesis, myelitis, and neuritis (S[LOCATION_003]R cases) were reported in another patient in 
the Q4W cohort.  In Study BN40423 ODC, ataxia (S[LOCATION_003]R case) and dysarthria were 
reported in 1 patient each in the Q4W cohort.  In Study BN40955, t reatment -emergent 
event of ataxia was reported in 1 patient each in the Q8W and Q16W cohorts, 
respectively, pleocytosis was reported in 1 patient in the Q8W cohort, and two 
neurological S[LOCATION_003]R cases were reported in 2 patients in the Q8W cohort (1 patient 
each for arachnoiditis and aseptic meningitis).  For details see the RO7234292 
Investigator’s Brochure. Following LP administration and post -LP mobilization, 
neurologic examinations should be conducted.  In addition, patients should be observed 
in-clinic f or any complications or complaints post -LP and ITbolus injection of 
RO7234292 .
[IP_ADDRESS] Elevations in CSF WBCs and Protein
The CSF W BC elevations were also observed in the chronic non- human primate study 
with slight increases over time.  Increases were mild, and t here was no apparent dose 
dependency.
CSF protein and WBC increases have been observed in the RO7234292 program. 
In Study BN40697, one patient was diagnosed with chemical meningitis (S[LOCATION_003]R case) 
in the Q4W cohort. As of [ADDRESS_835457] udy BN40955, one 
patient experienced aseptic meningitis (clinically not infectious) and one patient 
experienced arachnoiditis, in the Q8W cohort.  
For details on CSF proteins and WBC laboratory values and non -serious AEs of CSF 
WBC and protein increases, please refer to the RO7234292 Investigator’s Brochure.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
64/Protocol BN40955, Version [IP_ADDRESS] Thrombocytopenia
Reductions in platelet count have been observed after systemic administration of some 
2-MOE chimeric ASOs to clinical trial subjects.  However, no clinically significant 
reductions in platelet counts have been observed in clinical studies for RO7234292 to 
date.  Inone 13- week and one 9 -month IT toxicity studies of RO7234292 in the 
cynomolgus monkey, there were no effects on hematology or coagulation parameters.
No clinically significant reduction in platelet counts hasbeen observed in the completed 
and ongoing studies in the RO7234292 program to date.
Platelet counts will be monitored at each study visit prior to LP.  See Table 2for patient 
stoppi[INVESTIGATOR_626871].
[IP_ADDRESS] Kidney  Effects
Reductions in renal function have been observed after administration of some 2 -MOE 
containing chimeric ASOs to clinical trial subjects.  In the [ADDRESS_835458] article related 
histologic findings in the visceral organs or effects on clinical chemistries.
No clinically significant reduction in kidney f unction was observed in the completed 
RO7234292 Phase I/IIa study. Among the other completed and ongoing studies, in the 
recently completed Phase II OLE study BN40697, one case of moderate and non -serious 
proteinuria was reported in the Q4W cohort, whi ch resolved without any intervention, 
was considered by [CONTACT_343500], and the patient 
continued study drug administration.   No other clinically significant kidney abnormality 
has been observed.
Kidney function will be monitored at each study visit.  Guidelines for management of 
patients who develop decreased renal function are provided in Table 2 .
[IP_ADDRESS] Liver Effects
Elevations in liver enzymes have been observed after administration of some 2 -MOE 
chimeric ASOs to clinical trial subjects. However, no clinically significant elevation in 
liver enzymes have been observed in the clinical studies for RO7234292 to date.
In the 13 -week and 9- month toxicity studies of RO7234292 in cynomolgus monkeys, 
there were no drug related histologic findings in the visceral organs, including the liver, 
or effects on clinical chemistry test levels. No clinically significant elevations in liver 
enzymes were observed in the completed RO7234292 Phase I/IIa study. Among the 
other completed and ongoing studies, in the recently completed Phase II OLE study 
BN40697, one mild AE of hepatic enzyme increase was reported in 1 patient in the
Q4W cohort, which resolved without any intervention and was considered by [CONTACT_626938]7234292. Nodrug-related clinically significant hepatic 
abnormality has been observed to date .

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
65/Protocol BN40955, Version 7Liver enzymes will be monitored at each study visit.  Guidelines for manageme nt of 
patients who develop decreased liver function are provided in Table 2 .
[IP_ADDRESS] Hydrocephalus
Hydrocephalus is included as a warning in the label ingof one marketed IT- administered 
2-MOE chimeric ASO.  
Ventricular volume expansion has been described in the RO7234292 Investigator’s 
Brochure and is being monitored in all RO7234292 studies.
An SAE of hydrocephalus following chemical meningitis was reported in a patient who 
has undergone shunting in the Q4W cohort of the recently completed Phase II OLE 
Study BN40697.  In ongoing blinded Study BN40423, 1 patient with symptomatic 
communicating hydrocephalus has been shunted (S[LOCATION_003]R case) and 1 patient with a 
medical history of hydrocephalus had an event of hydrocephalus (verbatim: worsening 
hydrocephalus) that was considered by [CONTACT_626939]. 
For details, and description of non- serious AEs, refer to the RO7234292 Investigators 
Brochure; for management guidelines, see Section [IP_ADDRESS] .
[IP_ADDRESS] Neuropsy chiatric Changes
RO7234292 is directly administered to the CNS, with limited clinical experience. 
Nonclinical studies in animals did not show any adverse effects on the CNS.  Though a
single case of completed suicide has occurred in the ongoing Phase II OLE study 
(Study BN40697), when weighing all available details of the case, the investigator has 
concluded that this event was not related to RO7234292.  Patients should be closely 
moni tored for signs and symptoms of neuropsychiatric changes in addition to routine 
monitoring with the C -SSRS and the MoCA battery.
[IP_ADDRESS] Potential Risk due to Reduction of Target Protein HTT
By [CONTACT_626940], RO7234292 lowers le vels of both 
mHTT protein and normal wild -type huntingtin (wtHTT) protein in all patients, regardless 
of genetic variations.   The ASO modality provides partial, transient, reversible, and 
titratable HTT lowering.  Partial HTT lowering is safe and well tolerated in normal rodents 
and non- human primates, as shown in multiple studies using ASOs and non -reversible 
approaches.  Furthermore, no safety signals of concern emerged during the completed
Phase I/IIa study of RO7234292 in adults with HD 
(see RO7234292 Investigator's Brochure), in which partial lowering was achieved.
Transgenic mice expressing human mHTT develop progressive HD -like phenotypes that 
recapi[INVESTIGATOR_626872].  Antisense oligonucleotide -mediated mHTT 
lowering provides therapeutic benefits and often restores normal functioning in 
transgenic and fully humanized animal models of HD, with generally similar results 

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
66/Protocol BN40955, Version 7regardless of whether wtHTT is also lowered.  Moreover, no detrimental effects of partial 
wtHTT lowering in animal mod els have been reported in multiple studies using ASOs 
and non- reversible approaches.
Still, the current understanding of the diverse cellular functions of HTT suggests potential 
theoretical risks associated with reducing total HTT levels in people with HD.   More than 
two decades of research findings implicate HTT in a wide array of cellular functions, 
including microtubule- based transport, F actin -based trafficking, Rab -based trafficking, 
brain- derived neurotrophic factor transport, ciliogenesis, transcription, chromatin 
modification, post -transcriptional gene- expression regulation, neurogenesis, 
synaptogenesis, synaptic plasticity, signaling pathways, cell stress responses, cell 
survival, selective macro -autophagy and DNA damage repair, as detailed in a recent 
review article (Liu and Zeitlin 2017).
Although functional HTT (mutant or wild -type) is essential for embryogenesis, 
near-complete genetic ablation of HTT has little or no reported neurological effect in 
normal adult animals.  However, comple te ablation of wtHTT protein expression 
throughout life results in a worsening motor phenotype and, in male transgenic mice, 
age-dependent emergence of brain atrophy and decreased testicular size 
(Van Raamsdonk et al. 2005).  In contrast, decreases in mHTT protein expression 
ameliorate disease, and increases in mHTT protein exacerbate disease in animal 
models of HD, regardless of concomitant changes in wtHTT protein levels.
No clinically significant new neurologic events were observed in the completed 
Phase I/IIa study.  As a precaution, a full neurologic examination will be conducted at 
each study visit (on dosing days before and after dosing), and additional monitoring of 
cognition will be conducted throughout the study using the MoCA.
5.1.3 Management of Patien ts who Experience A dverse Events
[IP_ADDRESS] Dose Modifications
No dose modifications are permitted in this study, whether by [CONTACT_626941] (i.e., all 
participants will receive 20 mL of study drug at every study drug administration either on 
a Q8 W or Q16W  basis as assigned by [CONTACT_23624]).
[IP_ADDRESS] Treatment Interruption
Study drug may be tempora rily suspended in patients who experience toxicity 
considered to be related to study drug.  If study drug has been withheld for 60days
from the date of the first missed dose, because of signs of persistent drug -induced 
toxicity or if the scheduled dose has been missed, the investigator sh ould consult the 
Medical Monitor to determine if discontinuation from study drug is warranted .  Study drug 
may be suspended for reasons other than toxicity (e.g., surgical procedures) with 
Medical Monitor approval.  The investigator and the Medical Monitor will determine the 
acceptable length of treatment interruption.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
67/Protocol BN40955, Version [IP_ADDRESS] Management Guidelines
Guidelines for management of specific AEs are outlined in Table [ADDRESS_835459] be available prior 
to administering the next dose of study drug. In general, patients who do not reach the 
stoppi[INVESTIGATOR_626873] ;however ,the investig ator and Sponsor should confer 
as to whether additional close monitoring of the patient is indicated.

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
68/Protocol BN40955, Version 7Table 2Guidelines for Management of Patients Who Experience A dverse 
Events
Event Action to Be Taken
Elevations in CSF WBC 
count or proteins or 
suspected meningitis, 
radiculitis, arachnoiditis, 
hydrocephalus, or other 
acute neurologic sy mptoms Withhold study drug if diagnosis of meningitis, radiculitis, 
arachnoiditis, hydrocephalus, or acute neurologic sy mptoms is 
suspected and initiate appropriate diagnostic work -up as 
indicated.
 Clinical signs and sy mptoms of hydrocephalus (e.g., new onset 
of persistent or worsening gait disturbance, change in level of 
consciousness/cognition, changes in continence, or a 
combination of all 3signs) are required for diagnosis of 
suspected hydrocephalus.
 Clinical signs and sy mptoms of meningitis (e.g., headache, stiff 
neck, fever) plus confirmatory W BC count are required for 
diagnosis of suspected meningitis ;and clinical signs and 
symptoms are required for diagnosis of radiculitis, 
arachnoiditis, or acute neurolog ic symptoms.  Isolated low -level 
(e.g., 5 50LWBC count) elevations in CSF W BC count 
without clinical s ymptoms does not meet criteria for diagnosis 
of suspected meningitis.
 The Medical Monitor should be consulted in all cases where 
CSF WBC count elevatio ns above 10 /Lare present, or a 
change from baseline in CSF proteins greater than 2×baseline 
or where there is uncertainty to discuss next steps of patient 
managem ent in the study.
 If diagnosis of suspected meningitis, radiculitis, arachnoiditis,
hydroce phalus, or other acute neurologic sy mptoms is refuted, 
the study drug may be resumed after consultation with the 
Medical Monitor.
 In the event meningitis, radiculitis, arachnoiditis,
hydrocephalus, or acute neurologic sy mptom diagnosis is 
confirmed, standa rdofcare therapi[INVESTIGATOR_626874].
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
69/Protocol BN40955, Version 7Table 2Guidelines for Management of Patients Who Experience A dverse 
Events (cont.)
Event Action to Be Taken
Thrombocy topenia  If platelet count is 100,000/mm3:
–Monitor platelet count weekly .
 If platelet count is 75,000/mm3and 50,000/mm3in the 
absence of major bleeding or clinically relevant non -major 
bleeding:
–Withhold study drug until the platelet count has recovered 
to 100,000/mm3.
–The suitability of the patient for continued dosing and
frequency of monitoring should be discussed with the 
Medical Monitor.
 If platelet count is 50,000/mm3:
–Permanently discontinue study drug.
–Monitor platelet counts daily until two successive values 
show improvement.  Then monitor ever y 2[ADDRESS_835460] weekly until platelet 
count returns to normal.
 Treatment per standard of care should be considered for 
patients whose platelet count is  25,000/mm3.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
70/Protocol BN40955, Version 7Table 2Guidelines for Management of Patients Who Experience A dverse 
Events (cont.)
Event Action to Be Taken
Decreased renal function  Withhold study drug in the event of a persistent ( 2 weeks) 
decrease in eGFR or CrCl or increase in creatinine, as defined 
below:
–eGFR or CrCl (using Cockcroft -Gault) 60mL/min.
–Creatinine level increase of 2.0 above baseline .
–Study drug may be resumed when follow -up test results 
show that the patient no longer meets the dose interruption 
criteria.
Elevated liver enzy mes  ALT or AST is 3ULN:
–Monitor weekly until ALT and AST return to  1.2ULN.
–Further investigation into the liver enzy me elevations may 
include hepatitis serologies and other diagnostic tests at 
the discretion of the investigator in consultation with the 
Medical Monitor.
 Withhold study  drug in the event of liver enzy mes that meet the 
following criteria without an alternative explanation 
(asdiscussed with the Medical Monitor):
–ALT or AST 5ULN.
–ALT or AST 3ULN, combined with total bilirubin 
2ULN or INR 1.5.
–ALT or AST 3ULN coinciding with new appearance of 
fatigue, nausea, vomiting, right upper quadrant pain or 
tenderness, fever, rash, and/or concomitant eosinophilia.
–Discontinue study drug permanently if levels do not return 
to baseline after 30 days.
CrClcreatinine clearance; CSF cerebrospi[INVESTIGATOR_872]; eGFR estimated glomerular filtration rate; 
ULNupper limit of normal.
5.[ADDRESS_835461] of monitoring and recording AEs, including serious 
adverse events (SAEs) and adverse events of special interest (AESIs) , performing 
protocol -specified safety laboratory assessments, measuring protocol -specified vital 
signs, and conducting other protocol -specified tests that are deemed critical to the safety 
evaluation of the study.
Certain types of events require immediate reporting to the Sponsor, as outlined in 
Section 5.4.

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
71/Protocol BN40955, Version 75.2.[ADDRESS_835462], regardless of causal attribution.  An AEcan therefore be any of the following:
Any unfavorable and unintended sign (i ncluding an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal product, 
whether or not considered related to the medicinal product
Any new disease or exacerbation of an existing disease (a worsening in the 
character, frequency, or severity of a known condition) (see Sections [IP_ADDRESS]
and5.3.5.10 for more information)
Recurrence of an intermittent medical condition (e.g., headache) not present at 
baseline
Any deterioration in a laboratory value or other clinical test (e.g., ECG, X -ray) that is 
associated with symptoms or leads to a change in study treatment or concomitant 
treatment or discontinuation from study drug
Adverse events that are related to a protocol -mandated intervention, including those 
that occur prior to assignment of study treatm ent (e.g., screening invasive 
procedures such as biopsies)
5.2.2 Serious A dverse Events (Immediately  Reportable to the 
Sponsor)
A SAE is any AEthat meets any of the following criteria:
Is fatal (i.e., the AEactually causes or leads to death)
Is life-threatening (i.e., the AE, in the view of the investigator, places the patient at 
immediate risk of death)
This does not include any AEthat, had it occurred in a more severe form or was 
allowed to continue, might have caused death.
Requires or prolongs inpatient hospi[INVESTIGATOR_059] (see Section [IP_ADDRESS] )
Results in persistent or significant disability/incapacity (i.e., the AEresults in 
substantial disrupti on of the patient's ability to conduct normal life functions)
Is a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to 
study drug
Is a significant medical event in the investigator's judgment (e.g., may jeopardize the 
patient or may require medical/surgical intervention to prevent one of the outcomes 
listed above)
The terms severe and serious are notsynonymous.  Severity refers to the intensity 
of an AE(e.g., rated as mild, moderate, or severe, or according to National Cancer 
Institute Common Terminology Criteria for Adverse Events [NCI CTCAE]; 
seeSection 5.3.3 ); the event itself may be of relatively minor medical significance (such 
as severe headache without any further findings).

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
72/Protocol BN40955, Version 7Severity and seriousness need to be independently assessed for each AErecorded on 
the eCRF.
Serious adverse events ar e required to be reported by [CONTACT_25741] (i.e., no more than 24 hours after learning of the event; see Section 5.4.2 for 
reporting instructions).
5.2.[ADDRESS_835463] (Immediately  Reportable to 
the Sponsor)
Adverse events of special interest are required to be reported by [CONTACT_33473] (i.e., no more than 24 hours after learning of the event; 
seeSection 5.4.2 for reporting instructions).  Adverse events of special interest for this 
study are as follows:
Cases of potential drug-induced liver injury that include an elevated ALT or AST in 
combination with either an elevated bilirubin or clinical jaundice, as defined by 
[CONTACT_25742]'s Law (see Section [IP_ADDRESS] )
Suspected transmission of an infectious agent by [CONTACT_5257], as defined below :
Any organism, virus, or infectious particle (e.g., prion protein transmitting 
transmissible spongiform encephalopathy), pathogenic or non -pathoge nic, is 
considered an infectious agent.  A transmission of an infectious agent may be 
suspected from clinical symptoms or laboratory findings that indicate an 
infection in a patient exposed to a medicinal product.  This term applies only
when a contaminati on of the study drug is suspected.
5.3 METHODS A ND TIMING F OR CA PTURING A ND ASSESSING 
SAFETY PARAMETERS
The investigator is responsible for ensuring that all AEs (see Section 5.2.1 for definition) 
are recorded on the Adverse Event eCRF and reported to the Sponsor in accordance 
with instructions provided in this section and in Sections 5.45.6.
For each AErecorded on the Adverse Event eCRF, the investigator will make an 
assessment of seriousness (see Section 5.2.2 for seriousness criteria), severity 
(see Section 5.3.3 ), and causality (see Section 5.3.4 ).
5.3.[ADDRESS_835464].  All AEs, whether 
reported by [CONTACT_70155] l,will be recorded in the patient's 
medical record and on the Adverse Event eCRF.

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
73/Protocol BN40955, Version 7After informed consent has been obtained but prior to initiation of study drug , only SAEs
caused by a protocol -mandated intervention (e.g., invasive procedures such as LP) 
should be reported (see Section 5.4.2 for instructions for reporting SAEs ).
After initiation of study drug, all adverse events will be reported until 5 months after the 
final dose of study drug.
Instructio ns for re porting AEs that occur after the AEreporting period are provided in 
Section 5.6.
5.3.2 Eliciting A dverse Ev ent Information
A consistent methodology of non -directive questioning should be adopted for eliciting 
AEinformation at all patient evaluation timepoints.  Examples of non-directive questions 
include the following:
How have you felt since your last clinic visit? 
Have you had any new or changed health problems since you were last here? 
5.3.3 Assessment of Severity  of A dverse Events
The Adverse Event Severity Grading Scale indicated in Table 3 provides guidance for
assessing AEseverity .  Laboratory values determined as an AEshould be graded as per
Appendix 10, which is b ased on the NCI CTCAE ( v5.0).
Table 3Adverse Event Severity Grading Scale
Severity Description
Mild Discomfort noticed, but no disruption of normal daily activity
Moderate Discomfort sufficient to reduce or affect normal daily activity
Severe Incapacitating with inability to work or to perform normal daily activity
Note:  Regardless of severity, some events may  also meet seriousness criteria.  
Refer to definition of a serious adverse event (see Section 5.2.2).
5.3.4 Assessment of Causali ty of Adverse Events
Investigators should use their knowledge of the patient, the circumstances surrounding 
the event, and an evaluation of any potential alternative causes to determine whether an 
AEis considered to be related to the study drug, indicatin g yesor noaccordingly.  
The following guidan ce should b e taken into consideration (see also Table 4 ):
Temporal relationship of event onset to the initiation of study drug
Course of the event, with special consideration of the effects of dose reduction, 
discontinuation of study drug, or reintroduction of study drug (as applicable)
Known association of the event with the study drug or with similar treatments
Known association of the event with the disease under study

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
74/Protocol BN40955, Version 7Presence of risk factors in the patient or use of concomitant medications known to 
increase the occurrence of the event
Presence of non -treatment -related factors that ar e known to be associated with the 
occurrence of the event
Table 4Causal A ttribution Guidance
Is the adverse event suspected to be caused by [CONTACT_25745], evidence, 
science -based rationales, and clinical judgment?
YES There is a plausible temporal relationship between the onset of the adverse event and 
administration of the study drug, and the adverse event cannot be readily explained by 
[CONTACT_102]'s clinical state, intercurrent illness, or concomitant t herapi[INVESTIGATOR_014]; and/or the 
adverse event follows a known pattern of response to the study drug; and/or the 
adverse event abates or resolves upon discontinuation of the study drug or dose 
reduction and, if applicable, reappears upon re -challenge.
NO An adverse e vent will be considered related, unless it fulfills the criteria specified below .  
Evidence exists that the adverse event has an etiology other than the study drug 
(e.g., preexisting medical condition, underlying disease, intercurrent illness, 
orconcomit ant medication); and/or the adverse event has no plausible temporal 
relationship to administration of the study drug (e.g., cancer diagnosed 2 days after 
firstdose of study drug).
5.3.[ADDRESS_835465] medical terminology/concepts when recording AEs on 
the Adverse Event eCRF.  Avoid colloquialisms and abbreviations.
Only 1AEterm should be recorded in the event field on the Adverse Event eCRF.
[IP_ADDRESS] Injection Reactions
Adverse events that occur during or within 24 hours after study drug administration 
should be captured as individual signs and symptoms on the Adverse Event eCRF 
rather than an overall diagnosis (e.g., record dyspnea and hypotension as separate 
events rather than a diagnosis of IT bolus -related reaction or anaphylactic reaction).
[IP_ADDRESS] Diagnosis versus Signs and Sy mptoms
For AEs other than injection reactions (see Section [IP_ADDRESS] ), a diagnosis (if known) 
should be recorded on the Adverse Event eCRF rather than individual signs and 
symptoms (e.g., record only liver failure or hepatitis rather than jaundice, asterixis, and 
elevated transaminases).  However, if a conste llation of signs and/or symptoms cannot 
be medically characterized as a single diagnosis or syndrome at the time of reporting, 
each individual event should be recorded on the Adverse Event eCRF.  If a diagnosis is 
subsequently established, all previously r eported AEs based on signs and symptoms 
should be nullified and replaced by [CONTACT_371429], with a 
starting date that corresponds to the starting date of the first symptom of the eventual 
diagnosis.

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
75/Protocol BN40955, Version [IP_ADDRESS] Adverse Events That A re Seco ndary  to Other Events
In general, AEs that are secondary to other events (e.g., cascade events or clinical 
sequelae) should be identified by [CONTACT_5252], with the exception of severe or 
serious secondary events.  A medically significant secondary AEthat is separated in 
time from the initiating event should be recorded as an independent event on the 
Adverse Event eCRF.  For example:
If vomiting results in mild dehydration with no additional treatment in a healthy adult, 
only vomiting should be repor ted on the eCRF
If vomiting results in severe dehydration, both events should be reported separately 
on the eCRF
If a severe gastrointestinal hemorrhage leads to renal failure, both events should be 
reported separately on the eCRF
If dizziness leads to a f all and consequent fracture , all 3events should be reported 
separately on the eCRF
If neutropenia is accompanied by [CONTACT_25747], both events should be reported 
separately on the eCRF
All AEs should be recorded separately on the Adverse Event eCRF if it is unclear as to 
whether the events are associated.
[IP_ADDRESS] Persistent or Recurrent A dverse Events
A persistent AEis one that extends continuously, without resolution, between patient 
evaluation timepoints.  Such events should only be recorded once on the 
Adverse Event eCRF.  The initial severity (intensity or grade) of the event will be 
recorded at the time the even t is first reported.  If a persistent AEbecomes more severe, 
the most extreme severity should also be recorded on the Adverse Event eCRF.  If the 
event becomes serious, it should be reported to the Sponsor immediately (i.e., no more 
than 24 hours after learning that the event became serious; see Section 5.4.2 for 
reporting instructions).  The Adverse Event eCRF should be updated by [CONTACT_70156] non-serious to serious, providing the date that the event became serious, 
and completing all data fields related to SAEs .
A recurrent AEis one that resolves between patient evaluation timepoints and 
subsequently recurs.  Each recurrence of an AEshould be recorded as a separate event 
on the Adverse Event eCRF.
[IP_ADDRESS] Abnormal Laboratory Values
Not every laboratory abnormality qualifies as an AE.  A laboratory test result must be 
reported as an AEif it meets any of the following criteria:
Is accompanied by [CONTACT_4659]
Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation)

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
76/Protocol BN40955, Version 7Results in a medical intervention (e.g., potassium supplementation for hypokalemia) 
or a change in concomitant therapy
Is clinically significant in the investigator's judgment
It is the investigator's responsibility to review all laboratory findings.  Medical and 
scientific judgment should be exercised in deciding whether an isolated laboratory 
abnormality should be classified as an AE.
If a clinically significant laboratory abnormality is a sign of a disease or syndrome 
(e.g., alkaline phosphatase and bilirubin 5 ULN associated with cholestasis), only the 
diagnosis (i.e., cholestasis) should be recorded on the Adverse Event eCRF.
If a clinically significant laboratory abnormality is not a sign of a disease or syndrome, 
the abnormality itself should be recorded on the Adverse Event eCRF, along with a 
descriptor indicating whether the test result is above or below the normal range 
(e.g., elevated potassium, as opposed to abnormal potassium ).  If the laboratory 
abnormality can be characterized by a precise clinical term per standard definitions, the 
clinical term should be recorded as the AE.  For example, an elevated serum potassium 
level of 7.0 mEq/L should be recorded as hyperkalemia. 
Observations of the same clinically significant laboratory abnormality from visit to visit 
should only be recorded once on the Adverse Event eCRF (see Section [IP_ADDRESS] for 
details on recording persistent AEs).
[IP_ADDRESS] Abnormal Vital Sign Values
Not every vital sign abnormality qualifies as an AE.  A vital sign result must be reported
as an AEif it meets any of the following criteria:
Is accompanied by [CONTACT_4659]
Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation)
Results in a medical intervention or a change in concomitant therapy
Is clinically significant in the investigator's judgment
It is the investigator's responsibility to review all vital sign findings.  Medical and scientific 
judgment should be exercised in deciding whether an isolated vital sign abnormality 
should be classified as an AE.
If a clinically significant vital sign abn ormality is a sign of a disease or syndrome 
(e.g., high blood pressure), only the diagnosis (i.e., hypertension) should be recorded on 
the Adverse Event eCRF.
Observations of the same clinically significant vital sign abnormality from visit to visit 
should only be recorded once on the Adverse Event eCRF (see Section [IP_ADDRESS] for 
details on recording persistent AEs).

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
77/Protocol BN40955, Version [IP_ADDRESS] Abnormal Liver Function Tests
The finding of an elevated ALT or AST ( 3ULN) in combination with either an elevated 
total bilirubin ( 2ULN) or clinical jaundice in the absence of cholestasis or other causes 
of hyperbilirubinemia is considered to be an indicator of severe liver injury (as defined by 
[CONTACT_25742]'s Law).  Therefore, investigators must report as an AEthe occurrence of either of the 
following:
Treatment -emergent ALT or AST 3ULN in combination with total bilirubin 2ULN
Treatment -emergent ALT or AST 3ULN in combination with clinical jaundice
The most appropriate diagnosis or (if a diagnosis cannot be established) the abnormal 
laboratory values should be recorded on the Adverse Event eCRF (see Section [IP_ADDRESS]) 
and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of 
the event) ;either as a SAE or an adverse event of special interest (see Section 5.4.2 ).
[IP_ADDRESS] Deaths
All deaths that occur during the protocol -specified AEreporting period 
(see Section 5.3.1 ), regardless of relationship to study drug, must be recorded on the 
Adverse Event eCRF and immediately reported to the Sponsor (see Section 5.4.2 ).  This 
includes death attributed to progression of HD.
Death should be considered an outcome and not a distinct event.  The event or condition 
that caused or contributed to the fatal outcome should be recorded as the single medical 
concept on the Adverse Event eCRF.  Generally, only one such event should be 
reported.  If the cause of death is unknown and cannot be ascertained at the time of 
reporting, unexplained death should be recorded on the Adverse Event eCRF.  If the 
cause of death later becomes available (e.g., after autopsy), unexplained death should 
be replaced by [CONTACT_25749].  The term sudden death should not be 
used unless combined with the presumed cause of death (e.g., sudden cardiac death ).
If the death is attributed solely to progression of HD,  Huntington's disease progression 
should be recorded on the Adverse Event eCRF.
Deaths that occur after the AEreporting period should be repo rted as described i n 
Section 5.6.
[IP_ADDRESS] Preexisting Medical Conditions
A preexisting medical condition is one that is present at the inclusion visit for this study.  
Such conditions should be recorded on the General Medical Histor y and 
Baseline Conditions eCRF.
A preexisting medical condition should be recorded as an AEonly if the frequency, 
severity, or character of the condition worsens during the study.  W hen recording such 
events on the Adverse Event eCRF, it is important to c onvey the concept that the 

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
78/Protocol BN40955, Version 7preexisting condition has changed by [CONTACT_9672] 
(e.g., more frequent headaches ).
[IP_ADDRESS] Lack of Efficacy  or Worsening of Huntington's Disease
Events that are clearly consistent with the expected pattern of progre ssion of the 
underlying disease should notbe recorded as AEs.  These data will be captured as 
efficacy assessment data only.  If there is any uncertainty as to whether an event is due 
to disease progression, it should be reported as an AE.
[IP_ADDRESS] Hospi[INVESTIGATOR_371415] (i.e., inpatient admission to a hospi[INVESTIGATOR_307]) or prolonged 
hospi[INVESTIGATOR_25676] a SAE (per the definition of SAE
inSection 5.2.2 ), except as outlined below.
An event that leads to hospi[INVESTIGATOR_371416] a SAE:
Hospi[INVESTIGATOR_25678]
Planned hospi[INVESTIGATOR_33402]
Hospi[INVESTIGATOR_272] a preexisting condition, provided that all of the following criteria 
are met:
The hospi[INVESTIGATOR_626875] t he 
study when elective surgery became necessary because of the expected 
normal progression of the disease .
The patient has not experienced an AE.
An event that leads to hospi[INVESTIGATOR_33405] a SAE, but should be reported as an AEinstead:
Hospi[INVESTIGATOR_25682] .
[IP_ADDRESS] Reporting Requirements for Cases of A ccidental Overdose or 
Medication Error
Accidental overdose and medication error (hereafter collectively referred to as 
special situations ), are defined as follows:
Accidental overdose:  accidental administration of a drug in a quantity that is higher 
than the assigned dose
Medication error:  accidental deviation in the administration of a drug
In some cases, a medication error may be intercepted prior to administration of 
the drug.
Special situations are not in themselves AEs, but may result in AEs.  
Each AEassociated with a special situation should be recorded separately on the 
Adverse Event eCRF.  If the associated AEfulfills seriousness criteria, the event should 

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
79/Protocol BN40955, Version 7be reported to the Sponsor immediately (i.e., nomore than 24 hours after learning of the 
event; see Section 5.4.2 ).  For RO7234292 , AEs associated with special situations 
should be recorded as described below for each situation:
Accidental overdose:  Enter the AE ter m.  Check the Accidental overdose and 
Medication error boxes .
Medication error that does not qualify as an overdose:  Enter the AEterm.  
Check the Medication error box.
Medication error that qualifies as an overdose:  Enter the AEterm.  Check the 
Accidental overdose and Medication error boxes .
In addition, all special situations associated with RO7234292 , regardless of whether they 
result in an AE, should be recorded on the Adverse Event eCRF as described below:
Accidental overdose:  Enter the drug name [INVESTIGATOR_1238] accidental overdose as the event 
term.  Check the Accidental overdose and Medication error boxes .
Medication error that does not qualify as an overdose:  Enter the name [CONTACT_26865] a desc ription of the error (e.g., wrong dose administered, wrong 
dosing schedule, incorrect route of administration, wrong drug, expi[INVESTIGATOR_26669]) as the event term.  Check the Medication error box.
Medication error that qualifies as an overdose:  Ent er the drug name [INVESTIGATOR_1238] 
Accidental overdose as the event term.  Check the Accidental overdose and 
Medication error boxes.  Enter a description of the error in the additional case 
details .
Intercepted medication error:  Enter the drug name [INVESTIGATOR_1238] 
Intercept edmedication erroras the event term.  Check the Medication error box.  
Enter a description of the error in the additional case details.
As an example, an accidental overdose that resulted in a headache would require 
twoentries on the Adverse Event eCRF, one entry to report the accidental overdose and 
one entry to report the headache.  The Accidental overdose and Medication error 
boxes would need to be checked on both eCRF pages.
[IP_ADDRESS] Patient -Reported Outcome Data
Adverse event reports will not be derived by [CONTACT_626942] (HD mobile app) data, and safety analyses will not be performed using PRO or 
digital wearable device data.  Sites are not expected to review the PRO or digital 
wearable device data for AEs.
[IP_ADDRESS] Safety  Biomarker Data
Adverse event reports will not be derived from safety biomarker data by [CONTACT_1034], 
and safety biomarker data will not be included in the formal safety analyses for this study.  
In addition, safety biomarke r data will not inform decisions on patient management.

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
80/Protocol BN40955, Version 75.[ADDRESS_835466] report 
such events to the Sponsor immediately; under no circumstances should reporting take 
place more than [ADDRESS_835467] rep ort to the Sponsor within 24 hours after learning 
of the event, regardless of relationship to study drug:
Serious adverse events (defined in Section 5.2.2 ; see Section 5.4.2 for details on 
reporting requirements)
Adverse events of special interest (defined in Section 5.2.3 ; see Section 5.4.2 for 
details on reporting requirements)
Pregnancies (see Section 5.4.3 for details on reporting requirements)
The investigator must report new significant follow -up information for these events to the 
Sponsor immediately (i.e., no more than 24 hours after becoming aware of the 
information).  New significant information includes the following:
New signs or symptoms or a change in the diagnosis
Significant new diagnostic test results
Change in causality based on new information
Change in the event's outcome, including recovery
Additional narrative information on the clinical course of the event
Investigators must also comply with local requirements for reporting SAEs to the local 
HAand IRB/ EC.
5.4.[ADDRESS_835468] Information for A ll Sit es
Medical Monitor: , M.D., Ph.D .
Telephone No.:
Mobile Telephone No.:
To ensure the safety of study patients, an Emergency Medical Call Center Help Desk will 
access the [COMPANY_002] Medical Emergency List, es calate emergency medical calls, provide 
medical translation service (if necessary), connect the investigator with a 
[COMPANY_002] Medical Responsible (listed above and/or on the [COMPANY_002] Medical Emergency List), 
and track all calls.  The Emergency Medical Call Center Help Desk will be available 
24hours per day, [ADDRESS_835469] information, will be distributed to all 
investigators.

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
81/Protocol BN40955, Version 75.4.[ADDRESS_835470]
[IP_ADDRESS] Events That Occur prior to Study  Drug Initiation
After informed consent has been obtained but prior to initiation of study drug, only SAEs
caused by a protocol -mandated intervention should be reported.  The paper Clinical Trial 
Serious Adverse Event/Adverse Event of Special Interest Reporting Form provided to 
investigators should be completed and submitted to the Sponsor or its designee 
imme diately (i.e., no more than 24 hours after learning of the event), either by [CONTACT_626943] e-mail address provided to 
investigators.
[IP_ADDRESS] Events That Occur after Study  Drug Initiation
After initiation of study drug, SAEs and AESIs will be reported until [ADDRESS_835471] all case details that can be 
gathered immediately (i.e., within 24 hours after learning of the event) on the 
Adverse Event eCRF and submit the report via the electronic data capture (EDC) system.  
Areport will be generated and sent to [COMPANY_002] Safety Risk Management by [CONTACT_25751].
In the event that the EDC system is unavailable, the paper Clinical Trial Serious Adverse 
Event/Adverse Event of Special Interest Reporting Form provided to investigators should 
be completed and submitted to the Sponsor or its designee immediately (i.e., no more 
than 24 hours after learning of the event), either by [CONTACT_330353] e-mail address provided to investigators.  Once the 
EDC system is available, all information will need to be entered and submitted via the 
EDC system.
Instructions for reporting SAEs that occur 5months after the final dose of study 
treatment are provided in Section 5.6.
5.4.3 Reporting Requirements for Pregnancies
[IP_ADDRESS] Pregnancies in Female Patients
Female patients of childbearing potential will be instructed to immediately inform the 
investigator if they become pregnant during the study or within 5 months after the final 
dose of study drug.  A paper Clinical Trial Pregnancy Reporting Form should be 
completed and submitted to the Sponsor or its designee immediately (i.e., no more than 
24hours after learning of the pregnancy), either by [CONTACT_330353] e- mail addre ss provided to investigators.  Pregna ncy 
should not be recorded on the Adverse Event eCRF.  The investigator should 
discontinue study drug and counsel the patient, discussing the risks of the pregnancy 
and the possible effects on the fetus.  Monitoring of the patient should continue until 
conclusion of the pregnancy.  Any SAEs associated with the pregnancy (e.g., an event in 
the fetus, an event in the mother during or after the pregnancy, or a congenital 
anomaly/birth defect in the child) should be reported on the Adverse Event eCRF.  In 

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
82/Protocol BN40955, Version 7addit ion, the investigator will submit a Clinical Trial Pregnancy Reporting Form when 
updated information on the course and outcome of the pregnancy becomes available.
[IP_ADDRESS] Pregnancies in Female Partners of Male Patients
Male patients will be instructed through the ICFto immediately inform the investigator if 
their partner becomes pregnant during the study or within 5months after the final dose 
of study drug.  A paper Clinical Trial Pregnancy Reporting Form should be completed 
and submitted to the Sponsor or its de signee immediately (i.e., no more than 24 hours 
after learning of the pregnancy), either by [CONTACT_626944] e- mail addres s provided to investigators.  Attempts should be 
made to collect and report details of the course and outcome of any pregnancy in the 
partner of a male patient exposed to study drug.  W henpermitted by [CONTACT_779], the 
pregnant partner would need to sign an Authorization for Use and Disclosure of 
Pregnancy Health Information to allow for fo llow-up on her pregnancy.  If the 
authorization has been signed, the investigator should submit a Clinical Trial Pregnancy 
Reporting Form when updated information on the course and outcome of the pregnancy 
becomes available.  An investigator who is contact[CONTACT_77005], to support an informed decision in cooperation with the treating physician 
and/or obstetrician.
[IP_ADDRESS] Abortions
Any aborti on should be classified as a SAE (asthe Sponsor considers abortions to be 
medically significant), recorded on the Adverse Event eCRF, and reported to the 
Sponsor immediately (i.e., no more than 24 hours after learning of the event; see 
Section 5.4.2 ).
[IP_ADDRESS] Congenital A nomalies/Birth Defects
Any congenital anomaly/birth defect in a child born to a female patient exposed to study 
drug or the female partner of a male patient exposed to study drug should be classified 
as a SAE, recorded on the Adverse Event eCRF, and reported to the Sponsor 
immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2 ).
5.[ADDRESS_835472] to follow -up, or 
the patient withdraws consent.  Every effort should be made to follow all SAEs considered 
to be related to study drug or trial -related procedures until a final ou tcome can be reported.
During the study period, resolution of AEs (with dates) should be documented on the 
Adverse Event eCRF and in the patient's medical record to facilitate source data 
verification.

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
83/Protocol BN40955, Version 7All pregnancies reported during the study should be fo llowed until pregnancy outcome.
5.5.2 Sponsor Follow -Up
For SAEs , AESIs , and pregnancies, the Sponsor or a designee may follow up by 
[CONTACT_756], fax, e -mail, and/or a monitoring visit to obtain additional case details and 
outcome information (e.g., from hospi[INVESTIGATOR_8838], consultant reports, 
autopsy reports) in order to perform an independent medical assessment of the reported 
case.
5.6 ADVERSE EVENTS THA T OCCUR AFTER THE A DVERSE 
EVENT REPORTING PERI OD
The Sponsor should be notified if the investigator beco mes aware of any SAE that 
occurs after the end of the AEreporting period (defined as 5months after the final dose 
of study drug), if the event is believed to be related to prior study drug treatment.  These 
events should be reported through use of the Ad verse Event eCRF.  However, if the 
EDC system is not available, the investigator should report these events directly to the 
Sponsor or its designee, either by [CONTACT_200052]/Adverse Event o f Special Interest Reporting Form using the 
fax number or e -mail address provided to investigators.
5.[ADDRESS_835473] 
experience to identify and expeditiously communicate possible new safety findings to 
investigators, IRBs, ECs, and applicable HAs based on applicable legislation.
To determine reporting requirements for single AEcases , the Sponsor will assess the 
expectedness of these events using the following reference document:
RO7234292 Investigator's Brochure
The Sponsor will compare the severity of each event and the cumulative event 
frequency reported for the study with the severity and frequency reported in the 
applicable reference document.
Reporting requirements will also be based on the investigator's assessment of causality 
and seriousness, with allowance for upgrading by [CONTACT_25753].
6. STATISTICA L CONSIDER ATIONS AND ANAL YSIS PLA N
6.1 ANAL YSIS POPULA TIONS
The intent -to-treat (ITT) population will consist of all patients who received any study 
treatment.  Randomized patients who received incorrect therapy from that intended will 
be summarized in the group according to their planned randomized treatment.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
84/Protocol BN40955, Version 7The ITT population will be the primary population for all analyses of efficacy and 
biomarker variables.
The safety population will consist of all patients who received any study treatment.
Thesafety population will be the primary population for all safety analyse s. For the 
purpose of all safety analyses, it will be assessed whether patients received a treatment 
different from the one they were randomized to at any time during the course of the 
study . In case the number and duration of such treatment switches warrants it, the 
safety population may be redefined by [CONTACT_626945], as opposed to which treatment they were randomized to.
6.[ADDRESS_835474] one dose of study drug, with patients grouped according to treatment received.
All verbatim AEterms will be mapped to Medical Dictionary for Regul atory Activities 
(MedDRA )thesaurus terms .  TheAdverse Event Severity Grading Scale (see 
Section 5.3.3 ) will be used f or as sessing  AEseverity.  Laboratory values determined as 
an AEshould be graded as per Appendix 10, which is based on the NCI CTCAE ( v5.0).
All safety data , including AEs, laboratory tests, neurologic examination, C -SSRS, MoCA, 
ECG ,and vital signs ,will be reported in individual listings and summarized by [CONTACT_626946]. Forcontinuous variables, both the 
original value as well as the change from baseline will be reported.
The incidence of AEs will be summarized on the basis of body systems and dictionary 
preferred terms. The incidence of AEs by [CONTACT_626947].

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
85/Protocol BN40955, Version 76.6 EXPLORA TORY EFFICA CY ANAL YSES
The efficacy endpoints will be sum marized by [CONTACT_626948], in terms of both absolute values and change from baseline.
Additional statistical model ingmay be considered and will eventually be specified in the 
Statistical Analysis Plan (SAP).
6.[ADDRESS_835475] deviations, and coefficients of variation.  Nonlinear mixed -effects modeling will 
be used to analyze the concentration time data for RO7234292 in CSF and plasma 
following IT administration.  A covariate analysis will be conducted to evaluate the effect 
of covariates such as body weight, age, and sex on RO7234292 exposure.  Population 
and individual estimates of primary PK parameters (e.g., clearance, distribut ion volume) 
and secondary PK parameters (e.g., average trough plasma concentration) will be 
computed and used to explore the exposure -response relationship on selected 
endpoints, as well as safety measures.  The data from this study may be pooled with 
data from other studies conducted with RO7234292 to support the population PK/PD
modeling.
Details of this mixed- effects modeling and exploration of exposure -response analysis 
and results will be described and reported in a document separate from the 
Clinical Study Report.
6.[ADDRESS_835476] 
oneADA assessment. Patients will be grouped according to treatment received. 
Thenumbers and proportions of ADA -positive patients and ADA -negative patients at 
baseline (baseline prevalence) will be summarized by [CONTACT_1570].   For those who 
are ADA -positive, titers will be estimated ,as well as antibody subtype. In addition, the 
numbers and proportions of ADA -positive pa tients and ADA -negative patients at 
baseline (baseline prevalence) and after drug administration (post -baseline incidence) 
will be summarized.
When determining post -baseline incidence, patients are considered to be ADA -positive if 
they are ADA -negative or have missing data at baseline but develop an ADA response 
following study drug exposure (treatment -induced ADA response), or if they are 
ADA-positive at baseline an d the titer of one or more post -baseline samples is at least is 
at least 4 -fold greater than the titer of the baseline sample (treatment -enhanced ADA 
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
86/Protocol BN40955, Version 7response). Patients are considered to be ADA -negative if they are ADA -negative or 
have missin g data at baseline and all post -baseline samples are negative, or if they are 
ADA-positive at baseline b ut do not have any post -baseline samples with a titer that is at 
least 4 -fold greater than the titer of the baseline sample (treatment unaffected).
6.[ADDRESS_835477] data clarification from the sites, which the sites 
will resolve electronically in the EDC system.
The Sponsor will produce an EDC Study Specification document that describes the 
quality checking to be performed on the data.  Central laboratory data, electronic data 
from clinic visits (see Section 7.3) and electronic data obtained from the [COMPANY_002] HD 
mobile app (see Section 7.4)will be sent directly to the Sponsor, using the Sponsor's 
standard procedures to handle and process the electronic transfer of t hese data.
Electronic Case Report Forms and correction documentation will be maintained in the 
EDC system's audit trail.  System backups for data stored by [CONTACT_70172]'s standard procedures.
Patient -reported outcome , ClinRO, and PerfO data will be collected through the use of 
an electronic device provided by a vendor (see Section 7.3for details).

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
87/Protocol BN40955, Version 77.[ADDRESS_835478] that is attributable, secure, and
accurate, in compliance with U.S. FDA regulations for electronic records 
(21CFR Part 11).  The data will be transmitted to a centralized database maintained by 
[CONTACT_40893].
The electronic data will be available for view access only, via a secure vendor web portal .  
Only identified and trained users may view the data, and their actions will becom e part of 
the audit trail.  The Sponsor will have view access only.  System backups for data stored 
by [CONTACT_626949] s tudy data will be consistent with the 
Sponsor's standard procedures.
Once the study is complete, the data, audit trail, and trial and system documentation will 
be archived.  The investigator will receive patient data for the site in both human -and 
machine- readable formats on an archival -quality compact disc that must be kept with the 
study records as source data.  Acknowledgement of receipt of the compact disc is 
required.  In addition, the Sponsor will receive all data in a machine -readable format on a 
compact disc.
7.4 ELECTRONIC DA TA OBTA INED BY [CONTACT_626950] L 
MOBILE A PPLICA TION
During active tests and passive monitoring, the smartphone and wrist -worn wearable 
record smovement and location data.  Data on the technical status and connectivity of 
the devices is also recorded.  Patients can choose to pause location data recording.  
Nopatient identifiable information is stored on the devices.  For selected active test 
tasks, touch and sound is also recorded.  Video is not recorded.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
88/Protocol BN40955, Version 7[COMPANY_002] HD mobile app (smartphone and wrist -worn wearable) sensor data are encrypted 
and uploaded to secure servers whenever the smart phone is connected to Wifi. 
Allsensor data will be managed by [CONTACT_626951].  This includes, but is not limited, to the analysis of 
sensor data together with protocol -specified assessments and activities associated with 
routine daily living.   The data will not be analyzed for efficacy until study end, unless they 
are chosen to be a part of a pre -specified interim analysis along with other clinical and/or 
biomarker endpoints.
7.5 SOURCE DA TA DOCUMENT ATION
Study monitors will perform ongoing source data verification and review to confirm that 
critical protocol data (i.e., source data) entered into the eCRFs by [CONTACT_77038], complete, and verifiable from source documents.
Source documents (paper or electronic) are those in w hich patient data are recorded 
and documented for the first time.  They include, but are not limited to, hospi[INVESTIGATOR_1097], 
clinical and office charts, laboratory notes, memoranda, PROs , evaluation checklists, 
pharmacy dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_70069], 
microfiche, photographic negatives, microfilm or magnetic media, X -rays, patient files, 
and records kept at pharmacies, laboratories, and medico -technical departments 
involved in a clinical trial.
Before study initiation, the types of source documents that are to be generated will be 
clearly defined in the Trial Monitoring Plan.  This includes any protocol data to be 
entered directly into t he eCRFs (i.e., no prior written or electronic record of the data) and 
considered source data.
Source documents that are required to verify the validity and completeness of data 
entered into the eCRFs must not be obliterated or destroyed and must be retain ed per 
the policy for retention of records described in Section 7.7.
To facilitate source data verification and review, the investigators and institutions must 
provide the Sponsor direct access to applicable source documents and reports for 
trial-related moni toring, Sponsor audits, and IRB/EC review.  The study site must also 
allow inspection by [CONTACT_626952].
7.6 USE OF COMPUTERIZED SYSTEMS
When clinical observations are entered directly into a study site's computerized medical 
record system (i.e., in lieu of or iginal hardcopy records), the electronic record can serve 
as the source document if the system has been validated in accordance with 
HArequirements pertaining to computerized systems used in clinical research.  
Anacceptable computerized data collection s ystem allows preservation of the original 
entry of data.  If original data are modified, the system should maintain a viewable audit 

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
89/Protocol BN40955, Version 7trail that shows the original data as well as the reason for the change, name [CONTACT_40916], and date of the change.
7.[ADDRESS_835479] of this study and the distribution of 
IMP, including eCRFs, electronic or paper PRO , PerfO ,and ClinRO data (ifapplicable), 
ICFs , laboratory test results, and medication inventory records, must be retained by [CONTACT_1268] [INVESTIGATOR_8178] [ADDRESS_835480] to local regulations.
No records may be disposed of without the written approval of the Sponsor.  
Written notification should be provided to the Sponsor prior to transferring any records to 
another party or moving them to another location.
[COMPANY_002] will retain study data for 25 years after the final Clinical Study Report has been 
completed or for the length of time required by [CONTACT_626953], whichever 
is longer.
8. ETHICA L CONSIDERA TIONS
8.1 COMPLIA NCE WITH LA WSAND REGULAT IONS
This study will be conducted in full conformance with the ICH E6 guideline for Good 
Clinical Practice and the principles of the Declaration of Helsinki, or the applicable laws
and regulations of the country in which the research is conducted, whicheve r affords the 
greater protection to the individual.  The study will comply with the requirements of the 
ICH E2A guideline (Clinical Safety Data Management:  Definitions and Standards for 
Expedited Reporting).  Studies conducted in the U.S. or under a U.S. Investigational 
New Drug (IND) Application will comply with U.S. FDA regulations and applicable local, 
state, and federal laws.  Studies conducted in the European Union (E.U.) or European 
Economic Area will comply with the E.U. Clinical Trial Directive (20 01/20/EC) and 
applicable local, regional, and national laws .
8.2 INFORMED CONSENT
The Sponsor's sample ICF(and ancillary sample ICFs ) will be provided to each site.  If 
applicable, it will be provided in a certified translation of the local language.  The 
Sponsor or its designee must review and approve any proposed deviations from the 
Sponsor's sample ICFs or any alternate consent form s proposed by [CONTACT_779] (collectively, 
the Consent Forms ) before IRB/EC submission.  The final IRB/EC approved Consent 
Forms must be provided to the Sponsor for HAsubmission purposes according to local 
requirements.
If applicable, the ICFwill contain separate sections for any optional procedures.  The 
investigator or authorized designee will explain to each patient the objectives, methods, 
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
90/Protocol BN40955, Version 7and potential risks associated with each optional procedure.  Patients will be told that 
they are free to refuse to participate and may withdraw their consent at any time for any 
reason.  A separate, specific signature [CONTACT_22862] a patient's 
agreement to participate in optional procedures.  Patients who decline to participate will 
not provide a separat e signature.
The Consent Forms must be signed and dated by [CONTACT_12718]'s legally 
authorized representative before his or her participation in the study.  The case history or 
clinical records for each patient shall document the informed conse nt process and that 
written informed consent was obtained prior to participation in the study.   Ifthe legally 
authorized representative signs the Consent Form with the patient, the patient will still 
need to provide assent in the case he/she is no longer capable of providing consent.  
Assent implies willingness or, minimally, lack of objection to taking part and will need to 
be documented by [CONTACT_779].  (Note: Patients in [LOCATION_013] who are not fully capable of 
providing informed consent are not eligible for participation ).
The Consent Forms should be revised whenever there are changes to study procedures 
or when new information becomes available that may affect the willingness of the patient 
to participate.  The final revised IRB/EC -approved Consent Forms must be provided to
the Sponsor for HAsubmission purposes.
Patients must be re -consented to the most current version of the Consent Forms (or to a 
significant new information/findings addendum in accordance with applicable laws and 
IRB/EC policy) during their participation in the study.  For any updated or revised 
Consent Forms, the case history or clinical records for each patient shall document the 
informed consent process and that written informed consent was obtained using the 
updated/revised Consent Forms for continued participation in the study.  If the legally 
authorized representative signs the Consent Form for the patient, the patient will still 
need to provide assent in the case that he/she is no longer fully capable of providing 
consent .  (Note: Patients in [LOCATION_013] who are not fully capable of providing informed 
consent are not eligible for participation).
A copy of each signed Consent Form must be provided to the patient or the patient's 
legally authorized representative.  All signed and dated Consent Forms must r emain in 
each patient's study file or in the site file and must be available for verification by [CONTACT_33483].
For sites in the U.S., each Consent Form may also include patient authorization to allow 
use and disclosure of personal health info rmation in compliance with the U.S. Health 
Insurance Portability and Accountability Act (HIPAA) of 1996.  If the site utilizes a 
separate Authorization Form for patient authorization for use and disclosure of personal 
health information under the HIPAA reg ulations, the review, approval, and other 
processes outlined above apply except that IRB review and approval may not be 
required per study site policies.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
91/Protocol BN40955, Version 78.[ADDRESS_835481] be submitted to the IRB/EC by [CONTACT_079] [INVESTIGATOR_162412]/EC before the study is initiated.  In addition, any 
patient recruitment materials must be approved by [CONTACT_941] I RB/EC.
The Principal Investigator [INVESTIGATOR_25685]/EC annually or more frequently in accordance with the requirements, 
policies, and procedures established by [CONTACT_1201]/EC.  Investigators ar e also responsible 
for promptly informing the IRB/EC of any protocol amendments (see Section 9.7).
In addition to the requirements for reporting all AEsto the Sponsor, investigators must 
comply with requirements for reporting SAEs to the local HAand IRB/EC.  Investigators 
may receive written IND safety reports or other safety -related communications from the 
Sponsor.  Investigators are responsible for ensuring that such reports are reviewed and 
processed in accordance with HArequirements and the policies and procedures 
established by [CONTACT_11577]/EC, and archived in the site's study file.
8.[ADDRESS_835482] parties only as permitted by [CONTACT_9535](orseparate authorization for use and 
disclosure of personal health information) signed by [CONTACT_102], unless permitted or 
required by [CONTACT_2371].
Medical information may b e given to a patient's personal physician or other appropriate 
medical personnel responsible for the patient's welfare, for treatment purposes.
Given the complexity and exploratory nature of exploratory biomarker analyses, data 
derived from these analyses will generally not be provided to study investigators or 
patients unless required by [CONTACT_2371].  The aggregate results of any conducted research will 
be available in accordance with the effective Sponsor policy in the study data publication 
(see Section 9.6).
Data generated by [CONTACT_626954], Sponsor monitors, representatives, and 
collaborators, and the IRB/EC for each study site, as appropriate.
Study data may be submitted to government or other health research databases or 
shared with researchers, government agencies, companies, or other groups that are not 
participating in this study.  These data may be combined with or linked to other data and 

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
92/Protocol BN40955, Version 7used for research purposes, to advance science and public health, or for analysis, 
development, and commercialization of products to treat and diagnose disease. 
Linkin gof data will be facilitated by [CONTACT_601379] (see Section 4.5.2 ).The HDID is a 
unique coded identifier for persons participating in studies in HD.  This HDID will stay the 
same for a person throughout all trials.  The use of the unique identifier will assure that 
people are only enrolled once in large observational studies like ENROLL -HD, 
REGISTRY, COHORT, PREDICT -HD, and TRACK- HD and will also a llow approved 
comparison and combination of data between studies.  The HDID is a 9-digit number 
created by a secure one -way algorithm, based on unchanging information (date of birth, 
birth name, place of birth ,and mother’s maiden name). The identifying data are used for 
the split second needed by [CONTACT_626955]. It is expected that 
patients from preceding studies have a pre- existing HDID number.  For patients without 
a pre -existing HDID number in the source notes, t he investigator should store the 
original data and the newly generated HDID in the patient’s source documents and in the 
investigator file.   The HDID can be generated within the web portals of the observational 
studies or in the specially defined portal for the HDID generation under:
https://hdid.enroll -hd.org.
In addition, redacted Clinical Study Reports andother summary reports will be provided 
upon request.
8.5 FINA NCIA L DISCLOSURE
Investigators will provide the Sponsor with sufficient, accurate financial information in 
accordance with local regulations to allow the Sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate HAs.  Inves tigators are 
responsible for providing information on financial interests during the course of the study 
and for 1 year after completion of the study (see definition of endofstudy inSection 3.2).
9. STUDY DOCUMENTATION, MONITORING, A ND 
ADMINISTRA TION
9.[ADDRESS_835483] of 
the study to be fully documented, including, but not limited to, the protocol, protocol 
amendments, ICFs , and documentation of IRB/EC and governmental approval.  In 
addition, at the end of the study, the investigator will receive the patient data, including 
an audit trail containing a complete record of all changes to data.
9.[ADDRESS_835484] on patient safety and 
data integrity to the Sponsor and to the IRB/EC in accordance with established IRB/EC 
policies and procedures.  The Sponsor will review all protocol deviations and assess 

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
93/Protocol BN40955, Version 7whether any represent a serious breach of Good Clinical Practice guidelines and require 
reporting to HAs.  As per the Sponsor' s standard operating procedures, prospective 
requests to deviate from the protocol, including requests to waive protocol eligibility 
criteria, are not allowed.
9.3 MANAGEMENT OF STUDY QUA LITY
The Sponsor will implement a system to manage the quality of the study, focusing on 
processes and data that are essential to ensuring patient safety and data integrity. 
TheSponsor will identify potential risks associated with critical trial processes and data 
and will implement plans for evaluating and controlling these risks. Risk evaluation and 
control will include the selection of risk -based parameters (e.g., AErate, protocol 
deviation rate) and the establishment of quality tolerance limits for these parameters. 
Detection of deviations from quality tolerance limits will trigger an evaluation to 
determine if action is needed. Details on the establishment and monitoring of quality 
tolerance limits will be provided in a Quality Tolerance Limit Manageme nt Plan.
9.4 SITE INSPECTIONS
Site visits will be conducted by [CONTACT_26833], patients' medical records, and eCRFs.  The investigator will 
permit national and local HAs; Sponsor monitors, representativ es, and collaborators; and 
the IRBs/ECs to inspect facilities and records relevant to this study.
9.5 ADMINISTRA TIVE STRUC TURE
This trial will be sponsored and managed by F. Hoffmann -La [COMPANY_002] Ltd.  The Sponsor 
will provide clinical operations management, data management, and medical monitoring.
Approximately 100 sites globally will participate to enroll up to approximately 
1100patients .  Enrollment will occur through an IxRS.
Central facilities will be used for certain study assessments throughout the study 
(e.g.,specified laboratory tests, biomarker and PK analyses), as specified in 
Section 4.5.6 .  Accredited local laboratories will be used for routine monitoring; local 
laboratory ranges will be collected.
9.6 DISSEMINA TION OF DA TA AN D PROTECTION OF TRA DE 
SECRETS
Regardless of the outcome of a trial, the Sponsor is dedicated to openly providing 
information on the trial to healthcare professionals and to the public, at scientific 
congresses, in clinical trial registries, and in peer -reviewed journals. The Sponsor will 
comply with all requirements for publication of study results.  Study data may be shared 
with others who are not participating in this study (see Section 8.4for details) and 
redacted Clinical Study Reports and other summary reports will be made available upon 
request, provided the requirements of [COMPANY_002]'s global policy on data sharing have been 
met.  For more information, refer to the [COMPANY_002] Global Policy on Sharing of Clinical Trials 
Data at the following website:

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
94/Protocol BN40955, Version 7www.roche.com/roche_global_policy_on_sharing_of_clinical_study_i nformation.pdf
The results of this study may be published or presented at scientific congresses.  For all 
clinical trials in patients involving an IMP for which a Marketing Authorization Application 
has been filed or approved in any country, the Sponsor aims to submit a journal 
manuscript reporting primary clinical trial results within [ADDRESS_835485] editorial and ethical practice, the Sponsor will generally 
support publication of multicenter trials only in their entirety and not as individual center 
data.  In this case, a coordinating investigator [INVESTIGATOR_1317] d esignated by [CONTACT_11402].
Authorship will be determined by [CONTACT_43217].  Any formal 
publication of the study in which contribution of Sponsor personnel ex ceeded that of 
conventional monitoring will be considered as a joint publication by [CONTACT_626956].
Any inventions and resulting patents, improvements, and/or know -how originating from 
the use of data from this study will become and remain the exclusive and unburdened 
property of the Sponsor, except where agreed otherwise.
9.7 PROTOCOL A MENDMENTS
Any protocol amendments will be prepared by [CONTACT_1034].  Protocol amendments will 
be submitted to the IRB/EC and to regulatory authorities in accordance with local 
regulatory requirements.
Approval must be obtained from the IRB/EC and regulatory authorities (as locally 
required) before implementation of any changes, except for changes necessary to 
eliminate an immediate hazard to patients or changes that involve logistical or 
administrative aspects only (e.g., change in Medical Monitor or contact [CONTACT_3031]).
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
95/Protocol BN40955, Version 710. REFERENCES
Adams JL, Dinesh K, Xiong M, et al. Multiple wearable sensors in parkinson and 
Huntington disease individuals: a pi[INVESTIGATOR_626876]. Digit 
Biomark 2017:1:52 63.
Andrzejewski KL, Dowling AV, Stamler D, et al. Wearable sensors in Huntington disease: 
a pi[INVESTIGATOR_799]. J Huntington's Dis 2016;5.2:199 206.
Baig SS, Strong M, Quarrell OW . The global prevalence ofHuntington's disease: a 
systematic review and discussion. Neurodegener Dis Manag 2016;6:331 43.
Beglinger LJ, Prest L, Mills JA, et al. Clinical predictors of driving status in Huntington's 
disease. Mov Disord 2012;27:1146 52.
By[CONTACT_597684], Rodrigues FB, Blennow K, et al. Neurofilament light protein in blood as a 
potential biomarker of neurodegeneration in Huntington's disease: a retrospective 
cohort analysis. Lancet Neurol 2017;16:601 9.
Cerritelli SM, Crouch RJ. Ribonuclease H: the enzymes in eukaryotes. FEBS J 
2009;276:1494 505.
Crooke ST, Bennett CF. Progress in antisense oligonucleotide therapeutics. Annu Rev 
Pharmacol Toxicol 1996;36:107 29.
EuroQoL Group. EuroQoL a new facility for the measurement o f health -related quality of 
life. Health Policy 1990;16:199 208.
[FDA] Food and Drug Administration. Guidance for industry: suicidal ideation and 
behavior: prospective assessment of occurrence in clinical trials [resource on the 
Internet] 2012 [cited 28 February 2018]. Available from: 
https://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/guidances/uc
m315156.htm.
Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new 
five-level version of EQ -5D (EQ -5D-5L). Qual Life Re s 2011;20:1727 36.
Hogarth P, Kayson E, Kieburtz K, et al. Interrater agreement in the assessment of motor 
manifestations of Huntington's disease. Mov Disord 2005;20:293 7.
Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and 
consistency. Mov Disord 1996;11:136 42.
Janssen MF, Pi[INVESTIGATOR_19370], Golicki D, et al. Measurement properties of the EQ -5D-5L 
compared to the EQ -5D-3L across eight patient groups: a multi -country study. 
Qual Life Ares 2013;22:1717 27.
Johnson EB, By[CONTACT_597684], Gregory S, et al. Neurofilament light protein in blood predicts 
regional atrophy in Huntington disease. Neurology 2018;90:e717 23.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
96/Protocol BN40955, Version 7Kordasiewicz HB, Stanek LM, W ancewicz EV, et al. Sustained therapeutic reversal of 
Huntington's disease by [CONTACT_626957]. Neuron 
2012;74:1031 44.
Lipsmeier F, Taylor KI, Kilchenmann T, et al. Evaluation of smartphone- based tsting to 
generate exploratory outcome measures in a phase 1 Parkinson's disease clinical 
trial. Mov Disord 2018 ;33:1287 97.
Maet zler W , Domingos J, Srulijes K, et al. Quantitative wearable sensors for objective 
assessment of Parkinson's disease. Mov Disord 2013;28:1628 37.
Moumné L, Betuing S, Caboche J. Multiple aspects of gene dysregulation in 
Huntington's disease. Front Neurol 2013;4:127.
Nance M, Paulsen JS, Rosenblatt A, et al. A physician's guide to the management of 
Huntington's disease, 3rd edition. Huntington's Disease Society of America, 2011.
Paulson HL, Albin RL. Huntington’s disease: clinical features and routes to therapy. In: 
Lo DC, Hughes RE, editors. Neurobiology of Huntington's disease: applications to 
drug discovery. Boca Raton (FL): CRC Press/Taylor & Francis; 2011: Chapter 1.
Posner K, Brown GK, Stanley B, et al. The Columbia -Suicide Severity Rating Scale: 
initial validity and internal consistency findings from three multisite studies with 
adolescents and adults. Am J Psychiatry 2011;168:1266 77.
Ross CA, Pantelyat A, Kogan J, et al. Determinants of functional disa bility in 
Huntington's disease: role of cognitive and motor dysfunction. Mov Disord 
2014;29:1351 8.
Schobel SA, Palermo G, Auinger P, et al. Motor, cognitive, and functional declines 
contribute to a single progressive factor in early HD. Neurology 2017;89: 2495502.
Schoch KM, Miller TM. Antisense oligonucleotides: translation from mouse models to 
human neurodegenerative diseases. Neuron 2017;94:1056 70.
Shoulson I, Fahn S. Huntington disease: clinical care and evaluation. 
Neurology 1979;29:1 3.
Smith, A. Sy mbol Digit Modalities Test (SDMT). Manual (rev.). Los Angeles: Western 
Psychological Services, 1982.
Sorensen SA, Fenger K. Causes of death in patients with Huntington's disease and in 
unaffected first degree relatives. J Med Genet 1992;29:911 4.
Stanek LM , Yang W, Angus S, et al. Antisense oligonucleotide -mediated correction of 
transcriptional dysregulation is correlated with behavioral benefits in the YAC128 
mouse model of Huntington's disease. J Huntingtons Dis 2013;2:217 28.
Van Raamsdonk JM, Pearson J, Rogers DA, et al. Loss of wild -type huntingtin 
nifluences motor dysfunction and survival in the YAC128 mouse model of 
Huntington disease. Human Mol Genet 2005;14:1379 92.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
97/Protocol BN40955, Version 7Walker FO. Huntington's disease. Semin Neurol 2007;27:143 50.
Wexler NS, Young AB, Tanzi RE, et al. Homozygotes for Huntington's disease. Nature 
1987;326:194 7.
Wild EJ, Boggio R, Langbehn D, et al. Quantification of mutant huntingtin protein in 
cerebrospi[INVESTIGATOR_601335]'s disease patients. J Clin Invest 
2015;125:1979 86.
Wild EJ, Tabrizi SJ. Therapi[INVESTIGATOR_601336]'s disease. Lancet 
Neurol 2017;16:837 47.
Zhang Y, Long JD, Mills JA, et al. Indexing Disease Progression at Study Entry with 
Individuals At -Risk for Huntington Disease. Am J Med Genet B Neurpsychaitr 
Genet. 2011;156:751 63.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
98/Protocol BN40955, Version 7Appendix 1a
Schedule of A ctivities for A ll Patients Except Those Undergoing Screening
Inclusion Visit ª Treatment Period bEoTcSFUd
WeekLast applicable 
visit of preceding 
study ªTreatment and Assessment Frequency 4weeks 20 weeks
Day (W indow) 1 weeke1 week 1 week
Signed informed consentfx
Review of inclusion and exclusion criteriax
Demographic data x
Medical histor y and baseline conditionsgx
Vital signshxiAt each clinic visit x x
Complete phy sical examinationjxiQ32W x x
Neurologic examination lxiAt each clinic visit (see Appendix 12) x x
ECG mxiQ32W x x
Hematology nxi
At each clinic visitx x
Chemistry  oxix x
Pregnancy test pxix x
Urinalysis qxix x
Local PT and/or INR, aPTT, platelet 
countsxiAt each study drug administration visit x x

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
99/Protocol BN40955, Version 7Appendix 1a
Schedule of A ctivities for A ll Patients Except Those Undergoing Screening (cont.)
Inclusion Visit ª Treatment Period bEoTcSFUd
WeekLast applicable 
visit of preceding 
study ªTreatment and Assessment Frequency 4weeks 20 weeks
Day (W indow) 1 weeke1 week 1 week
Plasma sampling for PK rxi
Q16Wfor 48 weeks and then Q32W thereafterPlasma sampling for immunogenicity 
testing rxix x
Plasma samples for biomarkers xix x
CSF sample for PK/safety/biomarkerssxiAt each study drug administration x
MoCA xiQ16W x
C-SSRStxiAt each study drug administration x
Mandator y Structural MRI uxiQ32Wkx
Optional resting -state functional MRI and 
diffusion -weighted MRI / NODDIuxiQ32W kx
Optional MRI brain and spi[INVESTIGATOR_626877]40697 vx Q32W x
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
100/Protocol BN40955, Version 7Appendix 1a
Schedule of A ctivities for A ll Patients Except Those Undergoing Screening (cont.)
Inclusion Visit ª Treatment Period bEoTcSFUd
WeekLast applicable 
visit of preceding 
study ªTreatment and Assessment Frequency 4weeks 20 weeks
Day (W indow) 1 weeke1 week 1 week
HD-DAS xi
Q16Wx
TFCwxix
TMSwxix
CGI-S xix
CGI-C x
SDMTwxix
SWRwxix
[COMPANY_002] HD mobile appxiContinuous remote data collection ,as well as Q16 W
in-clinicxx
EQ-5D-5L x At each study drug administration yx
Q8W study  drug administration s, cc x Q8W
Q16Wstudy drug administration s, cc x Q16W
Telephone Safety follow -up zQ8W:  Q8W(alternating with in- clinic visits) for 1 year
Q16W arm: Q8W(alternating with in -clinic visits) for 
1year;then Q16W
Concomitant medications aax Each clinic visit and telephone safety follow -up call x x
Adverse events bbx Each clinic visit and telephone safety follow -up call x x
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
101/Protocol BN40955, Version 7Appendix 1a
Schedule of A ctivities for A ll Patients Except Those Undergoing Screening (cont .)
CGI-CClinical Global Impression, Change; CGI -SClinical Global Impression, Severity; C SSRS Columbia -Suicide Severity Rating Scale; 
CSFcerebrospi[INVESTIGATOR_872]; cUHDRS composite Unified Huntington's Disease Rating Scale; eCRF electronic Case Report Form; 
EoTend-of-treatment; EQ-5D-5LEuroQol 5-Dimension, 5 Level Questionnaire; HDHuntington's disease; HD -DASHD Daily Activities Scale; 
LPlumbar puncture; MoCA Montreal Cognitive Assessment; MRI magnetic resonance imaging; NODDI Neurite Orientation Dispersion and 
Density Imaging; PK pharmacokinetic; SDMT Symbol Digit Modalities Test; SFUsafety  follow -up; SW RStroop Word Reading; TFC Total 
Functional Capacity Scale; TMS Total Motor Score; Q8 Wevery 8; Q16W every  16 weeks ; Q32 Wevery  32 weeks .
Notes:  All assessments should be performed at the scheduled visit, unless otherwise specifie d.  On treatment days, all assessments should be 
performed prior to dosing, unless otherwise specified.
aInclusion visit should be the last applicable visit of the preceding study as defined in Section 3.1.[ADDRESS_835486] applicable visit in Study BN40697, a se parate inclusion visit should be scheduled 4 weeks or 8 weeks ( 1 week) for a patient previously 
treated Q4 W or 8weeks ( 1 week) later for a patient previously treated Q8 W.
bIf dosing at the inclusion visit is not possible, the Medical Monitor should be consulted and a short treatment interruption may be permitted .
cPatients who complete treatment (e.g., will continue treatment on commercially available drug) or who discontinue study drug prematurely will 
return to the clinic for a treatment completion visit 4 weeks ( 7 days) after the decision to discontinue .  For patients continuing treatment with 
RO7234292 outside of the study, the end of study visit should occur before the patient's next dose of RO7234292.
dSafety follow -up visit occurs [ADDRESS_835487] a visit window of  14 to [ADDRESS_835488] be documented before any Study BN40955 specific procedure is performed and may be obtained up to 12 weeks before 
initiation of Study BN40955 study treatment.
gMedical histor y, including clinically significant diseases, surgeries, and reproductive status, will be recorded at baseline (inclusion visit).
hVital signs include respi[INVESTIGATOR_697], pulse, temperature, and s ystolic and diastolic blood pressure while the patient is in a seated position after 
resting for at least [ADDRESS_835489] new or worsened clinically significant a bnormalities on the Adverse Event eCRF.

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
102/Protocol BN40955, Version 7Appendix 1a
Schedule of Activities for A ll Patients Except Those Undergoing Screening (cont.)
iAssessments do not need to be repeated if completed as part of the last visit in the preceding study and the inclusion visit occurs at the last visit 
in the preceding study.  If the inclusion visit is delayed (see footnote a), then the following assessments should be repeated: vital signs; 
complete phy sical examination; neurologic examination; ECG; hematology; chemistry ; pregnanc y test; local PT and/or INR, aPTT, platelet cou nt; 
urinaly sis; plasma sample for PK/immunogenicity/biomarkers; CSF sample for PK/safety/biomarkers; C -SSRS; and any clinical outcome  
assessments (i.e., HD-DAS, TFC, TMS, CGI -S, SDMT, S WR) that were not completed at the last visit in the preceding study.
jA complete physical examination should include an evaluation of the head, eyes, ears, nose, and throat, and the cardiovascular, dermatologic, 
musculoskeletal, respi[INVESTIGATOR_696], gastrointestinal, and neurologic systems; genitourinary examinations may be performed if clinic ally indicated.  
Thephysical examinations should be conducted in the same manner on each occasion to ensure comparabil ity to previous examinations , 
including weight .  Any abnormality identified at baseline (inclusion visit) should be recorded on the General Medical History and 
Baseline Conditions eCRF.  Changes from baseline abnormalities should be recorded in patient not es.  New or worsened clinically significant 
abnormalities (i.e., beyond expected variation or normal age -related change) should be recorded as adverse events on the 
Adverse Event eCRF.  Height will be obtained from preceding study.
kFor patients who are a lready enrolled in this study who previously had an MRI before they transitioned to the new dosing regimen, the scheduled
post-inclusion visit MRI should be calculated from the date of the inclusion visit. As the [ADDRESS_835490] their Week48 MRI collected then 
follow the 32 -week lyschedule thereafter. For exa mple:MRI will be collected at W eek 49, followed by [CONTACT_10585] 65 andWeek 97. Patients from 
Study BN40423 (enrolled prior to Study BN40423 protocol Versions 4) who have reached or have passed the [ADDRESS_835491] unscheduled MRI at the next clinic visit once the site is active on Protocol v4.0 then 
continue with the 32- weekly schedule thereafter. For example: unscheduled MRI (next clinic visit following protocol being active at site ), then 
followed by [CONTACT_10585] [ADDRESS_835492] unscheduled MRI at the next clinic visit once the site is active on Study BN40955 Protocol v4.0
then continue with the 32 -weekly schedule thereafter. For example: unscheduled MRI (next clinic visit following protocol being active at site), 
then followed by [CONTACT_10585] 33, Week 65, and Week 97.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
103/Protocol BN40955, Version 7Appendi x 1a
Schedule of A ctivities for A ll Patients Except Those Undergoing Screening (cont .)
lA neurologic examination (including fundoscopy ), performed at ever y clinical visit, should include assessment of mental status, level of 
consciousness, cranial nerve function, motor function, sensory function, reflexes, gait, and coordination.  The neurologic examinations should be 
conducted in the same manner on each occasion to ensure comparability to previous examinations.  Neurologic examinations shou ld be 
performe d before and after treatment on each dosing day , or before the lumbar puncture, if there is no study treatment administration .Weight 
should also be measured at each visit. Any abnormality identified at baseline (inclusion visit) should be recorded on the General Medical History 
and Baseline Conditions eCRF.  Changes from baseline abnormalities should be recorded in patient notes.  New or worsened clin ically 
significant abnormalities (i.e., beyond expected variation ,normal age -related change or HD -related clinical progression) should be recorded as 
adverse events on the Adverse Event eCRF.
mInclusion visit ECG is in accordance with the preceding study requirements.  Subsequent ECGs should be a single ECG performed after the 
patient has been resting in a s upi[INVESTIGATOR_21683] 10 minutes.  Lead placement should be as consistent as possible.  ECGs for each 
patient should be obtained from the same machine whenever possible.  All ECGs are to be obtained prior to other invasive proc edures 
scheduled at tha t same time ( e.g., blood draws) and should not be obtained within 30 minutes after any meal.
nHematology includes WBC count, RBC count, platelet count, hemoglobin, hematocrit, differential count (neutrophils, eosinophil s, basophils, 
monocy tes, ly mphocy tes).
oSerum chemistry  panel includes bicarbonate or total carbon dioxide (if considered standard of care for the region), sodium, p otassium, chloride, 
glucose, BUN or urea, creatinine, total protein, albumin, phosphorus, calcium, total and direct bilirubin, ALP, ALT, AST, uric acid, 
gamma -glutam yl transferase, and CPK.
pBaseline pregnancy test is in accordance with preceding study requirements.  Urine pregnanc y tests will be performed at speci fied subsequent 
visits.  If aurine pregnancy test is positive, i t must be confirmed by a serum pregnancy test.
qUrinalysis includes dipstick (pH, specific gravity, glucose, protein, ketones, blood) and microscopic examination if clinical ly indicated (sediment, 
RBCs, W BCs, casts, cry stals, epi[INVESTIGATOR_1663], bacteria).
rPharmacokinetics and immunogenicity samples will be collected prior to dosing. PK plasma samples are not required to be collected after the 
study treatment is paused. Immunogenicity plasma samples will continue to be collected .
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
104/Protocol BN40955, Version 7Appendix 1a
Schedule of Activities for A ll Patients Except Those Undergoing Screening (cont.)
SWhile study dosing is paused, the CSF sample for safety/biomarkers and local PT and/or INR, aPTT and Platelet count will be collected every 
16weeks for all patients . Details about the lumbar puncture schedule are addressed in Appendix 2b .  CSF sample for PK analysis is not 
required after the treatment is paused. Within 72 hours prior to performing each scheduled LP, local laboratory analy sis of coagulation factors 
(INR and/or PT, aPTT ) and platelets must be conducted and the results reviewed.  Collection for these local laborator y tests may occur at any 
time in the 72 hours prior to the LP.  The LP should be performed at approximately the same time at each visit (ideally in the morning between 
8:00 a.m. and 12:00 p.m. or in the early afternoon between 12:00 p.m. and 3:00 p.m.) to minimize potential diurnal variation of CSF parameters.  
Cerebrospi[INVESTIGATOR_872] (20 mL) is to be collected for analyses using a LP collection kit.  If there are difficulties in collecting [ADDRESS_835493] confirm CSF flow is present prior to injecting drug at 60 minutes.  A 24G atraumatic needle , as specified in the LP procedure and 
CSF collection guidelines, should be used.  Depending on institutional guidelines, local anesthesia should be used for the procedure.   Sedation 
may not be used.  Spi[INVESTIGATOR_626878], but is not required.  Ultrasound guidance may be 
used if attempts at LP without imaging are unsuccessful, if it is local practice to use ultrasound, or if institutional guidelines dictate use of 
ultrasound with each LP.  Fluoroscopy guidance can also be used, if local institutional guidelines dictate and local IRB/ECs and health authorities 
have approved the use of the technique, but it is not required.  W here fluoroscopy is used, patients should also be informed and consent 
obtained.   Patients will be discouraged from resting supi[INVESTIGATOR_626879] a minimum and, if feasible, walking briskly for approximately [ADDRESS_835494] LP procedure (e.g., air travel, scuba diving, or hot air balloons) .  In case of a 
failed IT bolus dosing procedure (e.g., due to an inadequate establishment of access to the IT space), a second dosing attempt may occur up to 
7 days after the originally scheduled dosing attempt.  For this additional visit, safety and tole rability evaluations on the day of LP administration 
will be performed as detailed in Appendix 1a, including neurological examination (p redose and postdose), vital signs, and a review of adverse 
events and concomitant medication.  If the second dosing attempt occurs more than [ADDRESS_835495], 
local laboratory analy sis of coagulation factors (INR and/or PT, aPTT) and platelets need to be conducted again and results reviewed prior to the 
LP attempt.  For patients entering from Study BN40697, the drug administered at the inclusion visit will be the last dose of Study BN40697 
unless the visit is dela yed as described in footnote a,in which case it will be the first dose in Study BN40955.  For patients entering from 
StudyML41885, the drug administered at the inclusion visit will be the first dose in Study BN40955.   For all other patients, the first dose in Study 
BN40955 will take place at the inclusion visit.
tThe C -SSRS will be used to monitor the patients throughout the study at clinic visits (follow -up version, requiring approximately 5 minutes to 
administer, assuming absence of suicidal ideation and no change in clinical status from previous administration). C-SSRS will continue to be 
performed as per the original schedule even if the study drug administration is paused.

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
105/Protocol BN40955, Version 7Appendix 1a
Schedule of A ctivities for A ll Patients Except Those Undergoing Screening (cont.)
uMagnetic resonance imaging must be scheduled to occur before the LP . The MRI scan should be performed 7 14days prior to the LPto allow 
time for re -scanning if the quality of the initial MRI is inadequate. If the re -scan cannot be performed prior to the LP, then it can be conducted the 
day after the LP, as long as there are no post- LPcontraindications and it occurs within [ADDRESS_835496].  If the EQ -5D-5L collection was duplicated in error (i.e., collected in [COMPANY_002] HD mobile app and site 
electronic device) during the study drug administration visit, the EQ -5D-5L data collected in the site electronic device will take precedence. The 
EQ-5D-5L will continue t o be performed as per the original schedule even if the study drug administration is paused .
zTelephone safety follow -up will be conducted Q8 W (alternating with in -clinic visits) for 1 year for all patients, and then Q16 W in between study 
administration visits for Q16 W armto check for any  change in patient status (e.g., adverse events and concomitant medications) since their last 
visit and depending on patient’s health status.  An unscheduled clinic visit may  be arranged, if needed.  If a patient is due for a telephone safety 
call and they are in -clinic then this telephone safety follow -up call can be completed in -clinic at the site’s discretion.  As a result of the COVID -19 
pandemic, only where sites are impacted, these telephone safety calls can be cond ucted instead of an in -clinic visit.
aaMedication (e.g., prescription drugs, over -the-counter drugs, vaccines, herbal or homeopathic remedies, nutritional supplements) used by a 
patient in addition to protocol -mandated treatment from the time of entry  into Study BN40955 to the study completion/discontinuation visit.
bbAfter initiation of study drug at baseline (inclusion visit), all adverse events will be reported until 5 months after the fi nal dose of study drug.  
After this period, all deaths, regardles s of cause, should be reported.  In addition, the Sponsor should be notified if the investigator becomes 
aware of any serious adverse event that is believed to be related to prior study drug treatment.
ccEffective 22 March 2021, Q8W and Q16W study drug administration is paused .
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
106/Protocol BN40955, Version 7Appendix 1b
Schedule of A ctivities for Patients who w ere Eligible for the GENERA TION-HD1 Study  but not 
Randomized due to Logistical Challenges Resulting from the COVID -19 P andemic
ScreeningaInclusion visit Treatment Period EoTbSFU bb
Week 4 to  1 1 Treatment Assessment and Frequency 4 weeks 20weeks
Day (W indow) 28 to  2 1 1 1 week v1 weekv1 week
Signed informed consentcx
Review of inclusion and exclusion criteria x x
Demographic data x
Medical histor y and baseline conditionsdx x e
Blood sample for CAG repeat lengthax
Viral serologyfx
Thyroid panelgx
Vital signs hx x eAt each clinic visit x x
Complete physical examination ix x eQ32W x x
Neurologic examinationjx x eAt each clinic visit (see Appendix 9) x x
ECGkx x eQ32W x x

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
107/Protocol BN40955, Version 7Appendix 1b
Schedule of A ctivities for Patients who w ere Eligible for the GENERA TION-HD1 Study  but not 
Randomized due to Logistical Challenges Resulting from the COVID -19 Pandemic (cont.)
ScreeningaInclusion 
visit Treatment Period EoTbSFU bb
Week 4 to  1 1 Treatment Assessment and Frequency 4 weeks 20weeks
Day (W indow) 28 to  2 1 1 1 week v1 weekv1 week
Hematologylx x At each clinic visit x x
Chemistrymx x x x
Pregnancy testnx x ex x
Urinalysis ox x x x
Local PT and/or INR, aPTT, P latelet countx, u x At each study drug administration visit x x
Plasma sample for PK px Q16Wfor 48 weeks and then Q32W
thereafter
Plasma sample for immunogenicity testing px x x
Plasma sample for biomarkers x x x
CSF sample for PK/safety/biomarkersu x At each study drug administrationX
Mandatory Structural MRIqx Q32W x
Optional resting -state functional MRI and
Diffusion -weighted MRI /NODDIrX Q32W x
Independence Scale x
MoCA x x Q16W x
C-SSRSrx xeAt each study drug administration x
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
108/Protocol BN40955, Version 7Appendix 1b
Schedule of A ctivities for Patients who w ere Eligible for the GENERA TION-HD1 Study  but not 
Randomized due to Logistical Challenges Resulting from the COVID -19 Pandemic (cont.)
ScreeningaInclusion visit Treatment Period EoTbSFU bb
Week 4 to  1 1 Treatment Assessment and Frequency 4 weeks 20weeks
Day (W indow) 28 to  2 1 1 1 week v1 weekv[ADDRESS_835497]
Q8W Study drug administration u,cc x Q8W
Q16W Study drug administrationu,cc x Q16W
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
109/Protocol BN40955, Version 7Appendix 1b
Schedule of A ctivities for Patients who w ere Eligible for the GENERA TION-HD1 Study  but not 
Randomized due to Logistical Challenges Resulting from the COVID -19 Pandemic (cont.)
ScreeningaInclusion visit Treatment Period EoTbSFU bb
Week 4 to  1 1 Treatment Assessment and Frequency 4 weeks 20weeks
Day (W indow) 28 to  2 1 1 1 week v1 weekv1 week
Telephone Safety follow -up xQ8W arm: Q8W(alternating with in -clinic 
visits) for 1 year
Q16W arm:Q8W(alternating with 
in-clinic visits) for 1 year, then Q16W
Concomitant medicationsyx x x Each clinic visit and telephone safety 
follow -up callx x
Adverse events zx x x Each clinic visit and telephone safety 
follow -up callx x
CAGcytosine, adenine, and guanine; CGI -CClinical Global Impression, Change; CGI-S Clinical Global Impression, Severity; 
CSFcerebrospi[INVESTIGATOR_872]; C SSRS Columbia -Suicide Severity Rating Scale; cUHDRS composite Unified Huntington's Disease Rating Scale; 
DCLdiagnostic confidence level; eCRF electronic Case Report Form; EoT end-of-treatm ent; EQ -5D-5LEuroQol 5 -Dimension, 5 -Level 
Questionnaire; HA health authority; HBsAg hepa titis B surface antigen; HCV hepatitis C virus; HD Huntington disease; HD- DASHD Daily 
Activities Scale; IRB/EC Institutional Review Board/Ethics Committee; LP lumbar puncture; MoCA Montreal Cognitive Assessment; 
MRI magnetic resonance imaging; NODDI Neuri te Orientation Dispersion and Density Imaging ;PKpharmacokinetic; Q8 Wevery 8 weeks; 
Q16Wevery 16weeks; Q32 Wevery 32 weeks; SDMT Symbol Digit Modalities Test; SFU safety  follow -up; S WRStroop W ord Reading; 
TFCTotal Functional Capacity Scale; TMS Total Motor Score.
Notes:  All assessments should be performed at the scheduled visit, unless otherwise specified.  On treatment days, all asses sments should 
be performed prior to dosing, unless otherwise specified.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
110/Protocol BN40955, Version 7Appendix 1b
Schedule of A ctivities for Patients who w ere Eligible for the GENERA TION-HD1 Study  but not 
Randomized due to Logistical Challenges Resulting from the COVID -19 Pandemic (cont.)
aA maxim um of 1re-screening will be allowed within 8 weeks of the initial screening failure for patients who fail the initial screening (e.g., as a 
consequence of abnormal laboratory values or general medical status not meeting inclusion or exclusion criteria). The CAG repeat length 
testing from Q2 Solutions will be accepted for this study. If re-screening is required, the CAG repeat length testing from Q2 Solutions does not 
need to be repeated . The screening MRI and viral serology from the initial screening may be acceptable as part of the re -screening 
assessments, if performed within 12 weeks of the inclu sion visit.
bPatients who complete treatment (e.g., will continue treatment on commercially available drug) or who discontinue study drug prematurely will
return to the clinic for a treatment completion visit 4 weeks ( 7 days) after the decision to discontinue . For patients continuing treatment with
RO7234292 outside of the study, the end of study visit should occur before the patient's next dose of RO7234292.
cInformed consent must be documented before any study -specific screening procedure is per formed and may be obtained more than 28 days 
before initiation of study treatment.
dMedical histor y, including clinically significant diseases, surgeries, reproductive status, will be recorded at screening and at baseline (inclusion 
visit).
eAssessments may take place on Day  1 or Day 1.
fViral serology: HBsAg and HCV antibody (or viral RNA if HCV antibody assay is positive) .
gThyroid panel:  thy roid-stimulating hormone and free thyroxine (also known as T4) levels.
hVital signs include respi[INVESTIGATOR_697], pulse, temperature, and s ystolic and diastolic blood pressure while the patient is in a seated position after 
resting for approximately [ADDRESS_835498] new or worsened clinically significant abnormalities on the Adverse Event eCRF.
iAcomplete physical examination should include an evaluation of the head, eyes, ear s, nose, and throat, and the cardiovascular, dermatologic, 
musculoskeletal, respi[INVESTIGATOR_696], gastrointestinal, and neurologic systems; genitourinary examinations may be performed if clinic ally indicated. 
Thephysical examinations should be conducted in the sa me manner on each occasion to ensure comparability to previous examinations, 
including weight. Any abnormality identified screening and at baseline (inclusion visit) should be recorded on the General Medical History and 
Baseline Conditions eCRF. Changes from baseline abnormalities should be recorded in patient notes. New or worsened clinically significant 
abnormalities (i.e., beyond expected variation or normal age -related change) should be recorded as adverse events on the Adverse Event eCRF. 
Height will be obtained from screening and inclusion visit only.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
111/Protocol BN40955, Version 7Appendix 1b
Schedule of A ctivities for Patients who w ere Eligible for the GENERA TION-HD1 Study  but not 
Randomized due to Logistical Challenges Resulting from the COVID -19 Pandemic (cont.)
jA neurologic examination (including fundoscopy), performed at ever y clinical visit, should include assessment of mental status, level of 
consciousness, cranial nerve function, motor function, sensory function, reflexes, gait, and coordination. The neurolo gic examinations should be 
conducted in the same manner on each occasion to ensure comparability to previous examinations. Neurologic examinations should be 
performed before and after treatment on each dosing day , or before the lumbar puncture, if there i s no study treatment administration .Weight 
should also be measured at each visit. Any abnormality identified at screening and baseline (inclusion visit) should be recorded on the General 
Medical Histor y and Baseline Conditions eCRF. Changes from baseline abnormalities should be recorded in patient notes. New or worsened 
clinically significant abnormalities (i.e., beyond expected variation, normal age -related change or HD-related clinical progression) should be 
recorded as adverse ev ents on the Adverse Event eCRF .
kElectrocardiograms should be triplicate at screening and subsequent ECGs should be a single ECG performed after the patient has been resting 
in a supi[INVESTIGATOR_21683] 10 minutes. Lead placement should be as consis tent as possible. Electrocardiograms for each patient should be 
obtained from the same machine whenever possible. All ECGs are to be obtained prior to other invasive procedures scheduled at that same 
time (e.g., blood draws) and should not be obtained wi thin 30 minutes after any meal.
lHematology includes WBC count, RBC count, platelet count, hemoglobin, hematocrit, differential count (neutrophils, eosinophil s, basophils, 
monocy tes, ly mphocy tes).
mSerum chemistry  panel:  includes bicarbonate or total carbon dioxide (if considered standard of care for the region), sodium, potassium, chloride, 
glucose, BUN or urea, creatinine, total protein, albumin, phosphorus, calcium, total and direct bilirubin, ALP, ALT, AST, uric acid, 
gamma -glutam yl transferase, an d CPK.
nAll women of childbearing potential will have a serum pregnancy test at screening.  Urine pregnanc y tests will be performed at specified 
subsequent visits.  If aurine pregnanc y test is positive, it must be confirmed by a serum pregnancy test.
oUrinalysis includes dipstick (pH, specific gravity, glucose, protein, ketones, blood) and microscopic examination for all abno rmal dipstick results 
(sediment, RBCs, W BCs, casts, cry stals, epi[INVESTIGATOR_1663], bacteria).
pPharmacokinetics and immunogenicity sa mples will be collected prior to dosing. PK plasma samples are not required to be collected after the 
study treatment is paused. Immunogenicity plasma samples will continue to be collected . 
qMagnetic resonance imaging should take place as early as possible within the screening window but may  take place at any time during 
screening.  The MRI safety and efficacy  screening scan will need to pass the central laboratory image quality control check and the results must 
be av ailable before the patient can be enrolled in the study. Magnetic resonance imaging must be scheduled to occur before the LP.  The follow -
up MRI scan should be performed 7 14days prior to the LPto allow time for re -scanning if the quality of the initial MRI is inadequate.   If the re -
scan cannot be performed prior to the LP, then it can be conducted the day after the LP, as long as there are no post- LPcontraindications and it 
occurs within 2 wee ks of the original scan.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
112/Protocol BN40955, Version 7Appendix 1b
Schedule of A ctivities for Patients who w ere Eligible for the GENERA TION-HD1 Study  but not 
Randomized due to Logistical Challenges Resulting from the COVID -19 Pandemic (cont.)
rThe C -SSRS will be used to assess eligib ility for the study (full version at screening, requiring approximately 20 minutes to administer) and to 
monitor the patients throughout the study at clinic visits (follow -up version, requiring approximately 5 minutes to administer, assuming absence of 
suicidal ideation and no change in clinical status from previous administration). C-SSRS will continue to be performed as per the original 
schedule even if the study drug administration is paused.
sThe cUHDRS is a composite motor, cognitive, and global functional clinical outcome measure in patients with HD comprised of the TFC, the 
TMS, the SDMT, and the SW R scores.
tThe electronic devices for remote data collection will be supplied to patients at screening and must be returned to the clini c in cases w here the 
patient does not meet eligibility criteria, at the end of the study, or upon early termination from the study.
uWhile study dosing is paused, the CSF sample for safety/biomarkers and local PT and/or INR, aPTT and Platelet count will be collected every 
16weeks for all patients. Details about the lumbar puncture schedule are addressed in Appendix 2b.  CSF sample for PK analysis is not 
required after the treatment is paused. Within 72 hours prior to performing each scheduled LP, local laboratory a nalysis of coagulation factors 
(INR and/or PT, aPTT) and platelets must be conducted and the results reviewed. Collection for these local laborator y tests may occur at any 
time in the 72 hours prior to the LP. The LPshould be performed at approximately the same time at each visit (ideally in the morning between
8:00 a.m. and 12:00 p.m. or in the early afternoon between 12:00 p.m. and 3:00 p.m.) to minimize potential diurnal variation of CSF parameters.   
Cerebrospi[INVESTIGATOR_872] (20mL) is to be collected for analyses using a LPcollection kit. If there are difficulties in collecting [ADDRESS_835499] confirm CSF flow is present prior to injecting drug at 60 minutes. A 24G atraumatic needle, as specified in the LP procedure and
CSF collection guidelines, should be used. Depending on institutional guidelines, loc al aesthesia should be used for the procedure. Sedation
may not be used. Spi[INVESTIGATOR_626878], but is not required. Ultrasound guidance may be 
used if attempts at LPwithout imaging are unsuccessful, if it is local practice to use ultrasound, or if institutional guidelines dictate use of 
ultrasound with each LP. Fluoroscopy guidance can also be used, if local institutional guidelines dictate and local IRB/ECs and HAs have 
approved the use of the techniqu e, but it is not required. Where fluoroscopy is used, patients should also be informed and consent obtained. 
Patients will be discouraged from resting supi[INVESTIGATOR_626880] a 
minimum and, if feasible, walking briskly  for approximately [ADDRESS_835500] LP procedure (e.g., air travel, scuba diving, or hot air balloons). In case of a failed IT bolus 
dosing procedure (e.g., due to an inadequate establishment of access to the IT space), a second dosing attempt may  occur up to 7 days after the 
originally scheduled dosing attempt. For this additional visit, saf ety and tolerability evaluations on the day of LP administration will be performed 
as detailed in Appendix 1b, including neurological examination (predose and postdose), vital signs, and a review of adverse events and 
concomitant medication. If the second dosing attempt occurs more than [ADDRESS_835501], local 
laborator y analysis of coagulation factors (INR and/or PT, aPTT) and platelets need to be conducted again and results reviewed prior to the LP 
attempt .

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
113/Protocol BN40955, Version 7Appendix 1b
Schedule of A ctivities for Patients who w ere Eligible for the GENERA TION-HD1 Study  but not 
Randomized due to Logistical Challenges Resulting from the COVID -19 Pandemic (cont.)
vExcluding MRIs, which have a visit window of  14 to 7 days.
wThe EQ -5D-5L will only be completed in -clinic at each study drug administration visit .The EQ -5D-5L will continue to be performed as per the 
original schedul e even if the study drug administration is paused .
xTelephone safety follow -up will be conducted Q8 W(alternating with in -clinic visits) for 1 year for all patients, and then Q16W in between study 
administration visits for Q16 W arm to check for any  change in patient status (e.g., adverse events and concomitant medications) since their last 
visit and depending on patient’s health status. An unscheduled clinic visit may  be arranged, if needed. If a patient is due for a telephone safety 
call and they are in -clinic then this telephone safety follow -upcallcan be completed in-clinic at the site’s discretion. As a result of the COVID -19 
pandemic, only where sites are impacted, these telephone safety calls can be conducted instead of an in -clinic visit.
yMedication (e.g., prescription drugs, over -the-counter drugs, vaccines, herbal or homeopathic remedies, nutritional supplements) used by a
patient in addition to protocol -mandated treatment from the time of entry  into Study BN40955 to the study completion/discontinuation visit.
zAfter informed consent has been obtained but prior to initiation of study drug, only serious adverse events caused by a proto col-mandated 
intervention should be reported. After initiation of study drug at baseline (inclusion visit ), all adverse events will be reported until 5 months after 
the final dose of study drug. After this period, all deaths, regardless of cause, should be reported. In addition, the Sponsor should be notified if 
the investigator becomes aware of any serious adverse event that is believed to be related to prior study drug treatment .
aa Safety follow -up visit occurs 20 weeks after E oT.
bbThe DCL will be assessed at screening only (i.e., without the full TMS assessment).  The TMS scale will be assessed (excl uding the DCL) at all 
other timepoints.
ccEffective 22 March 2021, Q8W and Q16W study drug administration isimmediately paused.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
114/Protocol BN40955, Version 7Appendix 2aVisit Schedule for the First 2 Years of Treatment
Month 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Week 1 5 9 13 17 21 25 29 33 37 41 45 49 53 57 61 65 69 73 77 81 85 89 93 97
Q8W study  drug 
administrationax P x P x P x P x P x P x x x x x x x b
Q16W study drug 
administrationax P CV P x P CV P x P CV P x P x P x P x c
Efficacy  
assessmentsx x x x x x xd
CVnon-treatment clinic visit; P phone call; Q8 Wevery 8 weeks; Q16 Wevery 16 weeks.
Notes: The non -treatment clinic visit includes collection of the following assessments during the first year of assignment to Q16 W regimen: 
vitalsigns, neurologic examination, hematology, chemistry , pregnanc y test, urinaly sis, concomitant medications, and adverse events.
aQ8W and Q16W study drug administration should be immediately paused until further assessments can be conducted following the release of 
the USM -DIL on March 22, 2021
bPatients will continue Q8 W dosing until end -of-treatment.
cPatients will continue alternating telephone safety follow -up and treatment visits until end- of-treatment.
dPatients will continue efficacy  assessments Q16 W throughout treatment period.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
115/Protocol BN40955, Version 7Appendix 2b Visit Schedule for the First 2 Years of Study Participation While on Treatment 
Pause
Month 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Week 1 5 9 13 17 21 25 29 33 37 41 45 49 53 57 61 65 69 73 77 81 85 89 93 97a
Q8W b, c LP P NLPdP LP P NLPdP LP P NLPdP LP NLPd LP NLPd LP NLPd LP
Q16We LP P CV P LP P CV P LP P CV P LP P LP P LP P LP 
CVnon-treatment clinic visit; P phone call; Q8W every 8 weeks; Q16W every 16 weeks; LP=clinic visit with lumbar puncture; NLP= clinic 
visit without lumbar puncture
Notes:  The non-treatment clinic visit includes collection of the following assessments during the first year of assignment to Q16W regimen: 
vital signs, neurologic examination, hematology, chemistry, pregnancy test, urinalysis, concomitant medications, and adverse events.
a All patients should continue performing the corresponding visits as described in Appendix 2bbeyond the first 2 years.
bQ8W patients randomized to Q8W and paused  from receiving RO7234292 study drug following the USM -DIL (dated 22 March 2021 ).
cPatients who were randomized to Q8W study drug administration and paused from receiving RO7234292 study drug will continue to 
undergo clinic visits performing LP and alternate non LP (NLP) visits. At the LP visits, CSF sample for safety/biomarkers will be performed. 
Local PT and/or INR, aPTT, Platelet count and neurological examinations will be performed prior to LP only. CSF sample for PK and plasma 
for PK will not be required after study treatment was paused. I mmunoge nicity samples will continue to be collected.
d Non -LP visits will continue as described in Appendix 1a and Appendix 1b. CSF samples for PK/safety/biomarkers and local PT/and/or INR, 
aPTT and platelet count are not required at these visits .Neurological e xaminations should be performed at Non -LP visits.
eQ16W patients randomized to Q16W and paused from receiving RO7234292 study drug following the USM -DIL (dated 22 March 2021). .

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
116/Protocol BN40955, Version 7Appendix 3Clinician -Reported Outcomes
Assessment Name [CONTACT_601384]. 
Duration Timing
IS Independence Scale 1 Functional Disability 3Screening (for patients required to undergo 
screening only)
TFC Total Functional Capacity Scale 5 Overall function 10 minInclusion visit, ever y 16 weeks ,and EoT 
visit
TMS Total Motor Score 31 Motor function 15 minDCL only: screening (only for patients 
required to undergo screening)
TMS without DCL: inclusion visit, 
every16weeks ,and EoT visit
C-SSRSaColum bia-Suicide Severity 
Scale5Suicidal ideation and
behavior20 min full 
version;
5 min 
follow -up 
versionFull version at screening in -clinic (only for 
patients required to undergo screening);
Follow -up version at each study drug 
administration visit
CGI-SClinical Global 
Impression Severity1Overall severity of 
patient status2 minInclusion visit, ever y 16 weeks ,and EoT 
visit
CGI-CClinical Global 
Impression Change1Overall change in 
patient status2 min Every 16 weeks and EoT visit
HD-DASHuntington's Disease Daily 
Activities Scale 25 Daily function 25 minInclusion visit, ever y 16 weeks ,and EoT 
visit
DCLdiagnostic confidence level ; EoT end-of-treatment ;ISIndependence Scale.
a C-SSRS will continue to be performed as per the original schedule even if the study drug administration is paused .
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
117/Protocol BN40955, Version 7Appendix 4Patient-Reported Outcomes, Performance Outcomes, and [COMPANY_002] HD Mobile 
Application
Assessment Name [CONTACT_601384].
Duratio
n(min)PRO, 
PerfO,
Behavior Timing Location
[COMPANY_002] HD 
mobile app[COMPANY_002] HD mobile app 
with daily Active Test 
and Passive 
MonitoringNATasks 
(active test) that 
assess motor 
symptoms (upper 
and lower body 
movements, upper 
limb dexterity, 
voice) and 
non-motor 
symptoms 
(processing 
speed/voice); 
continuous passive 
monitoring10Sensor 
data, 
PRO, 
PerfORemote: up to daily
Clinic visits: Inclusion visit, 
every 16 weeks, and EoT 
visit[COMPANY_002] HD 
mobile app
EQ-5D-5L aEuroQol 5 -Dimension, 
5-Level Questionnaire6 Health utilities 5 PRORemote:  up to weekly[COMPANY_002] HD 
mobile app
In-clinic:  a t each study 
drug administration visitIn-clinic
HD-SDIHuntington’s D isease ,
Speaking Difficulty 
Item1 Speech 1 PRO Remote: up to weekly[COMPANY_002] HD 
mobile appb
MoCAMontreal Cognitive 
Assessment11Overall cognitive 
status10 PerfOScreening (only for patients 
required to undergo 
screening), Inclusion visit, 
every 16 weeks ,and EoT 
visitIn-clinic
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
118/Protocol BN40955, Version 7Appendix 4Patient-Reported Outcomes, Performance Outcomes, and [COMPANY_002] HD Mobile 
Application (cont.)
Assessment Name [CONTACT_601384]. 
Duratio
n (min)PRO, 
PerfO, 
Behavior Timing Location
SDMT/
eSDMTSymbol Digit 
Modalities TestMax number in 
90secondsCognitive 5 PerfOInclusion visit, ever y 
16weeks, and EoT visitIn-clinic
Remote:  Up to weekly[COMPANY_002] HD 
mobile app 
(eSDMT)
SWR/eS WRStroop Word Reading 
TestMax numbers 
in 45 secondsCognitive 5 PerfOInclusion visit, ever y 
16weeks, and EoT visitIn-clinic
Remote:  Up to weekly[COMPANY_002] HD 
mobile app 
(eSWR)
WHODAS 2.0World Health 
Organisation 
Disability Assessment 
Schedule 2.015Health -related 
qualit y of life10 PRO Remote: Monthly[COMPANY_002] HD 
mobile appb
WPAIWork Productivity and 
Activity Impairment6 Work productivit y 5 PRO Remote: Monthly[COMPANY_002] HD 
mobile app b
app application; EoT end-of-treatment; HD Huntington disease; NA not applicable; PerfO performance outcome; PRO patient -reported 
outcome .
aComplete during in -clinic visit at each study drug administration and in cases where [COMPANY_002] HD mobile has reached the end of its life span or has 
been lost. EQ-5D-5L will continue to be performed as per the original schedule even if the study drug administration is paused.
bOnly applicable if previous study also used this remote assessment.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
119/Protocol BN40955, Version 7Appendix 5Clinical A ssessments Order and Duration for 
Patients Required to Undergo Screening Only
Table 1Screening Visit Clinical A ssessments
Block AssessmentsTotal Duration 
(minutes)Site S taff
Responsible
1 Diagnostic Confidence Level ª
Independence Scale
MoCA
C-SSRS~60 Qualified study
physician
C-SSRS Columbia -Suicide Severity Rating Scale; DCL Diagnostic Confidence Level; 
MoCA Montreal Cognitive Assessment; TMS Total Motor Score.
aThe DCL will be assessed at screening only (i.e., without the full TMS assessment). TheTMS 
scale will be assessed (excluding the DCL) at all other timepoints.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
120/Protocol BN40955, Version 7Appendix 6Diagnostic Confidence Level for Patients Required 
to Undergo Screening Only
The Diagnostic Confidence Level is calculated as shown below (from Unified 
Huntington’s Disease Rating Scale [ UHDRS ]Total Motor Score [TMS] Scale, Item 17):
DIAGNOSIS CONFIDENCE LEVEL
To what degree are you confident that this person meets the operational definition of the 
unequivocal presence of an otherwise unexplained extrapyramidal movement disorder
(e.g., chorea, dystonia, bradykinesia, rigidity) in a subject at risk for HD?
0normal (no abnormalities)
1non-specific motor abnormalities (less than 50% confidence)
2motor abnormalities that may be signs of HD (50% 89% confidence)
3motor abnormalities that are likely signs of HD (90% 98% confidence)
4motor abnormalities that are unequivocal signs of HD ( 99% confidence)
Copyright 1999
Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency.
Mov Disord 1996;11:136 42.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
121/Protocol BN40955, Version 7Appendix 7Clinical A ssessments Order and Duration
Table 1Clinical A ssessments
Block AssessmentsTotal Duration 
(minutes)Site Staff 
Responsible
1Huntington's Disease Daily Activities Scale
TFC
TMS
C-SSRSa
CGI-S
CGI-C (not required at inclusion visit)~60Qualified 
study 
physician
Break (if needed) ~2030
2MoCA
SDMT
SWR
EQ-5D-5L~20Qualified 
study 
personnel
Break (if needed) ~2030
3 [COMPANY_002] HD mobile application ~20Qualified 
study 
personnel
CGI-CClinical Global Impression, Change; CGI -SClinical Global Impression, Severity; 
C-SSRS Columbia -Suicide Severity Rating Scale; EQ-5D-5LEuroQol 5 -Dimension, 5 Level 
Questionnaire; MoCA Montreal Cognitive Assessment; SDMT Symbol Digit Modalities Test; 
SWRStroop W ord Reading; TFC Total Functional Capacity Scale; TMS Total Motor Score.
aCollected at Screening (for patients required to undergo screening) then r epeated at every 
study drug administration clinical visit. C-SSRS will continue to be performed as per the 
original schedule even if the study drug administration is paused.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
122/Protocol BN40955, Version 7Appendix 8Remote Clinical A ssessments Order and Duration 
(COVID-19 Impacted Sites w here a Patient Cannot A ttend the 
Clinic or the Investigator Site Has Closed due to Restrictions 
Imposed as a Result of COVID -19)
Table 1Revised Assessment Schedule for Remote Data Collection 
(During COVID -19 Pandemic Only ) Every Dosing Visit 
(forC-SSRS), 16 Weeks and EoT Visit
Block AssessmentsTotal Duration 
(minutes)Site Staff 
Responsible
1 Huntington's Disease Daily Activities Scale
Total Functional Capacity Scale
Colum bia-Suicide Severity Rating Scale
Clinical Global Impression Severity
Clinical Global Impression Change~60 Qualified study 
physician
Huntington's Disease Daily  Activities Scale (HD-DAS) and Total Functional 
Capacity  (Phone call)
Aphone call to the patient should be conducted by [CONTACT_5989].
The study physician should enter data for the scales directly onto the tablet, and for 
sites that use more than 1tablet, must ensur e that the appropriate tablet that has 
the patient data is used.
Columbia- Suicide Severity  Rating Scale (via a phone interview with the patient)
The study physician should also complete the Columbia -Suicide Severity Rating 
Scale ( C-SSRS) on the tablet via a phone interview with the patient.
This is a critical safety endpoint, and of particular importance in this population.
Clinical Global Impression scales
The study physician should complete the Clinical Global Impression scales 
(using the tablet) following the phone calls for the other Block [ADDRESS_835502] Reading, and Montreal Cognition 
Assessment
For the Performance Outcomes in Block 2 (Symbol Digit Modalities Test [SDMT], 
Stroop Word Reading [SWR], and Montreal Cognition Assessment [MoCA] ), 
currently these assessments should not be collected remotely.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
123/Protocol BN40955, Version 7Appendix 9[COMPANY_002] HD Mobile Application:  Active Test
The following tasks are part of the active tests conducted on the [COMPANY_002] Huntington's disease 
(HD) mobile application by [CONTACT_102].  This constitutes a comprehensive list; all patient -reported 
outcomes (PROs) (i.e., EuroQol 5 -Dimension, 5 -Level Questionnaire [EQ-5D-5L], 
WorkProductivity and Activity Impairment [WPAI], HD Speaking Difficulty Item [ HD-SDI], 
WHODisability Assessment Schedule [ WHODAS 2.0]) are not on all devices.
If a patient already has a preconfigured smartphone and wrist -worn wearable with installed 
software for the [COMPANY_002] HD mobile app assessments from the preceding study, they will continue 
to use these in this study.  If patients did not have a preconfigured smartphone and wrist -worn 
wearable in the preceding study, they will not be provided devices.
Tasks take 5 [ADDRESS_835503] on a certain 
day, scheduled tasks that occur less frequently than every second day (i.e., EQ -5D-5L, W PAI, 
HD-SDI, [ADDRESS_835504]) are rolled over to the next time the active test is completed.
Daily  Questions
Two daily single -item questions on mood and physical energy will be assessed, asking patients 
about their mood and physical health at the time they are performing the active tests.   
Theassessments aim to capture daily mood fluctuations a nd will be used as a control for the 
other motor and cognitive assessments.
Cognitive Test ( electronic Symbol Digit Modalities Test )
The Cognitive Test asks participants to match sy mbols with numbers according to a key  as 
quickly and accurately as possible .  The key , symbols, and numbers are all displayed on a 
smartphone screen.  The test assesses visuomotor integration and measures visual attention and 
motor speed.  It is modeled on the pen and paper Sy mbol Digit Modalities Test (SDMT ; 
Smith1968) .  The SDMT has been shown to be sensitive to s ymptom changes in patients with 
early HD (Tabrizi 2012) and is part of the Unified Huntington's Disease Rating Scale (UHDRS) 
assessment (Huntington’s Study Group, 1996).
Word Reading Test (eSWR)
The Word Reading Test asks participants to read aloud color words written in black font on a 
smartphone screen.  Their voice will be recorded.  The test assesses cognitive processing speed, 
and is modeled on the Stroop Word Reading (SW R) (Stroop 1935).  Th e Word Reading part of 
the S WR Test has been shown to be sensitive to sy mptom changes in patients with early HD 
(Tabrizi 2012) and is part of the UHDRS assessment (Huntington’s Study Group 1996).
Appendix 9:[COMPANY_002] HD Mobile Application: A ctive Test (cont.)
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
124/Protocol BN40955, Version 7Speeded Tappi[INVESTIGATOR_626881], using the index finger of both the left and right hands.  The test assesses 
brady kinesia.  Performance will also be impacted by [CONTACT_626958].  It is model edon 
tappi[INVESTIGATOR_626882] s ymptom changes in early HD (Bechtel et al. 2010; 
Tabrizi etal. 2012). A similar finger tappi[INVESTIGATOR_626883] (Huntington’s Study Group 1996).
Draw a Shape Test
The Draw a Shape Test asks partic ipants to trace a series of increasingly complex shapes on the 
smartphone screen. The shapes include lines, a square, a circle, an eight, and a spi[INVESTIGATOR_23585].  This test 
is designed to assess visuomotor coordination and fine motor impairment in patients with earl y 
HD.  It is model edon circle tracing tasks that have been shown to be sensitive to sy mptom 
changes in early HD (Say et al. 2011; Tabrizi et al. 2013).
Chorea Test
The Chorea Test asks participants to hold the smartphone still in their hand with their arm
outstretched, and wear the wrist -worn wearable.  As a dual task, participants will also need to 
count backwards aloud.  To ensure correct execution, voice will be recorded.  The test is 
designed to assess chorea.  It draws on other sensor -based approaches to measure chorea 
(Reilm ann et al. 2010, 2011 ; Kegelmeyer et al. 2017 ).  A chorea assessment is also part of the 
UHDRS (Huntington’s Study Group 1996).
Balance Test
The Balance Test asks participants to stand still while wearing the smartphone and wrist-worn 
wearable.  It is an assessment for patients’ static balance function.  Sensor -based approaches for 
measuring static balance have been shown to be sensitive to differences in sy mptoms in early 
HD (Dalton et al. 2013).  The test is also part of es tablished scales like the Berg Balance Scale 
(Berg et al. 1992), which are used in HD (Busse et al. 2009; Rao et al. 2009).  The test is 
anchored to the UHDRS assessments for maximal dystonia, maximal chorea, and tandem 
walking (Huntington Study Group 1996).
U-Turn Test
The U -Turn Test asks participants to walk and turn safely between 2points that are at least 
foursteps apart, while wearing the smartphone and wrist -worn wearable.  They need to make at 
least 5turns.  The test is designed to assess gait an d lower -body  brady kinesia, which are also 
assessed by [CONTACT_626959].  It is model edon the Timed Up and Go Test, which has been clinically 
validated for the HD population (Busse et al. 2009; Rao et al. 2009).  The test is anchored to the 
UHDRS gait, brady kines ia body, and tandem walking items (Huntington Study Group 1996).
Appendix 9:[COMPANY_002] HD Mobile Application: A ctive Test (cont.)
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
125/Protocol BN40955, Version 7Walk Test
The Walk Test asks participants walk as fast as is safely possible for [ADDRESS_835505] is conducted ona straight path with no obstacles (e.g., in a park).  
Sensor -based approaches for measuring gait have been shown to be sensitive to differences in 
symptoms in early HD (Dalton et al. 2013).  The test is anchored to the UHDRS gait, brady kinesia 
body , and t andem walking items (Huntington Study Group 1996).
EuroQoL 5 -Dimension, 5- Level Questionnaire
The EQ -5D-5L is a validated self -report health status questionnaire used to calculate a health 
status utility score for use in health economic analy ses ( EuroQol G roup 1990 ; Brooks 1996 ; 
Herdman et al. 2011; Janssen et al. 2013).  There are two components to the EQ -5D-5L:  
a 5-item health state profile that assesses mobility, self -care, usual activities, pain/discomfort, and 
anxiet y/depression, as well as a Visual A nalog Scale ( VAS)that measures health state.  
Published weighting s ystems allow for creation of a single composite score of the patient's health 
status (Index score) from the 5 -item scores (i.e., does not include the VAS).  The EQ -5D-5L takes 
approximatel y 5minutes to complete.  The Index score will be used in this study for informing 
pharmacoeconomic evaluations.  The VAS score will be used to assess health -related quality of 
life(HRQoL) .  The EQ -5D-5L will be completed remotely at specified timepoints by [CONTACT_626960].
Work Productivity  and A ctivity  Impairment
The WPAI contains [ADDRESS_835506] of disease on employ ment status (yes/no), 
hours missed due to disease, hours missed due to other reasons, hours worked, and impact on 
productivity and on daily activities (both using an [ADDRESS_835507]).  The WPAI takes approximately 5 minutes to complete.  
TheWPAI will be completed by [CONTACT_102] (about him/herself). It will be completed at specified 
timepoints remotely by [CONTACT_626932].
HD Speaking Difficulty  Item
The HD -SDI includes a single question assessing difficulty speaking over the past 7 days.  It is 
assessed using a 5 -point Likert s cale, where higher scores indicate a greater frequency of 
difficulty.  The HD- SDI can be completed in less than 1 minute and will be completed at specified 
timepoints remotely by [CONTACT_626932].
WHO Disability  Assessment Schedule 2.0
The WHODAS 2.0 (12 -item version) assesses disability and aspects of HRQoL.  It is intended for 
use in any disease population, and it is linked to the concepts in the International Classification of 
Functioning, Disability, and Health.  The 12 -item vers ion contains 15 items, 12 of which produce a 
total score, with 3 additional questions administered to assess overall difficulty and activity 
impairm ent.  All items are scored on a 0 4 Likert -type scale. The total raw score is converted 
Appendix 9:[COMPANY_002] HD Mobile Application: A ctive Test (cont.)
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
126/Protocol BN40955, Version 7onto a 0 [ADDRESS_835508] 
and s ymptomatic Huntington di sease. Neurology 2010;75:2150 60.
Berg KO, W ood-Dauphinee SL, W illiam s JI, et al. Measuring balance in the elderly: validation of 
an instrument. Can J Public Health 1992;83(Suppl 2):S7 11.
Brooks R. EuroQol: the current state of play. Health Polic y 1996;37 :5372.
Busse ME, W iles CM, Rosser AE. Mobility and falls in people with Huntington's disease. J Neurol 
Neurosurg Psychiatr y 2009;80:88 90.
Dalton A, Khalil H, Busse M, et al. Analysis of gait and balance through a single triaxial 
accelerometer in presy mptomatic and sy mptomatic Huntington’s disease. Gait Posture 
2013;37:49 54.
EuroQol Group. EuroQol a new facility for the measurement of health -related quality of life. 
Health Policy 1990;16:199 208.
Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five -level 
version of EQ -5D (EQ -5D-5L). Qual Life Res 2011;20:1727 36.
Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. 
Mov Disord 1996;11:136 42.Kegelmey er et al. [ADDRESS_835509] AS, Golicki D, et al. Measurement properties of the EQ -5D-5L compared to 
the EQ -5D-3L across eight patient groups: a multi -country study. Qual Life Res 
2013;22:1717 27.
Kegelmeyer DA, Kosty k SK, Fritz NE, et al. Quantitative biomechanical assessment of trunk 
control in Huntington’s disease reveals more impairment in static than dynamci tasks. 
JNeurol Sci 2017;376:29 34.
Rao AK, Muratori L, Louis ED, et al. Clinical measurement of mobility and balance impairments in 
Huntington's disease: validi ty and responsiveness. Gait Posture 2009;29:433 6.
Reilmann R, Bohlen S, Kirsten F, et al. Assessment of involuntary choreatic movements in 
Huntington's disease— toward objective and quantitative measures. Mov Disord 
2011;26:2267 73.
Reilmann R, Bohlen S, Klopstock T, et al. Graspi[INVESTIGATOR_626884]'s disease - shapi[INVESTIGATOR_626885]. Mov Disord 2010;25:2858 62.
Say MJ, Jones R, Scahill R, et al. Visuomotor integration deficits precede clinical onset in 
Huntington' s disease. Neuropsychologia 2011;49:264 70.
Appendix 9:[COMPANY_002] HD Mobile Application: A ctive Test (cont.)
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
127/Protocol BN40955, Version 7Smith A. The sy mbol-digit modalites test: a neurops ychologic test of learning and other cerebral 
disorders. In: Helmuth J, editor. Learning disorders. Seattle: Special Child Publications; 
1968:83 –91.
Stroop JR. S tudies of interference in serial verbal reactions. J Exp Psychol 1935;18:643 62.
Tabrizi SJ, Reilmann R, Roos RAC, et al. Potential endpoints for clinical trials in premanifest and 
early Huntington's disease in the TRACK -HD study: analy sis of 24 month obse rvational 
data. The Lancet Neurology 2012;11.1:42 53.
Tabrizi SJ, Scahill RI, Owen G, et al. Predictors of phenotypic progression and disease onset in 
premanifest and early -stage Huntington's disease in the TRACK -HD study: analysis of 36 -
month observational data. Lancet Neurol 2013;12:637 49.
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
128/Protocol BN40955, Version 7Appendix 10Grading Scale for Adverse Events Relating to 
Laboratory  Abnormalities
The following grading recommendations for adverse events relating to laboratory test 
abnormalities are based on the National Cancer Institute Common Terminology Criteria 
for Adverse Events, Version 5.0.

Appendix 10:  Grading Scale for A dverse Events Relating to Laboratory Abnormalities 
(cont.)
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
129/Protocol BN40955, Version 7

Appendix 10:  Grading Scale for A dverse Events Relating to Laboratory Abnormalities 
(cont.)
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
130/Protocol BN40955, Version 7LLNlower limit of normal; ULN upper limit of normal.

RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
131/Protocol BN40955, Version 7Appendix 11List of Preceding Clinical Trials
Patients from the following [COMPANY_002] -sponsored or Genentech -sponsored clinical trials are 
eligible for consideration for enrollment in Study BN40955.
Table 1Preceding Clinical Trials
Protocol Number Protocol Title
BP40410 AN OPEN- LABEL, ADAPTIVE MULTI -DOSE STUDY TO 
INVESTIGATE THE PHARMACOKINETICS AND 
PHARMACODYNAMICS OF RO7234292 IN CSF AND PLASMA, 
AND SAFETY AND TOLERABILITY FOLLOW ING 
INTRATHECAL ADMINISTRATION IN PATIENTS WITH 
HUNTINGTON’S DISEASE
BN40422 A MULTI -SITE, PROSPECTIVE, LONGITUDINAL, COHORT 
STUDY MEASURING CEREBROSPI[INVESTIGATOR_399226]- MUTANT 
HUNTINGTIN PROTEIN IN PATIENTS WITH HUNTINGTON’S 
DISEASE
BN40423 A RANDOMIZED, MULTICENTER, DOUBLE -BLIND, 
PLACEBO -CONTROLLED, PHASE III CLINICAL STUDY TO 
EVALUATE THE EFFICACY AND SAFETY OF 
INTRATHECALLY ADMINISTERED RO7234292 (RG6042) I N 
PATIENTS WITH MANIFEST HUNTINGTON'S DISEASE
BN40697 AN OPEN- LABEL EXTENSION STUDY TO EVALUATE THE 
SAFETY, TOLERABILIT Y, PHARMACOKINETICS AND 
PHARMACODYNAMICS OF RO7234292 (ISIS 443139) IN 
HUNTINGTON'S DISEASE PATIENTS WHO PARTICIPATED IN 
PRIOR INVESTIGA TIONAL STUDIES OF RO7234292 
(ISIS 443139)
ML41885 A PHASE II, MULTI -CENTER, OPEN- LABEL STUDY TO 
EVALUATE SAFET Y/TOLERABILITY OF INTRATHECALLY 
ADMINISTERED TOMINERSEN IN PATIENTS W ITH LATE -
ONSET MANIFEST HUNTINGTON’S DISEASE
RO7234292 F. Hoffmann -La [COMPANY_002] Ltd
132/Protocol BN40955, Version 7Appendix 12Guidance for Neurologic alExamination
Perform the neurologic alexamination in the same way every time at screening and at 
every clinic visit.  At dosing visit s, perform examination predose and postdose after the 
participant has walked for [ADDRESS_835510]drug injection.
Neurologic alExamination
Mental status (appearance, level of consciousness, behavior, 
speech)
Cranial Nerves II (including Visual Acuity and Fundoscopy) XII
Motor examination (bulk, tone, and strength)
Coordination
Abnormal movements
Gait
Reflexes
Sensation (vibration, light touch, pin prick/temperature)
Note:  The neurologic alexamination should be followed at the 
non-dosing clinic visits, end -of-treatment visit, and safety follow -up 
visit. At visits when a lumbar puncture is performed without 
study treatment administration, the neurological examination 
should be performed prior to the lumbar puncture.